Painting a Picture of the Ovarian Cancer N-Glycome by Briggs, Matthew Thomas
 




A thesis submitted for the degree of 
 
Doctor of Philosophy 
 
as a portfolio of publications by 
 
 



























The University of Adelaide 
 
School of Biological Sciences 
 





Professor Peter Hoffmann 
 
Professor Nicolle Packer 
 




This page is intentionally left blank 
Table of Contents 
 
Declaration ................................................................................................................................................ v 
Acknowledgements .................................................................................................................................. vii 
List of Publications .................................................................................................................................... ix 
Abbreviations ............................................................................................................................................ xi 
Abstract ................................................................................................................................................. xiii 
Chapter 1 | Introduction:  Setting the Stage ................................................................................................... 2 
1.1 | Summary ....................................................................................................................................... 2 
1.2 | Statement of Authourship ................................................................................................................ 4 
Translating N-Glycan Analytical Applications into Clinical Strategies for Ovarian Cancer ............................... 8 
1.3 | Aims ............................................................................................................................................ 24 
Chapter 2 | Materials and Methods ............................................................................................................ 26 
2.1 | Summary ..................................................................................................................................... 26 
2.2 | Statement of Authourship .............................................................................................................. 28 
N-Glycan matrix-assisted laser desorption/ionization mass spectrometry imaging protocol for formalin-fixed 
paraffin-embedded tissues .................................................................................................................... 32 
Chapter 3 | Developing N-Glycan MALDI Mass Spectrometry Imaging for FFPE Knee Osteoarthritis Tissue ..... 50 
3.1 | Summary ..................................................................................................................................... 50 
3.2 | Statement of Authourship .............................................................................................................. 52 
MALDI mass spectrometry imaging of N-glycans on tibial cartilage and subchondral bone proteins in knee 
osteoarthritis ........................................................................................................................................ 56 
3.3 | Supplementary Information ............................................................................................................ 62 
Chapter 4 | Investigating the Intrapatient Variation of Late-Stage Ovarian Cancer Tissues using N-Glycan MALDI 
Mass Spectrometry Imaging ...................................................................................................................... 64 
4.1 | Summary ..................................................................................................................................... 64 
4.2 | Statement of Authourship .............................................................................................................. 66 
N-glycan MALDI Imaging Mass Spectrometry on Formalin-Fixed Paraffin-Embedded Tissue Enables the 
Delineation of Ovarian Cancer Tissues .................................................................................................. 68 
4.3 | Supplementary Information ............................................................................................................ 82 
Chapter 5 | Investigating the Interpatient Variation of Early- and Late-Stage Ovarian Cancer Tissues using N-
Glycan MALDI Mass Spectrometry Imaging ................................................................................................ 84 
5.1 | Summary ..................................................................................................................................... 84 
5.2 | Statement of Authourship .............................................................................................................. 86 
MALDI Mass Spectrometry Imaging of Early- and Late-Stage Serous Ovarian Cancer Tissue Reveals Stage-
Specific N-Glycans ............................................................................................................................... 90 
5.3 | Supplementary Information .......................................................................................................... 120 
Chapter 6 | Discussion ............................................................................................................................ 132 
Chapter 7 | Conclusion:  Striking the Stage ............................................................................................... 140 
Chapter 8 | References ........................................................................................................................... 142 
Chapter 9 | Appendices .......................................................................................................................... 146 
9.1 | Statement of Authourship ............................................................................................................ 146 
The Glycomic Quest for the Holy Grail:  An Early Stage Biomarker for Ovarian Cancer ............................. 148 
9.2 | Statement of Authourship ............................................................................................................ 152 




I certify that this work contains no material which has been accepted for the award of any other 
degree or diploma in my name, in any university or other tertiary institution and, to the best of my 
knowledge and belief, contains no material previously published or written by another person, except 
where due reference has been made in the text. In addition, I certify that no part of this work will, in 
the future, be used in a submission in my name, for any other degree or diploma in any university or 
other tertiary institution without the prior approval of the University of Adelaide and where applicable, 
any partner institution responsible for the joint-award of this degree. 
 
 
I give consent to this copy of my thesis when deposited in the University Library, being made available 
for loan and photocopying, subject to the provisions of the Copyright Act 1968. 
 
 
I acknowledge that copyright of published works contained within this thesis resides with the copyright 
holder(s) of those works. 
 
 
I also give permission for the digital version of my thesis to be made available on the web, via the 
University’s digital research repository, the Library Search and also through web search engines, 
unless permission has been granted by the University to restrict access for a period of time. 
 
 
I acknowledge the support I have received for my research through the provision of an Australian 
Government Research Training Program Scholarship. 
 
 




Date                       06/07/18 









Writing a thesis is hard, but no harder than writing my acknowledgements. So, I decided to take an 
unconventional approach to writing them. 
 
2009. I was undecided on what I should study after year 12. Should I choose EcoChemistry or 
Molecular Biology? From an early age, I had a strange fascination with rocks. I had a collection that I 
would scrutinize. But in the end, I decided I should study Molecular Biology. 
2010. First year of university. I studied biology and chemistry. I also decided to study geology as an 
elective. Oh boy, what a mistake that was! Good thing I didn’t do EcoChemistry. I was also studying a 
Diploma of Languages in Indonesian. My grades were average.  
2011. Second year of university. My interest in performing arts had grown. I took an interest in stage 
management. I volunteered as a stage manager for IndoFest. I also volunteered as a stage manager 
for my old high school. My grades improved.  
2012. Third year of university. I then stage managed Sepia by award-winning playwright, Emily Steel. 
Sepia won the Tour Ready Award for the 2012 Adelaide Fringe. I was unable travel with the cast and 
creative team because I had exams. However, I received the opportunity to stage manage Emily Steel’s 
Rocket Town several months later. My grades improved again.  
2013. Last year of university. I turned 21. I came out of the closet. I got a boyfriend. But then, I lost a 
boyfriend. I lost a boyfriend during exam period. I spent days in bed when I should have been studying 
for my exams. My grades were the best they’ve ever been. Weird.           
2014. Honours. I arrived at the Adelaide Proteomics Centre. I entered a meeting with Professor Peter 
Hoffmann and Dr. Johan Gustafsson to discuss my project. I was excited by the prospects of my 
project. Skip forward. I published my first scientific paper. I finished writing my thesis. I submitted my 
thesis. I graduated with first class honours.      
2015. First year of my PhD. 2016. Second year of my PhD. 2017. Third year of my PhD.  
2018. Last year of my PhD. Stress. Conference. Stress. 2018 Adelaide Fringe. Stress. Writing my 
thesis. Stress. New job. Stress. Finished writing my thesis. Relief.   
 
2009-2018. University is a path to be discovered. The path can be long and an often unknown, but 
more often than not, taking the unknown path can be rewarding.    
 
I would like to thank following people who have made this thesis possible.    
 
1 | My supervisors, Professor Peter Hoffmann, Professor Nicolle Packer and Professor Martin 
Oehler, who have been instrumental in this project’s success. Without their insight and wisdom, 
this project would not be the success it is today.  
2 | My mentors, Dr. Arun Everest-Dass, Dr. Yin Ying Ho, Dr. Mark Condina,  
Dr. Manuela Klinger-Hoffmann and Dr. Georgia Arentz. Without their countless hours of critical 
analysis of my writing and experimental design, this thesis would not be possible.  
3 | My colleague, Professor Gurjeet Kaur, who has been invaluable to this project through her 
annotation of my ovarian cancer tissue samples. Without her expertise, my data could not be 
analysed and published.    
4 | My collaborators, Dr. Julia Kuliwaba, Dr. Dzenita Muratovic and Professor David Findlay, for 
their insight and wisdom into the knee osteoarthritis project. I am looking forward to continuing 
our collaboration into the future and beyond.  
5 | My colleagues, Parul Mittal, Chao Zhang, Mitchell Acland, Brooke Dilmetz and Christopher 
Cursaro. Thank you for your professionalism and continual collaboration.    
6 | My institutions, The University of Adelaide, the Adelaide Proteomics Centre, the Institute of 
Photonics and Advanced Sensing (IPAS), the Centre of Excellence in Nanoscale BioPhotonics 
(CNBP), and Macquarie University. Thank you for the memories. 
7 | My family. Roslyn, my mother. Jeffrey, my father. Samuel, my brother. Thank you for your 
unconditional love and endless support. Without it, I would have broken down in tears a lot 
more often.      
8 | My partner, Joshua Belperio. Thank you. Just thank you.   
 
List of Publications 
 
Chapter 1 | Introduction 
 
Matthew T. Briggs, Mark R. Condina, Arun V. Everest-Dass, Yin Ying Ho, Gurjeet Kaur, Martin K. 
Oehler, Nicolle H. Packer, Peter Hoffmann: From Analytical to Clinical: The Ovarian Cancer N-
Glycome. Proteomics – Clinical Applications 10/2018; DOI:10.1002/prca.201800099.  
 
Chapter 2 | Materials and Methods 
 
Matthew T Briggs, Yin Ying Ho, Gurjeet Kaur, Martin K Oehler, Arun V Everest-Dass, Nicolle H Packer, 
Peter Hoffmann: N-glycan matrix-assisted laser desorption/ionization mass spectrometry imaging 
protocol for formalin-fixed paraffin-embedded tissues. Rapid Communications in Mass Spectrometry 
03/2017; DOI:10.1002/rcm.7845 
 
Chapter 3 | Developing N-Glycan MALDI Mass Spectrometry Imaging for FFPE Knee 
Osteoarthritis Tissue 
 
Matthew T. Briggs, Julia S. Kuliwaba, Dzenita Muratovic, Arun V. Everest-Dass, Nicolle H. Packer, 
David M. Findlay, Peter Hoffmann: MALDI mass spectrometry imaging of N-glycans on tibial cartilage 
and subchondral bone proteins in knee osteoarthritis. Proteomics 03/2016; 16(11) 
DOI:10.1002/pmic.201500461 
 
Chapter 4 | Investigating the Intrapatient Variation of Late-Stage Ovarian Cancer Tissues using 
N-Glycan MALDI Mass Spectrometry Imaging 
 
Matthew T. Briggs, Arun V. Everest-Dass, Gurjeet Kaur, Martin K. Oehler, Peter Hoffmann, Nicolle H 
Packer: N -Glycan MALDI Imaging Mass Spectrometry on Formalin-Fixed Paraffin-Embedded Tissue 
Enables the Delineation of Ovarian Cancer Tissues. Molecular & Cellular Proteomics 07/2016; 
15(9):mcp.M116.059816, DOI:10.1074/mcp.M116.059816 
 
Chapter 5 | Investigating the Interpatient Variation of Early- and Late-Stage Ovarian Cancer 
Tissues using N-Glycan MALDI Mass Spectrometry Imaging 
  
Matthew T. Briggs, Yin Ying Ho, Mark R. Condina, Arun V. Everest-Dass, Gurjeet Kaur, Martin K. 
Oehler, Nicolle H. Packer, Peter Hoffmann: MALDI Mass Spectrometry Imaging of Early- and Late-
Stage Serous Ovarian Cancer Tissue Reveals Stage-Specific N-Glycans (unsubmitted).  
 
Chapter 9 | Appendices 
 
M Briggs, A Everest-Dass, M Oehler, N Packer, P Hoffmann: The Glycomic Quest for the Holy Grail: An 
Early Stage Biomarker for Ovarian Cancer.  
 
G. Arentz, P. Mittal, C. Zhang, Y.-Y. Ho, M. Briggs, L. Winderbaum, M.K. Hoffmann, P. Hoffmann:  
Applications of Mass Spectrometry Imaging to Cancer. Advances in Cancer Research 01/2017; 134, 
DOI:10.1016/bs.acr.2016.11.002 
This page is intentionally left blank 
 
 Abbreviations  
   
µL Microlitre  
   
ACN Acetonitrile  
   
CID Collision induced dissociation  
Da Dalton  
DE Delayed extraction  
DHB 2,5-Dihydroxybenzoic acid  
ECM Extracellular matrix  
ESI Electro-spray ionization  
ETD Electron transfer dissociation  
EtOH Ethanol  
FA Formic acid  
FF Fresh frozen  
FFPE Formalin-fixed paraffin-embedded  
FIGO International federation of gynaecology and obstetrics  
H&E Haematoxylin and eosin  
HCl Hydrochloric acid  
HPLC High performance liquid chromatography  
IT Ion trap  
LC Liquid chromatography  
LCM Laser capture micro-dissection  
m/z Mass to charge ratio  
MALDI Matrix-assisted laser desorption/ionization  
MeOH Methanol  
MCP Micro plate detector  
MS Mass spectrometry  
MSI Mass spectrometry imaging  
MS/MS Tandem mass spectrometry  
PNGase F Peptide-N-glycosidase  
PTMs Post-translational modifications  
PVDF Polyvinylidene fluoride  
Q Quadrupole  
qTOF/QTOF Quadrupole time-of-flight  
RP Reverse phase  
S/N Signal to noise ratio  
t Time  
TFA Trifluoroacetic acid  
TMA Tissue micro-array  
TOF Time-of-flight  
YAG Yttrium aluminium garnet  
This page is intentionally left blank 
Abstract 
 
Our story begins with the current clinical strategies that are used by clinicians today to (1) screen and 
detect ovarian cancer in the early-stages, (2) monitor treatment effectiveness, (3) detect ovarian cancer 
recurrence and (4) stratify ovarian cancer patients. However, these current strategies utilise FDA-
approved ovarian cancer biomarkers, such as CA125 and HE4, which are relatively unsuccessful and 
lack specificity, especially for early stage patients. In the introduction, it is highlighted that these ovarian 
cancer biomarkers and other disease biomarkers are typically glycoproteins, but their glycan structure-
protein function relationship remains unknown. 
 
Protein glycosylation is one of the most complex post-translational modifications (PTMs) found in 
humans, with N-linked glycans playing a significant role in protein folding and conformation, protein 
stability and activity, cell-cell interaction, and cell signalling pathways. The best approach to study and 
analyse N-glycans so far has been to structurally characterise them by firstly, releasing them from 
complex glycoprotein mixtures using PNGase F, and secondly, identifying specific structures using 
analytical strategies that may potentially translate into clinical strategies. Ultimately, this thesis focuses 
on analytical techniques, primarily mass spectrometry, that are available to qualitatively and 
quantitatively assess N-glycosylation while successfully characterising compositional, structural and 
linkage features with high specificity and sensitivity.  
 
Analytical techniques that were explored include liquid chromatography electrospray ionisation tandem 
mass spectrometry (LC-ESI-MS/MS) and matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry (MALDI-TOF-MS). These analytical techniques have previously been implemented in the 
clinic for other diseases, however, not yet for ovarian cancer. It may be possible to implement either 
LC-ESI-MS/MS or MALDI-TOF-MS in the clinic for ovarian cancer using N-glycomic-based approaches 
since aberrant N-glycosylation patterns have been observed consistently between clinical samples, 
such as serum, plasma, ascites and tissue.     
  
MALDI mass spectrometry imaging (MSI) has emerged as a platform to visualise N-glycans in tissue-
specific regions. Outlined in this thesis, our group studied the intrapatient and interpatient variability 
between early- and late-stage ovarian cancer patients. From our studies, specific N-glycan differences 
were identified between the early- and late-stage tumour microenvironment that could lead to the 
development of ovarian cancer diagnosis and prognosis strategies for the clinic.  
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Chapter 1 | Introduction:  
Setting the Stage 
 
 
1.1 | Summary 
 
This review article provides readers with a brief summary about the current clinical strategies that are 
available to clinicians today and the common lack of specificity for disease biomarkers, particularly the 
ovarian cancer biomarker, CA125. It is highlighted in this review that CA125 is a glycoprotein that is 
relatively uncharacterised, thereby opening the door to discuss analytical strategies that are available to 
scientists today to strcuturally characterise N-glycans. Characterisation is important because these N-
glycan structures have previously been observed to be aberrant when analysed from clinically-relevant 
ovarian cancer samples including serum, plasma, ascites and tissue. This review emphasises the use 
of mass spectrometry as an analytical strategy and highlights the potential the technique has to 
translate into a clinical setting. More specifically, matrix-assisted laser desorption/ionisation (MALDI) 
mass spectrometry imaging (MSI) has shown much promise in the analysis of clinical samples, such as 
formalin-fixed paraffin-embedded (FFPE) tissues.         
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Translating N-Glycan Analytical Applications into 
Clinical Strategies for Ovarian Cancer 
 
Matthew T. Briggs, Mark R. Condina, Manuela Klingler-Hoffmann, 
Georgia Arentz, Arun V. Everest-Dass, Gurjeet Kaur, Martin K. Oehler, 





Protein glycosylation, particularly N-linked glycosylation, is a complex 
posttranslational modification (PTM), which plays an important role in protein 
folding and conformation, regulating protein stability and activity, cell–cell 
interaction, and cell signaling pathways. This review focuses on analytical 
techniques, primarily MS-based techniques, to qualitatively and quantitatively 
assess N-glycosylation while successfully characterizing compositional, 
structural, and linkage features with high specificity and sensitivity. The analytical 
techniques explored in this review include LC–ESI–MS/MS and MALDI time-of-
flight MS (MALDI-TOF-MS), which have been used to analyse clinical samples, 
such as serum, plasma, ascites, and tissue. Targeting the aberrant N-
glycosylation patterns observed in MALDI–MS imaging (MSI) offers a platform to 
visualize N-glycans in tissue-specific regions. The studies on the intra-patient 
(i.e., a comparison of tissue-specific regions from the same patient) and inter-
patient (i.e., a comparison of tissue-specific regions between different patients) 
variation of early- and late-stage ovarian cancer (OC) patients identify specific N-
glycan differences that improve understanding of the tumor microenvironment 






Ovarian cancer (OC) is the most fatal gy-
necological malignancy in adult women 
with an estimated 1613 new cases diag-
nosed and 1069 deaths in Australia dur-
ing 2018.
[1]
 Early OC is asymptomatic in 
most cases, leading to late-stage di-
agnosis of patients that have developed 
metastatic stage III or IV cancer based on 
the International Federation of Gyne-
cology and Obstetrics (FIGO) staging sys-
tem (see Table 1).  
Surgery combined with chemotherapy 
is the current standard treatment for 
advanced OC. However, prognosis for 
FIGO stage III and IV is poor and the 5-
year overall survival rate is only 30%.
[2]
 
Novel clinical strategies that address 1) 
screening/early-detection, prediction and 
monitoring of treat-ment response, and 3) 
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Table 1. FIGO stages of ovarian cancer and the extent of tumor spread.  
 
FIGO stage Tumor spread  
 
I Confined to ovaries 
 
II Pelvic extension 
III Extrapelvic intra-abdominal spread and/or lymph node involvement 




2. Current Clinical Strategies for Ovarian Cancer 
 
In 2014, the World Health Organization (WHO) published a now 
widely used strategy to classify OC in parallel with the already 
established FIGO staging.
[3]
 Histological information is used to 
classify OC into five subtypes (serous, mucinous, endometrioid, 
clear cell, and transitional cell cancer). These subtypes can be 
further subdivided into tumor grades, for example, serous low-
grade carcinoma and serous high-grade carcinoma. This review 
focuses on the most common and widely studied form of OC that 
is serous high-grade carcinoma.  
The two most common clinical strategies used to screen and 
monitor women for OC include pelvic ultrasonography, such as 
transabdominal and transvaginal ultrasound (TVUS),
[4]
 and the 
cancer antigen 125 (CA125) blood test.
[5]
 However, these current 
strategies lack specificity and sensitivity that can lead to unneces-
sary treatment and an increase of burden on the health system.
[6]
 
The failure of such screening strategies is thought to be due to the 
complexity of OC, largely caused by genetic diversity and tumor 
heterogeneity.
[7]
 This review aims to address this complexity by 
focusing on N-glycans since they possess high structural com-
plexity relative to other biomolecules and altered N-glycosylation 
is a universal feature of cancer cells.  
This review also focuses on addressing the shortfalls of the cur-
rent classification system, and how screening, monitoring, and 
stratification strategies may be improved by the introduction of 
novel analytical capability into clinical practice. 
 
 
2.1. TVUS and CA125 
 
Transabdominal and TVUS provide a snapshot of the reproduc-
tive organs, such as the uterus, ovaries, fallopian tubes, and cervix, 
which can lead to the visualization of a mass, potentially tumor.
[8]
 
There are multiple benefits associated with this approach, such as 
shorter examination times, visualization of tumor size, and 
assessment of morphologic characteristics (i.e., presence of septae 
or cyst wall regularity).
[9]
 However, there are also limitations 
associated as it is not possible to determine whether the mass is 
cancerous or benign, and therefore further tests, such as the 
CA125 blood test, are required.  
CA125, or more formally known as mucin 16 (MUC16), is a 
glycoprotein that has been Food and Drug Administration (FDA)-
approved as a blood biomarker for the detection of recurrent 
OC.[10] CA125 is also used to monitor treatment response in 
patients that have undergone tumor debulking surgery and 
chemotherapy.[11] However, CA125 has been relatively unsuccess-
ful as an ovarian cancer biomarker, as it lacks the specificity in 
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cancer stages. Recent results from the UK Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS), which separately used 
CA125 levels and TVUS screening to monitor the development of 
OC in a large cohort of post-menopausal women over a period of 
11 years, found neither test to be of significant benefit in the 
monitoring of OC.
[12]
 CA125 is thought to lack specificity due to 
its production in multiple tissues derived from coelomic epithelia, 
such as the ovaries, fallopian tube, peritoneum, pleura, 
pericardium, colon, kidney, and stomach.
[10] 
 
There have been several attempts to improve CA125 as a 
screening biomarker for OC by combining ultrasound studies with 
the algorithm-based data of patient age, rate of change of CA125 
over time, and the absolute quantitation of CA125.
[13]
 With no 
success, CA125 studies have also utilized other unique 
 
 




techniques such as radio-imaging, radio-immunotherapy, and 
targeted delivery of cytotoxic agents.
[14]
 It has been discovered 
that 20% of high-grade OCs have little or no expression of 
CA125, leading to the need to identify novel biomarkers for OC 
diagnosis or monitoring.
[15]
 Over 30 other biomarkers have been 
evaluated in conjunction with CA125, including human 
epididymis protein 4 (HE4), mesothelin, macrophage colony-
stimulating factor (MCSF), osteopontin, kallikrein, soluble 
epidermal growth factor (EGF) receptor, and inhibin, however, the 
search for an improved OC biomarker continues.
[16] 
 
In 2009, an immunoassay based on the glycoprotein HE4 was 
approved by the FDA for the monitoring of OC recurrence and 
progression.
[17]
 However, this assay was not approved for the 
screening of early-stage OC in asymptomatic women. Therefore, a 
combined CA125 and HE4 test was established to assess the 
probability of detecting OC in women with a pelvic mass. The 
Risk of Ovarian Cancer Algorithm (ROMA) was applied to gen-
erate a score from 0 to 10. ROMA utilized clinical information, 
such as CA125 and HE4 concentration, and menopausal status, to 
determine the probability of the patient having OC. Women with 
ROMA scores above the predetermined cutoff were deemed to 
have an increased risk of OC and are referred to a gynecological 
oncologist. However, ROMA scores require further patient infor-
mation, such as a women’s menstrual status. It recently has been 
reported that at 75% specificity, pre-menopausal women are at 




In 2016, an American bioanalytical solutions company, Ver-
million, released a statement about a second-generation FDA-
approved biomarker for determining OC risk in conjunction with 
clinical information provided prior to surgery.
[18]
 Overa, also 
known as OVA2, replaced two of the five biomarkers from the 
first-generation test to improve specificity. The five OVA2 
biomarkers include CA125-II, HE4, apolipoprotein A-1, follicle 
stimulating hormone, and transferrin. However, these biomarkers 
are currently only used to monitor patients, not diagnose them due 




2.2. CA125: A Glycoprotein Biomarker 
 
MUC16 is overexpressed in OC and plays important roles in in-
vasion and metastasis. MUC16 is cleaved at a specific location, 
thus, releasing CA125 into the extracellular space. CA125 is a 
glycoprotein and its O-linked glycosylation is critical for both 
structure and function. More recently the focus of analysis has 
shifted to N-linked glycosylation, which regulates stability and 
function of CA125. The majority of glycans observed in the tumor 
microenvironment are N-glycans. Furthermore, N-glycosylation 
patterns have been observed to be aberrant in various cancers, 
including OC and other gynecological cancers, which highlights 
the importance and relevance of this review.  
Protein glycosylation can be divided into two main classes; N-
linked glycans, which are attached to asparagine residues, and O-
linked glycans, which are attached to serine/threonine residues.
[19]
 
N-glycans are the most common and complex type of protein 
glycosylation with 90% of glycoproteins presenting N-glycan 
structures. N-glycans are also of particular interest in 
www.clinical.proteomics-journal.com  
 
OC because structural alterations have been observed in the tu-
mor microenvironment, which contributes to tumor invasion and 
metastasis.
[20]
 A structural alteration of interest is the formation of 
bisecting N-acetylglucosamine (GlcNAc) on several N-
glycosylated glycoproteins from ovarian cancer samples. Previ-
ous studies have found that CA125 contains monofucosylated and 
bisecting GlcNAc N-glycans, however, this was not evaluated in a 
large patient cohort.
[21]
 See Figure 1 for a brief summary of the 
N-glycan biosynthesis pathway.  
As already discussed, altered N-glycan compositions and struc-
tures have been identified as a unique characteristic of tumorige-
nesis, tumor cell invasion, and metastasis and thus are an attrac-
tive target for monitoring and patient sample classification. This 
review outlines the current understanding of the OC N-glycome 




3. Analytical Applications for N-
Glycan Characterization 
 
The analytical strategies currently used to characterize N-glycans 
provide an important insight into their structural identity by 
obtaining monosaccharide composition, branching and linkage 
information.
[23]
 Initially, N-glycans are released from glycopro-
teins using an enzyme, peptide-N-glycosidase (PNGase F), which 
cleaves the GlcNAc residue from the asparagine residue (except in 
cases where fucose is attached at the core GlcNAc via an α-1,3 
linkage).
[24]
 These N-glycans can then be characterized using an 




3.1. Nuclear Magnetic Resonance 
 
NMR is currently considered the best approach to analyze N-
glycans, due to its ability to assign all structural features, such as 
composition, branching, and linkage.
[25]
 However, large quan-
tities of highly purified N-glycans are required to obtain such 
results.
[23]
 Therefore, this analytical strategy might not be feasi-
ble for analyzing clinically relevant samples due to the low abun-
dance of complex N-glycans. 
 
 
3.2. Ultraviolet–Visible Spectroscopy 
 
Ultraviolet–visible spectroscopy (UV/Vis) measures the ab-
sorbance or reflectance of the molecules in the visible range. 
However, N-glycans are poorly detected by UV/Vis absorption 
due to their lack of a chromophore.
[26]
 Instead, N-glycans are ini-
tially separated by HPLC or ultra-HPLC (UHPLC) using modes 
such as ion exchange, hydrophilic interaction LC (HILIC), or 
porous graphitized carbon (PGC) columns. HILIC utilizes polar 
interactions between the glycome and the stationary phase instead 
of separating specific glycans via alternative methods (i.e., lectin 
affinity chromatography).
[27]
 In PGC chromatography as well as 
reversed phase (RP) chromatography, increased number of 
hydrocarbons results in a proportional increase in 
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Figure 1. The N-linked glycan biosynthesis pathway. In the endoplasmic reticulum (ER), a glycan precursor composed of 14 monosaccharides is synthesized 
and attached to dolichol. 1) This precursor is then transferred onto an asparagine residue of a nascent polypeptide also located in the ER. 
Oligosaccharyltransferase (OST) protein complex, consisting of several protein subunits, transfers this precursor. 2) The glycan precursor is trimmed in the ER 
before being transferred to the Golgi apparatus on the nascent polypeptide. 3) Golgi mannosidases cleave mannose residues, followed by branching and chain 
extension by various glyco-enzymes, for example glycosyltransferase-III (GnT-III) attaches a GlcNAc in the β 1,4 linkage at the β -mannose of the mannosyl 




 However, it is still unknown how PGC sep-
arates N-glycans based on their isomeric structure and charge. 
UHPLC is fast becoming more popular than conventional HPLC, 
since UHPLC utilizes a smaller particle size, can withstand higher 
pressures, and provides better resolution while reducing the 
separation time down to 30 min or less.
[29]
 Glycan separation is 
then combined with a charged aerosol detector (CAD), providing a 
platform to quantitatively analyze glycans cleaved from 
glycoproteins.
[30]
 The CAD converts these glycans into dry parti-
cles, where a stream of positively charged gas collides, transfer-
ring its charge onto the particles. These particles are then trans-
ferred to a collector, where the charge is measured by a highly 
sensitive electrometer, thereby generating a signal, which is di-
rectly proportional to the quantity to the glycan measured. CAD 
offers a better performance than other detectors, such as refractive 
index (RI), low wavelength UV, and evaporative light scattering 
(ELS). Alternatively, high-performance anion exchange (HPAE) 
coupled with pulsed amperometric detection (PAD) has also 
emerged to quantitatively analyze glycans cleaved from 
glycoproteins.
[31]
 HPAE-PAD is capable of measuring glycans in 




3.3. Capillary Electrophoresis 
 
Another common technique used is capillary electrophoresis with 
laser induced fluorescence (CE–LIF), which is also suitable for 
profiling labeled glycans.
[32]
 An electric field mediates the 
migration of glycans, resulting in high resolution separation. 
Although CE–LIF is reproducible and highly sensitive, the 
approach lacks identification capabilities that MS and MS/MS 
 
strategies can offer. Ruhaak and colleagues are at the forefront of 
innovation by introducing multi-capillary formats for high-
throughput profiling of glycan changes.
[33]
 However, the main 
issue regarding this technology is identifying peaks, which cur-
rently is being addressed by setting up a CE database using an 8-
aminopyrene-1,3,6-trisulfonate (APTS) maltrin ladder to normal-
ize data. Studies have compared CE–LIF with UPLC to determine 
full characterization of N-glycans released from human IgG.
[34]
 It 
was determined that CE–LIF is a suitable profiling, characteriza-
tion, and detailed structural analysis tool, when an internal stan-
dard ladder and a database is applied. This technology has now 





3.4. Microarray-Based Approaches 
 
N-glycans can be immobilized in glycan binding assays (i.e., mi-
croarrays or microtritration plates) by binding either covalently or 
non-covalently. Specific carbohydrate-binding proteins (CBPs), 
such as animal or plant lectins or immunoglobulins, are applied. 
The bound-CBPs are then detected via fluorescence by either 
direct labeling or secondary antibody strategies.
[36]
 This 
application is useful in determining which N-glycans interact with 
which CBPs, but the technique lacks specificity in identifying the 
exact N-glycan structure required for binding. Additionally, N-
glycan antibodies are rare, with only 25 found in the Database of 
Anti-Glycan Reagents (DAGR). A total of 15 of these 25 
antibodies were extracted from HIV patients.
[37]
 Further 
disadvantages of N-glycan antibodies include their commercial 
unavailability, and their failure to recognize distinct 
 
 




structural features, with only recognizing N-glycan families. Mul-
tiple antibodies, for example, recognize multiple high mannose N-
glycans, such as Man7, Man8, and Man9.
[38]
 The challenge re-
garding N-glycan antibody recognition lies with the high degree of 
homology within the N-glycan structures, even though they are 
considered one of the most complex PTMs.  
Anti-glycan antibodies against 203 chemically synthesized gly-
cans were detected in serum of adult women with ovarian carci-
nomas at different stages in 2012.
[39]
 Following cluster analysis, 
repetitive patterns were identified revealing specific core carbo-
hydrate structures including 11 N-glycans. However, these were 
atypical N-glycan structures ranging from linear lactosamine and 
glucosamine structures to single core lactosamine structures. More 
recently, a multiplex glycan bead array (MGBA) was conducted 
on 961 ovarian cancer serum samples where natural anti-glycan 
IgM and IgG antibodies were analyzed, resulting in the discovery 
of potential anti-glycan biomarkers for OC.
[40] 
 
These traditional characterization techniques are isolated ex-
amples of how N-glycan analysis has previously been conducted 
on a range of biological samples. However, these approaches can 
often be tedious, unreliable, and difficult to use. Alternative 
methodologies for detecting N-glycans from OC patient samples 
can potentially assist in improving screening, monitoring, and 
stratification strategies. In order to be of use, however, such 
methodology would need to offer a high level of molecular infor-
mation that can be generated in short timeframes for subsequent 
patient assessment and treatment. 
 
 
4. N-Glycan Characterization using MS 
 
MS is a rapid and highly sensitive technique with the potential to 
address such clinical obstacles. Prior to MS analysis, N-glycan 
samples may be subjected to a separation technique in order to 
construct a more comprehensive library of characterized struc-
tures. Complex N-glycan mixtures are separated by capillary- or 
nano-LC prior to analysis with ESI. There are several advantages 
to this approach, such as the ability to measure and characterize N-
glycans with high sensitivity and reproducibility from low sample 
amounts. However, current N-glycan structural analysis can still 
be difficult due to the lack of high-throughput analysis software 
available. In addition to LC–ESI–MS, the other routinely used 
ionization method for the analysis of N-glycans is MALDI. 
MALDI–MS is an advantageous technique that can rapidly an-
alyze N-glycans directly from biological samples, such as tissue 
sections, using higher-energy collision-induced dissociation 
(CID). Additionally, MALDI favors singly charged species that 
make annotation simpler. 
 
 
4.1. Electrospray Ionization Mass Spectrometry 
 
ESI is a soft ionization technique that involves the application of a 
needle voltage to force the liquid analyte from the needle as a 
Taylor Cone.
[41]
 A filament forms at the tip of the Taylor Cone 
until the surface tension and electrostatic repulsion are equal (i.e., 
Rayleigh limit). Once reached, the filament breaks away and the 
highly charged droplets are attracted to a voltage supply from 
 
the mass analyzer entrance. In this transition, the Coulombic re-
pulsion exceeds the surface tension, leading to an explosive for-
mation of smaller droplets. Nitrogen nebulizing gas is also used to 
help produce a fine spray. As the ions fly towards the mass 
analyzer entrance, the charge density on the surface increases, 
thereby producing a mixture of singly and multiply charged ions. 
 
There are several different types of mass analyzers available to 
analyze N-glycans, including ion trap (IT), time-of-flight (TOF), 
quadrupole (Q), and Fourier-transform ion cyclotron resonance 
(FTICR) analyzers.
[42]
 These mass analyzers play an important 
role in mass sensitivity, mass accuracy, mass resolution, and data 
acquisition. For example, an IT mass analyzer possesses ideal MS 
fragmentation capabilities, but low mass resolution capabilities. 
Conversely, Q-TOF mass analyzers are capable of higher mass 
resolution and accuracy, therefore enabling detailed and compre-
hensive structural characterization of N-glycans.  
As already discussed, these complex N-glycan mixtures are first 
separated using fractionation techniques, such as HPAE 
chromatography, HILIC, RP chromatography, and PGC chro-
matography, prior to ESI. PGC chromatography possesses spe-
cific features that are valuable when analyzing complex N-glycan 
mixtures that contain N-glycans of different isomeric structures. 
For example, Anugraham et al. investigated the N-glycome of the 
SKOV 3 cell line as well as the IGROV 1, A2780, and OV-CAR 3 
OC cell lines.
[43]
 These N-glycan profiles were compared to the 
noncancerous ovarian surface epithelial cell lines, HOSE 6.3 and 
HOSE 17.1. Through PGC–LC–ESI–MS of N-glycans released 
from membrane glycoproteins, bisecting, α 2–6 linked sialylated, 
and LacdiNAc N-glycans were found to be highly abundant in 
membrane glycoproteins of the cancerous cell lines relative to the 
noncancerous HOSE cell lines. Further validation was completed 
by studying the gene transcript levels of glycosyltransferases, 
MGAT3, ST6GAL1, and B4GALNT3. For the first time, there 
was evidence that MGAT3 gene expression levels may be 
epigenetically regulated by DNA hypomethylation, leading to the 
synthesis of bisecting N-glycans. 
 
 
4.2. Matrix-Assisted Laser 
Desorption/Ionization Mass Spectrometry 
 
MALDI was first introduced by Karas and Hillenkamp.
[44]
 A typi-
cal MALDI–TOF-MS instrument uses an yttrium aluminum gar-
net (YAG) pulse laser under high vacuum conditions to stim-ulate 
an explosive transition from solid to gaseous phase. Ions are 
produced through a combination of charge neutralization and 
proton transfer reactions.
[45]
 Gaseous phase ions, typically singly 
charged, are accelerated via ion source voltages into a TOF mass 
analyzer. In terms of published N-glycan MALDI–TOF-MS 
studies, there are multiple which is evident in a series of reviews 
published by Harvey.
[46]
 Classically, complex N-glycan mixtures 
are prepared for MALDI–TOF-MS analysis by pipetting the 
mixture onto a target plate followed by a matrix solution. The 
matrix co-crystallizes with the N-glycan mixture resulting in dried 
spots, which now possesses strong absorption in the UV range. 
The most widely used matrix for N-glycan analysis is 2,5-
dihydroxybenzoic acid (DHB) where [M + Na]
1+ adducts are 
typically formed in positive ion mode. 
 
 




However, sialylated N-glycans are quite labile due to the 
MALDI source operating under vacuum and the TOF mass 
analyzer operating in reflectron mode as opposed to linear 
mode.
[47]
 This caveat has been addressed using several different 
approaches, such as permethylating the N-glycan mixture, prior to 
pipetting on the target plate, to dissipate the energy in an 
intermediate pressure MALDI source. Another solution to this 




 This reagent in 
combination with methanol creates an esterification reaction re-
sulting in α 2–3 linked sialic acid lactones and α 2–6 linked sialic 
acids that are esterified. This creates a 32 Da mass difference be-
tween the two linkages while also stabilizing the sialic acids for 
MALDI–TOF-MS analysis.  
In 2011, the first MALDI-based profiling study was conducted 
looking at the N-glycosylation patterns of glycoproteins from the 
OC cell line, SKOV 3, and more specifically a recombinantly ex-
pressed glycoprotein, erythropoietin (EPO).
[49]
 The released N-
glycans were analyzed by HPAE chromatography with PAD and 
MALDI–TOF-MS. From the total glycoproteins, high mannose 
and proximally fucosylated N-glycans were identified, with EPO 
containing predominantly core fucosylated tetra-antennary N-
glycans that partially lacked one or two galactose residues, par-
tially containing the LacdiNAc motif.  
Although OC cell lines, such as IGROV 1, A2780 OVCAR 3, 
and SKOV 3, provide an important insight into the N-
glycosylation patterns behind OC progression, there are multiple 
caveats with analyzing these particular sample types. For exam-
ple, it has been well documented that the most frequently used OC 
cell lines do not represent high-grade serous OC, based on their 
genomes.
[50]
 On the other hand, tissue samples are clinically 
relevant, but require invasive means to excise from patients. With 
the limitations discussed regarding cell lines and tissue, many 
studies are now utilizing serum and plasma from patients due its 




5. The Ovarian Cancer N-Glycome 
Characterised using Mass Spectrometry 
 
5.1. Serum and Plasma 
 
In 2007, Saldova et al. collected serum from healthy and stage III 
OC patients to identify which glycoproteins were contributing to 
changes in the serum N-glycome.
[51]
 Normal-phase HPLC (NPH-
PLC) fluorescence was performed to separate N-glycan species 
that were released from serum glycoproteins. See Table 2 for a 
brief history of N-glycans identified and characterized by MS 
from ovarian cancer serum, cell line, ascites, and tissue samples. 
N-glycan structures were confirmed by a combination of exogly-
cosidase digestions, NPHPLC, and MALDI-TOF MS. The relative 
percentage areas of mono-sialylated, di-sialylated, tri-sialylated, 
and tetra-sialylated N-glycans were calculated and compared be-
tween patients. It was concluded that mono-sialylated N-glycans 
were lower on average compared with control while tri-sialylated 
N-glycans were high on average. Immunoglobulin (IgG) was iso-
lated from all of the serum samples by affinity chromatography 
 
on a Protein G column. Previously, core fucosylated N-glycan lev-
els have been found to be twofold higher in patients with ovarian 
cancer, compared to healthy controls, and this was found to be 
consistent with these samples. 2D SDS-PAGE was employed to 
the ovarian cancer serum samples, and then the differential protein 
spots were excised for subsequent N-glycan profiling by ESI–
MS/MS. Haptoglobin β-chain, α1-acid glycoprotein, and α1-
antichymotrypsin were represented as examples of the glycopro-
teins with major N-glycosylation differences.  
In 2008, Leiserowitz et al. used MALDI-Fourier-transform ion 
cyclotron resonance (FTICR)–MS again to study the serum gly-
coproteins of OC patients, utilizing patient information such as 
grade and mucin 16 (CA125) expression.
[52]
 Serum samples from 
48 ovarian cancer patients and 24 healthy controls were used. Out 
of the 48 OC patients, 23 patients had CA125 levels with less than 
35 U mL
–1
 and 25 patients had CA125 levels with more than 150 
U mL
–1
. It was determined that 44 patients out of 48 OC patients 
had detectable glycan signals with CA125 values between 2 and 
17 044 U mL
–1
. Conversely, 23 out of 24 healthy controls had no 
detectable glycans with CA125 values between 10 and 64. 
Therefore, the sensitively and specificity was determined to be 
91.6% and 95.8% respectively for the classification of OC from 
controls.  
In 2013, Saldova et al. collected serum from mice that had been 
injected with OVCAR3 adenocarinoma cell lines.
[53]
 N-glycans 
were released from serum samples and analyzed by HILIC– and 
weak anion exchange (WAX)–HPLC, combined with 
exoglycosidase digestions to assign structural informa-tion. A total 
of 19 peaks were identified by HILIC–HPLC while only five 
peaks were detected by WAX–HPLC. Mice treated with the pro-
inflammatory drugs, thioglycolate (TG), and chlorite-oxidized 
oxyamylose (COAM), were shown to have increased sialylated 
and branching N-glycans. The same authors’ explored the 
glycosylation patterns of CA125 extracted from healthy and OC 
patient serum using SDS-PAGE and LC– ESI–MS/MS.
[53]
 The N-
glycans identified and characterized in-cluded mono-sialylated, di-
sialylated, core-fucosylated, bisected, and high-mannosylated N-
glycans. It was concluded that core-fucosylated bi-antennary 
mono-sialylated N-glycans were highly abundant in OC patients, 
while bisecting bi-antennary and non-fucosylated N-glycans were 
highly abundant in healthy patients. 
 
Hua et al. investigated isomeric differences of N-glycans 
released from OC serum samples compared with healthy 
controls.
[54]
 Nano-PGC–LC–ESI–MS/MS revealed 250 N-glycan 
compound peaks and over 100 distinct N-glycan compositions. 
The N-glycans were grouped into complex, hybrid, high man-
nose, sialylated, and fucosylated N-glycans, and then compared 
based on their average relative abundances and standard errors. 
Complex, hybrid and high mannose N-glycans were recorded to 
be lower intensity in OC serum samples relative to healthy 
controls while fucosylation and sialylation were found to be 
consistently higher in the OC serum. This study provides a 
valuable insightful into the complexity of N-glycans in serum. 
 
A comparison of the serum N-glycome from 63 preoperative 
primary OC patients and 33 age-matched healthy patients used 
MALDI–TOF-MS and MS/MS analysis to identify 11 N-glycan 
biomarkers; four high mannose and seven 
 
 




Table 2. A brief history of N-glycans identified and characterized by MS from ovarian cancer serum, cell line, ascites, and tissue samples.  
 
Year Publication Title Author Biological Sample Information Species Mass Spec- Journal Results 
   Sample   trometry   
         
2007 Ovarian cancer is associated Saldova et al. Serum Stage IIIC serous and Human MALDI–TOF Glycobiology Serum 
 with changes in   endometrioid carcinoma  ESI-QTOF  ↑Core-fucosylated 
 glycosylation in both   prior to surgery, stage III    ↑Tri-sialylated 
 acute-phase proteins and   serous carcinoma at the    ↓Mono-sialylated 
 IgG   time of relapse with     
    advanced disease, and     
    healthy controls     
2008 Glycomics analysis of serum: a Leiserowitz et al. Serum Less than 35 IU mL
–1
 (low Human MALDI–FT International Journal of Serum 
 potential new biomarker for   CA125) and greater than   Gynaecological N-glycans not stated 
 ovarian cancer?   150 (high CA125)   Cancer  
2011 N-Glycosylation of total Machado et al. Cell Line SKOV 3 ovarian carcinoma Human MALDI-TOF Glycobiology Cell Line 
 cellular glycoproteins from       ↑High mannosylated 
 the human ovarian       ↑Fucosylated 
 carcinoma SKOV3 cell line        
 and of recombinantly        
 expressed human        
 erythropoietin        
 
2013 Increase in sialylation and Saldova et al. 
 branching in the mouse  
 serum N-glycome correlates  
 with inflammation and  
 ovarian tumour progression  
2013 Exploring the glycosylation of Saldova et al. 
 serum CA125  
 
Serum OVCAR 3 adenocarcinoma  Mouse ESI–QTOF PLoS One Serum  
injected into mice and ↑Sialylated and  
serum extracted for branching in TG and  
analysis COAM-treated mice 
 
Serum Advanced ovarian cancer Human ESI-QTOF International Journal of Serum  





2013  Isomer-specific Hua et al. Serum Stage I-IV epithelial ovarian Human ESI–chip-TOF Journal of Serum 
chromatographic profiling   cancer and healthy Chromatography ↑Sialylated 
yields highly sensitive and   controls  ↑Core-fucosylated 
specific potential N-glycan     ↓High mannosylated 
biomarkers for epithelial     ↓Complex/hybrid 
ovarian cancer      
2013  Serum glycome profiling: a Biskup et al. Serum Stage I-IV primary ovarian  Human MALDI-TOF  Journal of Proteome Serum 
biomarker for diagnosis of   cancer patients and Research ↑Sialylated 
ovarian cancer   age-matched controls  ↑Core-fucosylated 
     ↓High mannosylated 
2014 The serum glycome to Biskup et al. 
 discriminate between  
 early-stage epithelial ovarian  
 cancer and benign ovarian  
 diseases  
2014 Mass spectrometric screening Jae-Han et al. 
 of ovarian cancer with  
 serum glycans  
Serum Stage I-III primary serous Human MALDI-TOF Disease Markers Serum  
ovarian cancer, benign ↑Sialylated  
ovarian diseases and ↑Fucosylated  




Serum Stage I-IV ovarian cancer Human MALDI-TOF Disease Markers Serum  




2014 Evaluation of glycomic Kim et al. Serum Epithelial ovarian cancer, Human ESI-chip-TOF Cancer, Epidemiology, Serum 
 profiling as a diagnostic   serous low malignant   Biomarkers & ↓High mannosylated 
 biomarker for epithelial   potential tumours, and   Prevention ↓Bisected 
 ovarian cancer   healthy controls    ↓Hybrid 
2014 Discovery of specific Zhang et al. Cell Line SKOV 3 serous ovarian Human MALDI–QIT- PLoS One Cell Line 
 metastasis-related N-glycan   cancer and its high  TOF  ↓Bisected in secretome 
 alterations in epithelial   metastatic derivative    of SKOV 3-ip (highly 
 ovarian cancer based on   SKOV 3-ip    metastatic) 
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Table 2. Continued.        
         
Year Publication Title Author Biological Sample Information Species Mass Spec- Journal Results 
   Sample   trometry   
         
2014 Specific glycosylation of Anugraham et al. Cell Line Serous ovarian cancer Human ESI-QIT Molecular and Cellular Cell Line 
 membrane proteins in   (SKOV 3, IGROV 1,   Proteomics ↑Bisected 
 epithelial ovarian cancer cell   A2780 and OVCAR 3),    ↑α 2–6 Sialylated 
 lines: Glycan structures   and non-cancerous    ↑LacdiNAc 
 reflect gene expression and   ovarian surface epithelial     
 DNA methylation status   (HOSE 6.3, HOSE 17.1)     
2015 Relative quantification and Hecht et al. Plasma Stage I-IV endometriosis, Human ESI-QIT Journal of Proteome N/A 
 higher-order modeling of   benign ovarian tumours,   Research  
 the plasma glycan cancer   cysts, and tubal disease     
 burden ratio in ovarian        
 cancer case-control samples        
2015 Glycomic analysis of Allam et al. Tissue Fresh frozen endometrioid Human ESI-QIT Journal of Proteome Tissue 
 membrane glycoproteins   ovarian cancer, serous   Research ↑Bisected 
 with bisecting glycosylation   ovarian cancer, and     
 from ovarian cancer tissues   normal ovaries     
 reveals novel structures and        
 functions        
2016 N-glycan MALDI imaging Everest-Dass et al. Tissue FFPE stage IIIC serous Human MALDI-TOF Molecular and Cellular Tissue 
 mass spectrometry on   ovarian cancer  and Proteomics ↑High mannosylated 
 formalin-fixed     ESI–QIT   
 paraffin-embedded tissue         
enables the delineation of  
ovarian cancer tissues 
 
2017 The ascites N-glycome of Biskup et al. Ascites Ascitic fluid from primary 
 epithelial ovarian cancer   serous epithelial ovarian 
 patients   cancer versus serum of 
    healthy controls 
2017 Simultaneous analyses of Yang et al. Cell Line OVCAR 3 
 N-linked and O-linked    
 glycans of ovarian cancer    
 cells using solid-phase    
 chemoenzymatic method    
 





Human MALDI-TOF Clinical Proteomics Cell Line  
and ↓High mannosylated in  
ESI-QIT BAG-treated OVCAR  
3 
 
2017 Mass spectrometric profiling Chen et al. Tissue FFPE stage I-III epithelial Human MALDI-TOF Tumor Biology Tissue 
 reveals association of   ovarian cancer and    ↑High mannosylated 
 N-glycan patterns with   normal ovaries    ↑Fucosylated 
 epithelial ovarian cancer        
 progression        
2017 Altered (neo-) lacto series Alam et al. Cell Line IGROV 1 and SKOV 3 Human ESI-QTOF Scientific Reports Cell Line 
 glycolipid biosynthesis       ↓ α 2–6 Sialylated in the 
 impairs α2-6 sialylation on       B3GNT5 mutant 
 N-glycoproteins in ovarian        
 cancer cells        
2017 Tissue glycomics distinguish Anugraham et al. Tissue Fresh frozen serous ovarian Human ESI-QIT Molecular Oncology Tissue 
 tumour sites in women with  and Cell and serous peritoneal    ↑LacdiNAc 
 advanced serous  Line cancer    ↑Bisected 
 adenocarcinoma   IGROV 1, A2780, SKOV 3,    ↑Branched 
    EFO27, and OVCAR 3    ↑ α 2–6 Sialylated 
 
complex fucosylated and sialylated.
[55]
 The high mannose N-
glycans were found to be downregulated in OC serum relative to 
the healthy controls while the complex fucosylated and sialylated 
N-glycans were upregulated. These results generated a sensitivity 
of 97% and a specificity of 98.4% whereas CA125 results showed 
a sensitivity of 97% and a specificity of 88.9%. 
 
The serum of OC and healthy patients had been extensively 
studied between 2007 and 2013, so Biskup et al. investigated the 
N-glycome of serum from early-stage OC patients and benign 
ovarian diseases.
[56]
 The serum was collected from 33 healthy, 20 
benign OC, and 20 OC patients for N-glycan release and analysis 
by MALDI–TOF-MS. A total of 47 N-glycan structures were 
detected with sialylated fucosylated tri- and tetra-antennary 
 
 




N-glycans being highly expressed in early-stage OC compared to 
benign and healthy samples. Alternatively, high mannose N-
glycans were seen to decrease in early-stage OC patients relative 
to benign and healthy samples.  
In 2014, Jae-Han et al. screened the serum of 40 OC patients 
and 40 healthy controls for aberrant N-glycans.
[57]
 MALDI–TOF-
MS analysis provided a multibiomarker panel composed of 15 
peaks which results in an AUC of 0.89, 80–90% sensitivity, and 
70–83% specificity in the training set. This panel was then tested 
against another 23 healthy controls and 37 OC patients, which 
generated 81–84% sensitivity and 83% specificity. The sensitivity 
and specificity of CA125 in these patients were 74% and 78%, 
respectively.  
In 2014, Zhang et al. also used the secretome of the SKOV 3 
cell line and highly metastatic derivative, SKOV 3-ip, to profile 
the N-glycome using a quantitative glycomics approach based on 
a metabolic stable isotope labeling strategy.
[58]
 A total of 17 N-
glycans were identified with bisecting N-glycans being signif-
icantly decreased in the SKOV 3-ip cell lines relative to SKOV  
This observation was further validated by the measurement of 
glycosyltransferase levels using real-time PCR, western blotting, 
transwell assays, lectin blotting, and immunohistochemistry 
analyses. 
In a study by Kim et al., 147 OC and 52 low malignant poten-
tial (LMP) serum samples were processed for N-glycan release 
and analyzed by ESI-chip-TOF-MS.
[59]
 It was concluded that high 
mannose, hybrid, and bisecting N-glycans were decreased on OC 
samples compared to healthy controls.  
In 2015, plasma was studied for the first time in 82 case-control 
samples, with 27% stage I, 12% stage II, 46% stage III, and 15% 
stage IV OC.
[60]
 The released N-glycans were analyzed by 
labeling with hydrazide tags for signal enhancement in LC–ESI–
MS/MS. A total of 71 N-glycans were identified and reduced to 63 
using the following parameters; N-glycans in greater than or equal 
to 90% of spectra and detected above an abundance of 1 × 10
5
. 
The glycan cancer burden ratios (GBRs) were calculated as the log 
ra-tio of specific structure abundance between cancer and control 
patients (i.e., stage I) and they were averaged over each triplicate 
MS injection. Fucosylated and sialylated N-glycans were found to 
be not significant while seven other varying N-glycans were iden-
tified to be significantly different relative to stage I ovarian cancer 
patients.  
Since 2007, the OC serum and plasma N-glycome has ex-
tensively been investigated with common N-glycan families 
showing a similar trend, such as sialylated structures increasing, 
core-fucosylated structures increasing, high mannose structures 
decreasing, and complex/hybrid structures decreasing. While 
studying the entire N-glycome of serum and plasma provides a 
valuable opportunity to potentially discover a novel OC 
biomarker, there is also the possibility this novel biomarker may 






Ascites is localized within the peritoneal cavity that can often 
result in abdominal pain and compromised respiratory, 
gastrointestinal, and urinary systems. This can lead to 
 
further complications, thereby making it difficult to treat OC pa-
tients. At the time of writing this review, there has only ever been 
one MS-based publication that investigates N-glycans derived 
from ascites. N-glycans were released from ascites of 18 epithelial 
OC patients and serum of 20 age-matched healthy controls.
[61]
 
Following MALDI–TOF-MS analysis, it was revealed that the 
ascites N-glycome consisted of increased antennarity, branching, 
sialylation and Lewis
x
 motives relative to the healthy serum. 
Since this is the only documentation of the ascites N-glycome 
so far, there is potential for more studies in the future. Although 
serum, plasma, and ascites fluid are extracted from OC patients 
with minimal invasiveness, there are still limitations, for exam-
ple, storage timeframes must be short due to biomolecular degra-





The first tissue-based study into the N-glycome of OC emerged in 
2015 where a lectin capture strategy coupled to nano-LC–ESI– 
MS/MS was used to isolate and identify N-glycans from mem-
brane glycoproteins.
[62]
 It was concluded that bisecting N-glycans 
were highly abundant in both serous and endometrioid OC tissue 
and this was further validated by amplification of GnT-III mRNA 
expression compared to normal ovarian tissue.  
An investigation into the N-glycome of women with ad-vanced 
serous adenocarcinoma identified α 2–6 sialylated structures in 
both OC and peritoneal cancer, with the ma-jority displaying bi-
antennary mono- and di-sialylation as well as bisecting.
[63]
 PGC–
LC–ESI–MS/MS revealed that Lac-diNAc motifs were unique to 
serous OC only and correlated with the elevated gene expression 
of the glycosyltransferases, B4GALNT3 and B4GALNT4, in 
patients. A total of 13 N-glycans were found to be significantly 
discriminatory between tumor sites with LacdiNAc, bisecting, and 
branched N-glycans being upregulated. 
 
More recently, N-glycosylation patterns of OC tissue, with dif-
ferent pathological grades, and healthy controls were studied.
[64]
 
A total of 80 N-glycan compositions were detected with high man-
nose N-glycans found to be elevated in the OC samples, whilst 
hybrid N-glycans were reduced, relative to the healthy controls. 
Receiver operating characteristic (ROC) analysis showed that 
combining four high mannose and three fucosylated complex 
neutral N-glycans provided good discrimination between cancer 
and noncancer samples. In addition, it was discovered that two 
high mannose, two fucosylated and sialylated, and ten fucosy-
lated complex neutral N-glycans change abundance across differ-
ent OC grades.  
While applicable to multiple OC sample types, including serum, 
plasma, ascites, and tissue, LC–ESI–MS and MALDI– TOF-MS 
have limitations with respect to glycoprotein and glycan 
distribution, as spatial information is removed through tissue 
disruption. This is of interest for disease classification using 
changes in molecular information with tissue morphology, and in 
particular, surgical pathology annotations. To address this ana-
lytical shortfall, MALDI–MSI is a relatively new spatially 
sensitive technique that directly analyzes analytes across tissue 
sections, including proteins and released N-glycans. 
 
 




6. Mass Spectrometry Imaging 
 
MSI typically employs a MALDI–TOF-MS instrument for 
acquisition of mass spectra in a 2D grid across tissue sections (see 
Figure 2).
[65]
 This allows visualization of the tissue-specific 
spatial distribution of the measured analytes (i.e., intact proteins, 
peptides, lipids, metabolites, small molecules, and N-glycans) 
across multiple samples at the same time (e.g., tissue micro-
arrays). Compared with conventional immunohistochemistry 
(IHC), hundreds of molecules and multiple molecule classes can 




Many MSI studies utilize fresh frozen tissue samples. Most of 
these studies used small sample numbers due to the expense and 
difficulty of maintaining large native tissue archives for long 
periods of time. To address low sample numbers, multiple groups 
are turning to archival storage forms such as formalin-fixed 





































Figure 2. A conventional MALDI–TOF-MS imaging workflow for FFPE tis-sue 
sections. Briefly, FFPE tissue is sectioned onto indium tin oxide (ITO)-coated 
slides, treated with citric acid antigen retrieval (CAAR) and digested with an 
enzyme, depending on the analyte of interest. Next, calibrants are applied 
and matrix is deposited across the tissue section. Then, mass spectra are 
acquired in a two-dimensional array using a YAG pulse laser from a MALDI–
TOF-MS instrument. Lastly, the data is analyzed using software such as 
flexImaging (Bruker Daltonics) or SCiLS Lab (Bruker Daltonics) by overlaying 
the annotated histological stained image. 
www.clinical.proteomics-journal.com  
 
thousands of FFPE tissue samples, from healthy and diseased 
individuals, are stored in large repositories world-wide.
[67]
 These 
FFPE tissue samples are annotated with clinical information such 
as patient diagnosis, treatment, and outcome. The formalin-
fixation process conserves tissue samples by cross-linking 
proteins.
[68]
 As a result, FFPE tissues can be stored under ambient 
conditions for long periods of time.  
ESI and MALDI are complementary soft ionization tech-
niques, such that some analytes have preferential ionization in one 
or the other. For released glycans, ionization efficiency and thus 
detection relies on the composition, which affects ionization 
efficiency depending on the MS mode of analysis (i.e., positive ion 
or negative ion mode). Furthermore, ESI- and MALDI–MS 
platforms offer different analyte fragmentation mechanisms, 
affecting the ability for connectivity evaluation of glycopeptides 
and/or released glycans. As such, comprehensive N-glycome 
characterization typically requires a combined MS strategy, ex-
ploiting ESI– and MALDI–MS platforms. However, maintaining 
spatial distribution of N-glycans improves the ease of correlation 
with tissue morphology and IHC to better understand the mech-
anisms behind OC progression. 
Our group recently published the first application of an N-
glycan MALDI–MSI method to FFPE OC tissue.
[69]
 The tissue 
analyzed in this study had been annotated by a pathologist, and it 
was found that specific N-glycan structures were differentially 
detected in specific tissue regions, such as tumor, stroma, adi-
pose, and necrotic tissue (see Figure 3). Analysis of stage III OC 
tissues resulted in the discovery of high mannose structures 
relatively abundant in the tumor regions, while tri-antennary 
complex structures in the cancer-associated stromal regions. This 
observation was consistent between not only the three patients 
investigated, but also between previous publications from the 
literature.  
We also compared early-stage (see Figure 4, Panels A, B and 
C) and late-stage (see Figure 4, Panels D, E and F) serous OC 
tissue sections by applying N-glycan MALDI– MSI and laser 
capture microdissecting (LCM) tumor-specific regions for PGC–
LC–ESI–MS/MS analysis. A total of 14 N-glycans were 
visualized as ion intensity maps by MALDI–MSI whereas 42 N-
glycans (including structural and compositional isomers) were 
identified and structurally characterized in the LCM tissue 
sections by ESI. The spatial distribution of high man-nose, 
complex neutral, bisecting (see Figure 4) and sialylated N-glycan 
families were only observed to be localized to the tumor regions 
of late-stage OC patients relative to early-stage patients. Potential 
N-glycans diagnostic markers that emerged include the high 
mannose structure, (Hex)6 + (Man)3(GlcNAc)2, the bisecting 
structure, (Hex)1 (HexNAc)3 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2, and the sialylated structure, (Hex)2 (HexNAc)2 
(NeuAc)1 + (Man)3(GlcNAc)2.  
In Figure 4 Panel I, the Z1 ion at m/z 350.11 and the Y2 ion at 
m/z 571.16 from the MS/MS fragmentation provide evidence for 
the presence of the chitobiose core fucose. Another diagnostic ion 
of significant importance is the D-ion. The D-ion arises from the 
loss of the chitobiose core (C ion cleavage between Manβ 1– 
4GlcNAc), and the Z ion cleavage between Manα1–3Man form-
ing the 3-antennae; thus, the D-ion mass corresponds to the 
composition of the six-arm antenna plus the two remaining 
branching core mannoses.
[70]
 Furthermore, the D and [D–18] ions 
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Figure 3. Glycan analysis of ovarian cancer (OC). The formalin-fixed paraffin-embedded stage III OC section was treated with antigen 
retrieval prior to printing of 15 nL per spot dialyzed PNGase F with 250 μm spacing. 2,5-DHB (20 mg/mL) was sprayed onto the sections 
and MS spectra were acquired by oversampling at 100 μm intervals using a MALDI-TOF/TOF MS instrument. A) Hematoxylin and eosin 
stain of the OC section with tumour (red), stroma (green), and adipose (blue) regions annotated by a pathologist. B) An ion intensity map of 
m/z 1743.7 (red), m/z 2174.9 (green), and m/z 933.3 (blue) on the OC section. Yellow circle, galactose (Gal); green circle, mannose (Man); 
blue square, N-acetylglucosamine (GlcNAc); red triangle, fucose (Fuc). 
 
have been used to identify the composition of the N-glycan 6-
antenna. If the N-glycan has a bisecting GlcNAc residue, the ad-
ditional loss of this bisecting β 1–4-linked GlcNAc gives rise to 
the D–221 ion. Figure 4 Panel I shows the MS/MS fragmentation 
contains the D–221 ion corresponding to m/z 507.88.  
In summary, all publications focusing on OC tissue found a 
relative increase in high mannose, bisecting, fucosylated, Lac-
diNAc, and α 2–6 sialylated N-glycans. The normal N-glycan 
biosynthetic pathway in the ER and Golgi membranes involves 
mannosidases cleaving mannose residues to only three mannose 
residues. However, it has been found, that on the tumor cell sur-
face and on secreted glycoproteins, there are complex high man-
nose structures with more than three mannose residues. It has also 
been discovered that there are auto-antibodies specific to high 
mannose structures within the sera from cancer and other diseased 
patients, although it is unclear why high mannose structures are 




7. Translating Analytical Applications to 
Clinical Strategies: The Current Challenges 
 
Based on the analytical information collated for this review, it is 
evident that there are several limitations with analytical applica-
tions focused on MS alone. Therefore, to tackle this caveat, recent 
studies have incorporated other well-established techniques with 
MS to further understand the biological mechanisms behind OC 
progression and search for clinically relevant biomarkers. Such 
approaches include the use of antibodies and lectins to spatially 
visualize N-glycans in situ, molecular biology to correlate gene 
expression levels with specific N-glycan structures, and glycopro-
teomics to obtain site-specific information. 
 
7.1. Antibodies and Lectins 
 
Specific lectins and anti-carbohydrate antibodies are routinely 
used to evaluate the spatial localization of N-glycans and other 
carbohydrates in situ. For example, the carbohydrate antigen 
CA19-9 is measured in the clinic to determine the prognosis of 
pancreatic and other gastrointestinal cancers.
[71]
 The CA19-9 an-
tibody used recognizes a distinct carbohydrate motif (GlcNAc-
Gal, α 1,4 fucose, and α 2,3 sialic acid).
[72]
 Another antigen, F77 
for prostate cancer, has also been previously described in the 
literature.
[73]
 The corresponding antibody for F77 recognizes the 
blood group H antigen-related Lewis Y glycan structures with α 
1,2 fucose. It is established that most antibodies for carbohydrate 
detection are required to recognize between one and four 
structural epitopes (i.e., portion of the glycan that forms the 
binding region).
[38]
 Using such antibodies are quite useful for 
tissue IHC-based staining methods, however, these methods 
cannot distinguish between the types of glycan classes (i.e., 
glycolipids, O-glycans, and N-glycans).
[74]
 Alternatively, lectins 
or carbohydrate-binding proteins (CBPs) for many decades have 
evaluated glycoproteins and their structural features.
[74]
 In a simi-
lar way to antibodies for carbohydrate antigens, lectins recognize 
between two and four structural epitopes. However, lectins pos-
sess poor affinity-binding constants in the low micromolar range, 
which limits the tissue histochemistry applications mentioned 
previously.
[75]
 Lectin histochemistry applications have been 
successfully established to analyze FFPE tissue.
[76]
 Again, it has 
been described as difficult to distinguish between the presenting 
conjugate since the recognizable glycan motif is often the same 
between N- and O-glycans. Hence, MALDI–MSI is an important 
tool that provides not only spatial information, but also some 
specific N-glycan structural features. However, there is potential 
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Figure 4. N-glycan MALDI–MSI of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 μm spacing. DHB matrix was 
sprayed onto the sections and MS spectra were acquired by oversampling at 100 μm intervals using a MALDI–TOF/TOF-MS instrument. 
Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) adducts for MALDI–MSI whereas PGC–LC–
ESI–MS/MS revealed doubly negatively charged monoisotopic masses ([M – 2H]2−). Panels A-F show ion intensity maps of m/z 16663.581 
from the stage I (green) and stage III (red) patients. The N-glycan, (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2, in panel (G) is 
the confirmed structure based on PGC chromatography (panel H) and MS/MS fragmentation (panel I). 
 
or lectin histochemistry applications, as well as MALDI–MSI, to 
rapidly visualize the spatial localization of specific glycan motifs. 
 
7.2. Molecular Biology 
 
A combination of MS with molecular biology has recently pro-
vided further insight into aberrant N-glycosylation patterns. Many 
of these studies have utilized glyco-gene editing in mammalian 
cell lines combined with high-throughput MS ap-proaches. Our 
most recent MS data has demonstrated that complex neutral and 
fucosylated N-glycans are highly intense in tissue from late-stage 
patients relative to early-stage (data not shown). These complex 
N-glycans are derived from the core N-glycan structure, utilizing 
glycosyltransferases to add 
 
monosaccharide subunits such as N-acetylglucosamine, galac-
tose, fucose, and sialic acid.
[77]
 Additionally, these complex N-
glycans are often observed in nontumor (i.e., cancer-associated 
stroma) regions. For example, bisecting structures primarily ex-
pressed in tumor regions of tissue derived from late-stage patients 
and also various OC cell lines.
[43,62,69]
 This observation is 
consistent with glyco-gene studies on GnT-III activity, which is 
the glycosyltransferase responsible for attaching a GlcNAc 
monosaccharide in the β 1,4 linkage at the β -mannose of the 
mannosyl core. Bisecting structures have been found to suppress 
the further processing of N-glycans catalyzed by GnT-V, which is 
the glycotransferase responsible for β 1,6 branching. OC tissues 
have be found to have much higher levels of GnT-III compared to 
normal ovarian and fallopian tube tissues while other cancers have 
been found to have lower levels of GnT-III 
 
 




than their respective normal tissues.
[20]
 With all of this infor-
mation considered, bisecting N-glycan structures could poten-
tially be highly specific and sensitive OC biomarkers. This is yet 





Glycoproteomics focuses on the analysis of glycosylated proteins 
(i.e., glycoproteins) from cells, tissue, or bodily fluid using MS 
techniques.
[78]
 Despite recent advances with respect to sample 
preparation and next-generation MS platforms, glycoproteomic 
analysis is quite difficult due to both instrument and method 
limitations.
[79]
 However, this type of analysis provides both gly-
can composition and modification site information, which is ul-
timately a key to understanding the role of specific glycosylations 
in disease.  
In addition to combining MS with other established tech-
niques, there are several other recent advancements that exist for 
clinical-based approaches. There has been a shift toward utilizing 
high-throughput platforms to analyze ‘omics’ data from large 
patient cohorts.
[80]
 Utilizing these cohorts is an important process 
in first identifying novel biomarkers, and second validating these 
potential biomarkers on the long road to the clinic. Another recent 
advancement into glycoconjugate research has emerged from 
investigating circulating exosomes from pancreatic cancer.
[81]
 
Proteoglycan glypican 1 (GPC1) was identified from circulating 
pancreatic cancer exosomes and contributed to early detection of 
this cancer. Therefore, this is a potential area for growth in OC 
research and the journey to better understand OC progression. 
Tumor-associated glycan antigens have also emerged as a 
potential application for early-stage detection of cancer. For 
example, specific auto-antibodies against aberrantly glycosylated 
MUC1 correlate with the detection of colorectal cancer, predicting 
this cancer with 95% specificity.
[82]
 However, other markers are 
still required in combination with this identified marker due to low 
sensitivity issues, therefore suggesting an array of antibodies may 
be required to detect cancer in its early stages. This approach has 
opened new avenues for investigating cancer-associated N-glycans 
and glycopeptides through microarray studies with the potential to 





8. Conclusions and Future Directions 
 
The glycomics field has immensely evolved over the past decade. 
Both technological and methodical advancements have emerged, 
with more recently MALDI–MSI being used as a platform to 
measure the spatial distribution of N-glycans on OC tissue sec-
tions. OC has shown to exhibit aberrant N-glycosylation patterns 
through the analysis of serum, plasma, cell line, and tissue sam-
ples. The recent advances in MALDI–MSI provides a rapid and 
robust platform to spatially study tissue sections, however, the 
current workflow fails to spatially identify isomeric structures of 
the same composition, although derivatization methods have re-
cently emerged to distinguish between α 2–3 and α 2–6 sialic acid 
linkages by MALDI. MALDI–MSI method development is still in 
 
its infancy with multiple facets requiring attention, such as N-
glycan detection in the higher mass range, the identification of 
isomeric structures, analysis of O-linked glycan structures, and 
increased MALDI resolution and sensitivity. With caveats in the 
field set to be addressed over the next decade, there is a potential 
to discover novel biomarkers for OC early-detection, prediction, 
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1.3 | Aims 
 
This PhD project aimed to further develop our established N-glycan MALDI mass spectrometry imaging 
workflow for other FFPE tissues, such as knee osteoarthritis, wherethere is difficulty with adherence to 
slides. Modifying this method also allowed us to investigate the N-glycosylation patterns of cartilage 
and bone marrow, which previously had not been characterised, in order to obtain a better 
understanding of disease progression.  
 
Furthermore, this PhD project aimed to investigate the ovarian cancer N-glycome through spatially 
mapping FFPE tissue sections from both early- and late-stage patients. Using MALDI-MSI, it was 
possible to compare intrapatient regions, such as tumour, stroma, adipose and necrotic regions, from 
late-stage ovarian cancer tissue sections, and interpatient regions, such as tumour regions, from early- 
and late-stage ovarian cancer tissue sections.    
 
To summarise, this thesis aimed to:  
 
1 | Develop N-glycan MALDI mass spectrometry imaging for FFPE knee osteoarthritis tissue. 
2 | Investigate the intrapatient variation of late-stage ovarian cancer tissues using N-glycan 
MALDI mass spectrometry imaging. 
3 | Investigate the interpatient variation of early- and late-stage ovarian cancer tissues using  
N-glycan MALDI mass spectrometry imaging. 
 
Long-term, this PhD project aims to discover potential diagnositic or prognostic markers which will 
improve stratification strategies and effective regimens for ovarian cancer patients.  
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2.1 | Summary 
 
Our group was the first group to combine complimentary mass spectrometry (MS) techniques to both 
spatially map and comprehensively characterise the N-glycome. We assigned N-glycan structures, 
confirmed by PGC-LC-ESI-MS/MS, to tissue-specific regions of FFPE murine kidney that were 
visualised by MALDI-MSI. For example, the oligomannose N-glycan (Hex)6 + (Man)3(GlcNAc)2 was 
observed in the medulla region while the fucosylated complex N-glycan 
(Hex)2(HexNAc)3(Deoxyhexose)3 + (Man)3(GlcNAc)2 was observed in the cortex region. More recently, 
this workflow was applied to FFPE tissue sections from late-stage ovarian cancer patients and then 
published as a protocol paper in Rapid Communications in Mass Spectrometry. This chapter presents 
this protocol paper and provides a step-by-step guide to its readers on how to establish our N-glycan 
MALDI-MSI workflow in their laboratory. 
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RATIONALE: Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) of the proteome of a tissue 
has been an established technique for the past decade. In the last few years, MALDI-MSI of the N-glycome has emerged as a novel 
MALDI-MSI technique. To assess the accuracy and clinical significance of the N-linked glycan spatial distribution, we have 
developed a method that utilises MALDI-MSI followed by liquid chromatography coupled to tandem mass spectrometry 
(LC/MS/MS) in order to assign glycan structures to the differentiating MALDI-MSI glycan masses released from the tissue 
glycoproteins.  
METHODS AND RESULTS: Our workflow presents a comprehensive list of instructions on how to (i) apply MALDI-MSI to 
spatially map the N-glycome across formalin-fixed paraffin-embedded (FFPE) clinical samples, (ii) structurally characterise N-
glycans extracted from consecutive FFPE tissue sections by LC/MS/MS, and (iii) match relevant N-glycan masses from MALDI-
MSI with confirmed N-glycan structures determined by LC/MS/MS. 
CONCLUSIONS: Our protocol provides groups that are new to this technique with instructions how to establish N-glycan MALDI-
MSI in their laboratory. Furthermore, the method assigns N-glycan structural detail to the masses obtained in the MALDI-MS 





Cells form tissues via a variety of highly specific and distinctive 
cell adhesion mechanisms typically involving adhesion receptors, 
cell-extracellular matrix (ECM) proteins and cytoplasmic 
peripheral membrane proteins. Cell adhesion receptors comprise 
transmembrane proteins which are glycosylated, specifically N-
linked glycosylated. N-Glycosylation is the principal chemical 
modification that involves a series of catalytic processes where 
carbohydrates (i.e. glycans) are attached to proteins. The 
biosynthesis of glycoproteins is not guided by a template as is 
DNA, RNA and protein synthesis, and as such is a factor 
contributing to the enormous complexity of the N-glycoproteome. 
It is referred to as N-linked glycosylation because the addition of 
N-linked glycans occurs on the asparagine residue in the tripeptide 
sequence of Asn-X-Serine/Threonine (Ser/Thr) (where X is any 
amino acid except Pro),
[1]
 and, in a small number of cases, N-
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on peptides with Asn-X-Cysteine (Cys) sequons.
[2–5] The 
biosynthesis of N-linked glycans begins in the rough ER with a 
dolichol phosphate-activated sugar as precursor and, in a 
sequential manner, a structure containing two N-
acetylglucosamine (GlcNAc), nine mannose (Man) and three 
glucose (Glc) (Glc3Man9GlcNAc2) is synthesised and 
subsequently transferred to a growing polypeptide chain in both 
prokaryotes and eukaryotes. From the ER into the Golgi apparatus 
and then to the cytoplasm, the N-linked glycans in vertebrates 
undergo processes such as trimming of the terminal 
monosaccharide residues and re-glycosylation with fucose (Fuc), 
sialic acid (SA), N-acetylglucosamine (GlcNAc) and galactose 
(Gal). The unique and specific structures of N-linked glycans play 
important roles in regulating signal transduction and cell functions 
such as growth, migration, differentiation and tumour 
progression.
[6,7]
 They have been increasingly considered as cancer 
biomarkers for early detection and disease prognosis since the 
altered glycan structures produced have been found to adversely 
affect cell adhesion, migration and tumour invasion.
[7–9] For 
example, in colorectal carcinoma an α-2,6-sialylated galactose 
epitope on carcinoembryonic antigen (CEA) is abundant 




















































































 An increase in α-2,6-sialylation in colorectal 
carcinoma is usually a consequence of increase in α-2,6-
sialytransferase activity.
[12]
 In other malignancies such as ovarian 
cancer, N-linked glycans are of particular interest because 
structural alterations have been observed in the tumour 
microenvironment that promote tumour invasion and metastasis. 
Two sialylated isomeric structures of glycans, where the terminal 
galactose residues of core fucosylated biantennary N-glycans with 
either a α-2,6 or α-2,3 sialic acid (N-acetylneuraminic acid, 
Neu5Ac) linked to either arm, were identified to be quantitatively 
different between cancerous and benign ovarian cell lines.
[13]
 
Interestingly, the α-2,6-linked sialic acids were exclusive to the 
ovarian cancer cell glycoproteins.
[13]
 This α-2,6-sialylated 
structure of N-glycans specific to ovarian cancer could be used to 
delineate cancerous from benign cells as a potential specific 
biomarker for ovarian cancer cells in tissue.  
 
Structural analysis of N-glycans released from glycoproteins is 
a well-established method, routinely used to identify and 
distinguish glycan isomers. Enzymatic release of the N-glycans 
from the protein is achieved using a commercially available 
enzyme PNGase F.
[14]
 This enzyme selectively cleaves the 
reducing end of GlcNAc, high mannose, hybrid and complex 
asparagine-linked oligosaccharides when attached to an asparagine 
residue on a polypeptide that is at least three amino acids 
long.
[15,16]
 PNGase F will also cleave asparagine-linked 
oligosaccharides when there is an α-1,6-fucose attached on the 
GlcNAc residue directly linked to the asparagine residue. 
However, PNGaseF cannot cleave asparagine-linked 
oligosaccharides containing an α-1,3-fucose substituent attached 
to the GlcNAc residue that is directly linked to the asparagine 
residue
[17]




Formalin-fixed paraffin-embedded (FFPE) tissue samples have 
been shown to be suitable for studying the spatial distribution of 
proteins in a variety of diseases. It has been shown that other 
molecules, such as N-glycans, can be extracted from these 
archived tissues without expiration date. Matrix-assisted laser 
desorption/ionization mass spectrometry imaging (MALDI-MSI) 
thus has the ability to measure the in situ spatial distribution of 
analytes, such as N-glycans. However, limited methods exist for 
N-glycan MALDI-MSI on FFPE tissues. MALDI-MSI data is also 
limited as there is not enough detail to elucidate structural 
isomers. Therefore, LC/MS/MS is incorporated in our method to 
characterise the N-glycan isomers observed in the MALDI-MSI 
data. 
 
Liquid chromatography coupled to tandem mass spectrometry 
(LC/MS/MS) has evolved to be a powerful tool in characterising 
glycan structures. In this methodology, glycans are released from 
the glycoproteins and separated by chromatography using porous 
graphitised carbon (PGC) that offers extra retention of hydrophilic 
analytes such as glycans compared with reversed-phase 
chromatography. Glycans with sialic acid have substantially 
stronger retention on PGC than neutral N-linked glycans. N-
Linked glycans are synthesised as mixtures of isobaric isomers 
and determination of the exact structure of the N-glycans is crucial 
in characterising the unique function of glycans. This structural 
elucidation of glycans requires the determination of 
monosaccharide sequence, linkage type between monosaccharide 
residues and their anomeric configuration.  
M. T. Briggs et al. 
 
The use of high-performance liquid chromatography (HPLC) and 
MS is increasingly popular in obtaining structural information 
from underivatised released glycan samples.
[14,19–21] Both 
electrospray ionization mass spectrometry (ESI-MS) and MALDI-
MS are commonly used to characterise the glycans enzymatically 
cleaved from glycoprotein samples. MALDI-MS of permethylated 
glycans is also used for detecting glycans in the higher mass range 
and has higher tolerance to contaminants.
[22,23]
 
Permethylation is a chemical reaction replacing hydrogens on 
hydroxyl groups, amine groups and carboxyl groups with methyl 
groups. This process has shown to enhance ionisation efficiency 
by up to 20-fold.
[24,25]
 With tandem mass spectrometry, not only 
can the cleavage of glycosidic bonds be observed, but the cross-
ring cleavages at the monosaccharide linkages can also be 
assigned, which is extremely useful for the structural 
characterisation of oligosaccharides.
[26]
 LC/MALDI-MS is 
possible whereby the glycan sample is separated by HPLC and 
then spotted directly onto the MALDI target plate. In LC/MS/MS, 
glycan samples can be directly loaded onto the PGC column and 
eluted for identification and detailed structural characterisation. 
The reducing end of cleaved glycans, i.e. the GlcNAc residue of 
released N-glycans, is readily reduced with sodium borohydride 
under alkaline conditions to remove separation of the reducing end 
alpha and beta structural glycan isomers on PGC-HPLC that 
complicate analysis. Reducing the N-glycans after release from the 
proteins also prevents degradative peeling reactions and provides a 
way to ’tag’ the reducing end of oligosaccharides simultaneously. 
 
 
Combining MALDI-MSI and subsequent LC/MS/MS using 
PGC chromatography has been successfully applied not only for 
the identifications of glycans from FFPE tissue of murine kidney, 
osteoarthritis and ovarian cancer tissue, but also the location and 
distribution of these glycans on tissue sections.
[27–30] It was found 
that high mannose glycans were significantly abundant in the 
tumour region whereas complex bi-antennary and tri-antennary 
were predominantly in the stromal region of ovarian cancer. This 
technique has clearly demonstrated the potential of obtaining 
glycan spatial information and structural identity from FFPE tissue 
samples in biomarker discovery experiments. 
 
 
Here, we provide a detailed protocol for MALDI-MSI followed 
by LC/MS/MS structural determination of N-glycan masses 
released from glycoproteins in FFPE tissue sections, based on 
optimised methods from our proof-of-principle papers.
[19,27]
 The 
protocols can also be applied in the reverse direction where the 
LC/MS/MS analysis of the released glycans from microdissected 
regions of the FFPE tissue sections can provide the differentiating 
structure-specific glycan masses on which targeted MALDI-MSI 
experiments can be based. The advantages of these protocols are 
easy sample handling, excellent reproducibility, the ability to 
demonstrate glycan molecular spatial distributions in situ, 
assignment of glycan structure(s) to mass and compatibility with 
high-throughput image analysis. It is expected that these 
approaches can rapidly be used to validate, and eventually replace, 
the traditional human-skills-based assessment of haematoxylin and 
eosin (H&E)-stained FFPE pathology slides. 
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Chemicals, consumables and equipment 
 
See Table 1 for a comprehensive list of chemicals, consumables 
and equipment used in this protocol. 
 
1. PROTOCOL-SPECIFIC SOLUTIONS 
 
1.1. Tissue collection 
 
The tissue is fixed in 4% (v/v) neutral-buffered formalin (Sigma-
Aldrich) at room temperature, processed with an automatic 
processor and embedded in paraffin wax. Fixation in formalin 
usually takes between 12 and 24 h depending on the tissue size. 
Formalin penetrates tissue at a rate of approximately 1 mm/h.
[31]
 
FFPE tissue can be stored at room temperature. 
 
 
1.2. Xylene and ethanol solutions 
 
Set up four glass Coplin jars (EMS), two with 100% (v/v) xylene 
(Merck, Australia) and two with 100% (v/v) ethanol (EtOH, 
Merck, Australia). Prepare these solutions fresh before the start of 
the experiment and discard them in waste at the end so that there 
is no contamination. 
 
1.3. 10 mM Ammonium bicarbonate solution 
 
Weigh out 0.3953 g of ammonium bicarbonate (NH4CO3, Merck, 
UK) to make 100 mM in a 50-mL Falcon tube (Corning). To make 
10 mM ammonium bicarbonate, take 50 mL of this 100 mM 
solution and add 450 mL of water. 
 
1.4. 10 mM Citric acid monohydrate solution 
 
Weigh out 1.05 g of citric acid (Sigma-Aldrich, Japan) into a 500-
mL measuring cylinder and add 480 mL water. Add a magnetic 
stirrer and stir while adding 12 mL of 1 M sodium hydroxide 
(NaOH, Merck, Germany). Then, measure the pH and add enough 
1 M NaOH to reach pH 6.0. Make up the volume to 500 mL with 
water to make the 10 mM solution. 
 
1.5. Calibration solution 
 
Dilute the three N-glycan standards (see Table 2) to 1 pmol/μL 
and mix together in a 0.5-mL microcentrifuge tube. Store the 
aliquots in a freezer at –80°C. 
 
1.6. Matrix solution 
 
To prepare 20 mg/mL of 2,5-dihydroxybenzoic acid (DHB, 
Sigma-Aldrich, USA) in 1 mM sodium chloride (NaCl, Merck, 
Germany) and 0.1% (v/v) trifluoroacetic acid (TFA, Merck, 
Germany) matrix solution, first make 100 mM NaCl and 10% 
(v/v) TFA in 1.5-mL microcentrifuge tubes. Then, weigh out 100 
mg of DHB to make 5 mL of matrix solution in a 15-mL Falcon 
tube and add water. Sonicate the solution for 30 min. Following 
sonication, add 1:100 dilution of 100 mM NaCl and 10% (v/v) 
TFA solutions made previously. 
 
Figure 1 shows a workflow of N-glycan MALDI-MSI on FFPE 
tissues. Our group uses the Chemical Inkjet Printer (ChIP-1000, 




Technologies) to apply PNGase F and DHB matrix, respectively. 
If alternative instruments are used, such as the ImagePrep (Bruker 
Daltonics) and SunCollect (SunChrom, Friedrichsdorf, Germany), 
the conditions need to be further tested and optimised. If a 
commercially available PNGase F is used, the ChIP-1000 is 
preferred as it requires lower loading volumes of the enzyme, and 
this is more cost-effective.  
 
 
2. FFPE TISSUE SECTIONING 
 
2.1. Fill the water bath (Leica HistoBath HI1210, Leica 
Instruments) with water and set the temperature to 39°C. 
 
• Do not set the temperature of the water too high or the paraffin 
will melt, thus making it more difficult to mount the tissue 
sections. 
 
2.2. Place the FFPE block onto the Microtome (Microm HM325, 
Zeiss) and adjust the angle of the holder appropriately. The 
microtome blade should be positioned parallel with the FFPE 
block. 
 
2.3. Clean a microtome blade (35 × 80 mm, Feather Safety Razor 
Co.) with methanol and insert it into the holder. 
 
2.4. Adjust the tissue thickness to between 4 and 10 μm and start 
sectioning. 
 
• Tissue thickness is dependent on the FFPE sample and the 
experiment. Our group has selected an optimised thickness of 
6 μm. 
 
2.5. Mount the tissue sections in the water bath onto indium tin 
oxide (ITO)-coated conductive slides (Bruker Daltonics) or PEN 
membrane slides (MicroDissect) by guiding the slides 
underneath the tissue sections and lifting upwards. 
 
• Make sure to mount the tissue sections in one smooth motion in 
order to prevent any folds or air bubbles forming. 
 
 
2.6. Tap the slides gently in a vertical, upright position onto lint-
free wipes. 
 
2.7. Place the slides into a container inside a 37°C room for  
1 h. 
 
2.8. Store the slides at 4°C until use. 
 
 
3. FFPE TISSUE SAMPLE PREPARATION 
 
3.1. Lay the ITO-coated conductive slides, with the tissue facing 
up, on a heating block at 60°C for 1 h.   
• Heating melts the paraffin, thereby improving tissue adherence 
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Table 1. List of chemicals, consumables, calibrants and equipment required for the workflow that is outlined in this publication 
 
 
Chemicals and consumables  Company  Product code 
    
2,5-Dihydroxybenzoic acid (DHB)  Sigma-Aldrich (St. Louis, MO, USA) Cat. No. 149357 – 10 g 
Ammonium bicarbonate (NH4HCO3)  Merck (Poole, UK)  Cat. No. 103025E – 1 kg 
Ammonium acetate (NH4CH3CO2)  Merck (Darmstadt, Germany)  Cat. No. 1.01116.0500 
Cation exchange resin (AG 50 W X8)  Bio-Rad (Hercules, CA, USA)  Cat. No. 142-1431 
Citric acid monohydrate  Sigma-Aldrich (Tokyo, Japan)  Cat. No. C0706 – 500 g 
Ethanol (EtOH)  Merck (Frenchs Forest, NSW, Australia) Cat. No. 4.10230.2511 
Eosin Y  ProSciTech (Kirwan, QLD, Australia) Cat. No. C0971 
Formalin solution, neutral buffered (10%) Sigma-Aldrich (Darmstadt, Germany) Cat. No. HT501128-4L 
Glacial acetic acid  Merck (Germany)  Cat. No. 1.0063.2511 
32% Hydrochloric acid (HCl)  Merck (Germany)  Cat. No. 1.00319.2511 
Isopropanol  Merck (Germany)  Cat. No. 1.01040.2500 
Mayer’s haematoxylin  ProSciTech (Australia)  Cat. No. AMH-500 
Methanol (MeOH)  Merck (Germany)  Cat. No. 1.06018.2500 
Peptide-N-glycosidase F (PNGase F,  New England Biolabs (Hitchin, UK) Cat. No. P0705L 
glycerol-free, 75, 000 units)     
Peptide-N-glycosidase F (PNGase F)  Roche (Mannheim, Germany)  Cat. No. 11365185001) 
Potassium hydroxide (KOH)  Sigma-Aldrich (USA  Cat. No. 484016 – 1 kg 
Sodium borohydride (NaBH4)  Sigma-Aldrich (USA)  Cat. No. 1001430785 
Sodium chloride (NaCl)  Merck (Germany)  Cat. No. 1.06404.0500 – 500 g 
Sodium hydroxide (NaOH)  Merck (Germany)  Cat. No. 1.06498.0500 
Trifluoroacetic acid (TFA)  Merck (Germany)  Cat. No. 1.08262.0100 
Water (H2O, ultrapure, ≥18.2 MΩ  Barnstead International  Cat. No. D11951 
from Barnstead purifier)  (Dubuque, IA, USA)   
Water-soluble Tipp-Ex  BIC (Eschborn, Germany)  Cat. No. 8806821 
Xylene  Merck (Australia)  Cat. No. 1.08681.2500 
     
     
Equipment   Company  
    
CanoScan 5600 F  Canon (Taipei, Taiwan)  
Chemical inkjet printer (ChIP-1000)  Shimadzu (Kyoto, Japan)  
Falcon tubes (15 mL)  Corning (Nueva Leon, Mexico) 
Falcon tubes (50 mL)  Corning (Mexico)  
Fume hood  Air Science (Fort Myers, FL, USA) 
Glass Coplin staining jars  EMS (Hatfield, PA, USA)  
Glass rectangular staining dishes  EMS (USA)   
HTX TM-Sprayer  HTX Technologies, LLC  
  (Chapel Hill, NC, USA)  
Indium tin oxide (ITO)-coated  Bruker Daltonics (Bremen, Germany) 
conductive slides     
Kimwipes  Kimtech (Milsons Point, Australia) 
Leica AS LCM microscope  Leica Instruments (Wetzlar, Germany) 
Leica HistoBath HI1210  Leica Instruments (Germany) 
Mass spectrometer  Bruker Daltonics (Germany)  
(e.g. ultrafleXtreme)     
Mass spectrometric data acquisition software Bruker Daltonics (Germany)  
(e.g. flexControl     
and flexImaging)     
Mass spectrometric data analysis software Bruker Daltonics (Germany)  
(e.g. flexImaging or SCiLS Lab)     
Microcentrifuge tubes  Eppendorf (Macquarie Park,  
(safe-lock tubes, 0.5 mL)  NSW, Australia)  
Microcentrifuge tubes  Eppendorf (Australia)  
(safe-lock tubes, 1.5 mL)     
Microm HM325 microtome  Zeiss (Oberkochen, Germany) 
MTP slide adaptor II  Bruker Daltonics (Germany)  
NanoZoomer automated microscope  Hamamatsu (Beijing, China)  
Nitrocellulose dialysis membrane  Millipore (Bayswater, VIC, Australia) 
(0.025 μm)     
    (Continues) 
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OSV Pack Assay (50) Shimadzu (Japan) 
PEN membrane slides MicroDissect (Herborn, Germany) 
Personal protective wear (e.g. gloves) MicroFlex (Malaysia) 
Piezo assay Shimadzu (Japan) 
SpeedVac concentrator Savant SVC 100 (Thermo Scientific, 
 Waltham, MA, USA) 
Stainless steel cryotome Feather Safety Razor Co. 
blades (35 × 80 mm) (Osaka, Japan) 
Temperature-controlled water bath Scientific Equipment Manufacturers 
 (Thebarton, SA, Australia) 
UFLC XR (LC pump) Shimadzu (Japan) 




3.2. Set a water bath to 70°C. 
 
3.3. Wash the slides with 100% xylene twice for 5 min to remove 
the paraffin. Place the slides vertically in the Coplin jar (see 
section 1.2. for instructions). 
 
3.4. Wash the slides with 100% EtOH twice for 2 min to 
remove the xylene and allow the slides to dry. 
 
3.5. Wash the slides with 10 mM NH4HCO3 twice for 5 min 
to rehydrate the tissue (see section 1.3. for instructions). 
 
 
3.6. Place one of the slides in a 50-mL Falcon tube with 10 mM 
citric acid monohydrate at pH 6.0 (see section 1.4. for 
instructions). 
 
3.7. Place the 50-mL Falcon tube in the water bath heated to 70°C 
for 3 h. 
 
3.8. Remove the slide from the Falcon tube and leave in a MTP 
AnchorChip box (Bruker Daltonics) to cool to room temperature. 
 
 
3.9. Wash the slides with 10 mM NH4HCO3 twice for  




Table 2. N-glycan standard mixture (GLY3; Prozyme, 
Hayward, CA, USA) used for calibration of the MALDI-
TOF/TOF MS instrument 
 




   
Man5GlcNAc2 1234.4333 1257.4225 
Man3GlcNAc5 1519.5659 1542.5551 
Man3Gal4GlcNAc6 2370.8565 2393.8457  
Concentration: 1 pmol/μL 
 
 




4. ENZYME DIALYSIS 
 
The enzyme is dialysed prior to its application due to the salt 
content, which can affect MALDI-MS ionisation. 
 
4.1. During step 3.7. fill a 1-L beaker with water (H2O, ultrapure, 
≥18.2 Ω from Barnstead). 
 
4.2. Float a nitrocellulose membrane (0.025 μm pore size, 
Millipore) on top of the water. 
 
4.3. Load 40 μL of Peptide-N-glycosidase F (PNGase F, New 
England Biolabs) on top of the nitrocellulose membrane (0.025 
μm pore size, Millipore) and dialyse for 2 h. 
 
• Make sure to use a glycerol-free PNGase F as there are no 
cleaning steps prior to the MALDI-MSI acquisition. Be 
careful when selecting PNGase F as different suppliers 
provide PNGase F with different activities. 
 
4.4. Remove the PNGase F by pipetting, estimating the 
volume removed, and pipette into a microfuge tube. 
 
4.5. Add 25 mM NH4HCO3 to obtain a total volume of  
200 μL. 
 




5. ENZYME APPLICATION 
 
5.1. Turn on the chemical inkjet printer (ChIP-1000, 
Shimadzu) and vacuum pump.   
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Figure 1. A workflow on how to spatially map the N-glycome by MALDI-MSI across FFPE clinical samples. First, the FFPE 
tissue is sectioned onto indium tin oxide (ITO)-coated slides, treated with citric acid antigen retrieval (CAAR) and digested 
with PNGase F to release N-glycans from glycoproteins. The PNGase F is printed using a chemical inkjet printer (ChIP-
1000) to print an array across the tissue section. Secondly, dihydroxybenzoic acid (DHB) is sprayed across the tissue section 
using a HTX TM-Sprayer. Thirdly, mass spectra are acquired using MALDI-MS in a two-dimensional grid across the tissue 
section. Lastly, the data is analysed using MALDI-MSI software (SCiLS Lab, Bremen, Germany) by overlaying the image 





































5.2. Load the slide onto the MTP slide adaptor II (Bruker 
Daltonics) and slide it into the left-hand slot of the stage with the 
tissue facing up. 
 
5.3. Double click on the ChIP-1000 software icon found on the 
desktop computer connected to the ChIP-1000 by a USB cable. 
 
 
5.4. Enter the UserID and Password to access the software. 
 
5.5. Next, select the Sample icon which is located below the word 
Operate. 
 
5.6. Select the Sample 1 tick box and click on Image 
Acquisition. 
 
• A light will appear from the back of the instrument which is the 
scanner turning on and scanning the slide. Ignore all error 
messages, except in the case where there is no light. 
 
5.7. Then, select the Create Area button, and click and drag to 





5.8. Once you have created the region, an Area Setting box will 
appear on the screen. Enter 250 μm into the boxes labelled print 
pitch x and print pitch y. 
 
• This will adjust the numbers in the boxes labelled print points 
of x and print points of y which tells you how many droplets 
are printed in the x and y axes. The maximum number of 
droplets for a selected area is 2000, but the instrument will 
still print more than this. 
 
 
5.9. Select the Ok button and the Stop Creating Area button. 
 
5.10. Select Request and click on a blank box to create a 
process name. 
 
5.11. Click on the box under the Job tab and select print. 
 
5.12. Double click on the box under the heading parameter and 
enter in the relevant details. 
 
• Solution: Process Name 
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Quantity of Solution: 15,000-30,000 pL is recommended for 
PNGase F printing. 
Method of print (droplet interval): 0 ms per 0 drops. 
 
5.13. Once finished, you will have to enter the UserID and 
Password. 
 
5.14. Click and drag the process name that you just created onto 
the region of interest. 
 
• The green region box will change to a blue grid once you have 
completed this step. 
 
5.15. Now, close the Request box and click Save on the box 
labelled Image Name 1. 
 
5.16. Enter the Project, Experiment and Sample details, and 
enter the UserID and Password after each detail is entered. 
 
5.17. Select Ok and close the box. 
 
5.18. Select Do Process located on the box labelled 
Sample. 
 
• Make sure that the details of the method are correct in the next 
box that appears. 
 
 
5.19. Select Ok, Ok and then Skip until you reach the 
window that is shown in Fig. 2.  
 
5.20. Clean the piezoelectric printing head using MeOH 
(Merck, Germany) by loading 200 μL of MeOH into the 
reservoir and pressing Start under the heading Load Solution. 
 
• The loading time is usually set between 100 and 1000 ms to 
clean the piezoelectric printing head. 
 
5.21. Once the reservoir is empty, twirl a lint-free wipe at the 
corner and clean the tip of the piezoelectric printing head. 
 
• Make sure to watch the computer screen to see that all the 
MeOH is removed (there is a camera on the piezoelectric 
printing head). 
 
5.22. Repeat steps 5.20. and 5.21., but with water (≥18.2 MΩ from 
Barnstead purifier) or 25 mM NH4HCO3 for PNGase F printing. 
 
5.23. Next, optimize the printing conditions by clicking the Start 
button located under the heading Test Printing and adjust the 
Dwell Voltage (V) and Dwell Time (μs). 
 
• There is a camera that points at the piezoelectric printing head. 
The camera takes multiple snapshots of test printing, thereby 
































Figure 2. The Print sequencer for lines and Print Monitor interface for the Chemical Inkjet Printer (ChIP-1000). Enter the information 
detailed in the screenshot above and optimise the printing conditions by modifying the Dwell Voltage and Dwell Time under the Test 
Printing tab. View the test printing in the Print Monitor window and use the Display Guide Line to determine if the droplets are stable. 
Optimizing the camera Brightness and Contrast can help visualize the droplets better. Note: The ChIP-1000 is no longer commercially 
available.   
 
 










































printing conditions so that there is minimal movement and 
deviation of these droplets over time. Also, the Dwell Voltage 
and Dwell Time will have to be adjusted for every experiment. 
 
 
5.24. Once the printing conditions have been optimised, add 200 
μL of the dialysed PNGase F into the reservoir located above the 
piezoelectric printing head and click the Start button under the 
heading Printing. 
 
5.25. Take the slide out of the MTP II adaptor and place it into a 
humid chamber (e.g. a plastic box containing wet lint-free wipes) 
and place it in a 37°C room for 16 h. 
 
• Our group uses a small box that raises the slide at one end 
while wet lint-free wipes sit at the other end so that the slide 
does not get wet. 
 
5.26. Clean the reservoir as outlined in steps 5.20. and 5.21. 
 
5.27. On the next day, take the humid chamber out of the 37° C 
room and spot 1 μL of GLY3 (see Table 2) onto the control tissue 
region. 
 
5.28. Mark the edges of the slides with water-based white-
out to create teach marks, required later for data acquisition. 
 
5.29. Scan the slides at 2400 dpi using a CanoScan 5600 F 
(Canon) scanner.  
M. T. Briggs et al. 
 
6. MATRIX DEPOSITION 
 
DHB was optimized as a matrix for this MALDI-MSI protocol, 
but other matrices can be optimised in positive or negative mode 
to obtain comparable results.
[27–30] 
 
6.1. Place the ITO-coated slide on the HTX TM-Sprayer (HTX 
Technologies) stage. 
 
• Apply sticky tape on the edges of the slide so that the slide 
remains in position. 
 
6.2. Turn on the TM-Sprayer and the nitrogen gas to 4 psi 
pressure. 
 
• Make sure that the nitrogen gas is attached to the TM-sprayer. 
 
 
6.3. Turn on the LC Pump (Shimadzu) and set it to a flow rate of 
0.05 μL/min. 
 
6.4. Double click on the HTX TM-Sprayer icon located on the 
desktop of the laptop. 
 
6.5. Set up the TM-sprayer method by clicking on the Spray 
Pattern Design tab and enter the details shown in Fig. 3. 
 
6.6. Click and drag to select a region of interest to be sprayed (i.e. 


































































Figure 3. The Spray Pattern Design interface for the HTX TM-Sprayer. Enter the method-specific settings detailed in the 
screenshot above. Then, click and drag a red grid on the overview of the stage to create a region of interest for spraying.   
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6.7. Click Save to save the method with the appropriate 
details, and then press Start to load the method. 
 
6.8. Inject 5 mL of 20 mg/mL DHB in (1 mM NaCl and 0.1% 
TFA) into the 5-mL sample loop using a syringe. 
 
• Make sure that the toggle is switched to LOAD and not  
SPRAY. 
 
6.9. Switch the toggle from LOAD to SPRAY and wait until the 
matrix moves through the sample loop and reaches the nozzle. 
 
6.10. Now click the Start button on the laptop to start the run. 
 
6.11. Once the run is complete, take the slide off the TM-Sprayer 
stage, insert it into a MTP slide adaptor II (Bruker Daltonics) and 
insert it into the MALDI-TOF/TOF mass spectrometer 
(ultrafleXtreme, Bruker Daltonics). 
 
7. MALDI-MSI DATA ACQUISITION 
 
7.1. Open the flexControl software (Bruker Daltonics) by double 
clicking on the icon located on the computer desktop. 
 
7.2. Load a reflectron positive mode method in 
flexControl. 
 
7.3. Optimise this loaded method for the instrument by 
adjusting the following settings: 
 
• Laser power (instrument specific)  
• Laser offset (instrument specific)  
• Laser repetition rate (typically between 1 and 2 kHz)  
• Detector gain (instrument specific)  
• m/z measurement range (at least m/z 800–4500)  
• Matrix suppression (700 Da, usually 100 Da below m/z range 
minimum) 
• Acquisition rate (at least 1 GS/s for reflectron MS) 
 
7.4. Open flexImaging (Bruker Daltonics) and select create a 
new sequence in the window that appears. 
 
7.5. Enter the following details: 
 
• Sequence name  
• Data directory  
• Sample preparation type (100 μm raster width for this 
workflow) 
• AutoXecute method (edit through flexControl) 
 
7.6. Load the scanned image (from step 5.29) to teach the 
instrument where the tissue is located. 
 
7.7. Assign the three teach marks applied earlier and then select 
move sample carrier from the edit drop down menu. Move the 
sample carrier to the edges of the assigned teach marks to 
confirm that the instrument teaching is accurate. 
 
 
7.8. Move the sample carrier onto a region of tissue that has been 
digested with PNGase F and optimise the loaded method as 
detailed in step 7.3.   
• An optimum laser power has been achieved when a high 
intensity spectrum can be acquired with 1000 
accumulated shots. The intensity will be variable and 
can exceed 10
4
 for some spectra. 
 
7.9. Test the selected laser power on several randomly 
selected spots including the external calibrant. 
 
7.10. Using the optimised method, move the sample carrier to the 
external calibrant. 
 
7.11. Acquire spectra, ensuring that the peaks in the isotopic 
profile can be resolved to baseline. 
 
7.12. Calibrate the instrument using the standard glycan 
calibration list and save the flexControl method. 
 
7.13. Ensure that the flexControl autoXecute method 
contains the appropriate parameters. 
 
• General (flexControl method only selected)  
• Laser (set optimum laser power and turn fuzzy control off)  
• Evaluation (should contain no background list)  
• Accumulation (fuzzy control off, 1000 shots acquired in 
1000 shot steps, dynamic termination off) 
• Movement (random walk off)  
• Processing (flexAnalysis method required – see below)  
• MS/MS (no method) 
 
7.14. Set up the flexAnalysis method by defining the 
additional settings in flexAnalysis Editing Processing 
Parameters and Edit Parameters windows. 
 
• Smoothing (Gaussian, 2 cycles with width of 0.02 m/z units)  
• Baseline subtraction (TopHat)  
• Peak detection (monoisotopic, e.g. SNAP) 
 
7.15. Start the imaging sequence from flexImaging by clicking on 
the icon shaped like a traffic light that is green (see Fig. 4). 
 
7.16. Once the run is complete, remove the slide. 
 
8. H&E STAINING 
 
8.1. Rinse the slide with 70% EtOH in a glass Coplin 
staining jar (EMS) until the removal of the matrix. 
 
8.2. Dip the slide into deionized water in a glass Coplin 
staining jar.  
 
8.3. Immerse the slide in haematoxylin solution 





Rapid Commun. Mass Spectrom. 2017, 31, 825–841 Copyright © 2017 John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/rcm 
 



































Figure 4. The Sequence interface for the flexImaging software (Bruker Daltonics). Regions of interest are created in the Image Display 
window by clicking on the blue polygon tool, and then by clicking and creating the region of interest on the scanned tissue section. Once 
the regions are created, save the sequence and acquire the data by clicking on the green traffic light icon. To visualise m/z values after data 




8.4. Wash the slide with tap water for 2–5 min in a glass 
Coplin staining jar. 
 
 
8.5. Immerse the slide in eosin solution (ProSciTech) 1 g/L in 
water for 1 min in a glass Coplin staining jar. 
 
 
8.6. Rinse the slide with 70% (v/v) EtOH for 30 s in a glass 
Coplin staining jar. 
 
8.7. Rinse the slide with 90% (v/v) EtOH for 30 s in a glass 




8.11. Apply mounting medium onto a cover slide and cover the 
tissue section with the cover slide by gently press it on. 
 
8.12. Let the cover slide dry overnight at room temperature. 
 
8.13. Scan the tissue section using a NanoZoomer 
automated slide scanner (Hamamatsu). 
 
8.14. Send the scanned tissue section to a pathologist to 
















8.8. Rinse the slide with 100% (v/v) EtOH for 30 s in a glass 
Coplin staining jar. 
 
8.9. Rinse the slide with 100% (v/v) isopropanol for 30 s in a glass 
Coplin staining jar. 
 
8.10. Rinse the slide twice with 100% (v/v) xylene for 1 min in a 
glass Coplin staining jar.  
 
9. MALDI-MSI DATA ANALYSIS 
 
9.1. Double-click on the desktop icon of SCiLS Lab and select 
New (from flexImaging sequence). 
 
9.2. Select the instrument type as Time-of-flight (TOF). 
 
9.3. In the Add and arrange data sets window, click on + 
located in the lower left corner. 
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9.4. Next, select the flexImaging file (name.mis) for 
importing. 
 
9.5. Then, select Import raw, fallback to reduced spectra (.dat) 
in the Select Preference window. 
 
9.6. Click on the next button in both the Add and the arrange 
data sets and Mass range settings window. 
 
9.7. Select TopHat as the Baseline removal algorithm and  
200 Narrow as the Peak width, and then click the next button. 
 
9.8. In the Import summary window, select the Import 
button and save as a SCiLS file (name.sl). 
 
9.9. Open the Imported Dataset and the summed spectrum will 
appear. 
 
9.10. Click on the Normalization tab located on the right and 
select Total Ion Count. 
 
9.11. Next, click on File and select File Properties. 
 
9.12. Change the Interval width to between ±0.1–0.5 m/z units 
depending on the resolution. 
 
9.13. Close the File Properties window and scroll using the 
mouse to zoom in on the summed spectrum. 
 
9.14. Click on monoisotopic peaks in the summed spectrum by 
holding the Shift button and left click. 
 
9.15. Manually scan through the summed spectrum recording m/z 
values that are only observed in the experimental tissue section 
and not the control tissue section. 
 
• Figure 6 represents an example of an m/z value that is not 
observed in the control region (Fig. 6(A)), but is in the PNGase 
F treated region (Fig. 6(B)). This m/z value (2012.775) was 
observed in the stroma/adipose regions and not in the tumour 
regions, based on the pathologist’s annotations in Fig. 5. 
 
9.16. To find out if this m/z value is a true N-glycan, open a  




9.17. Enter this m/z value into the box labelled Enter a list of 
experimental masses. 
 
9.18. Enter the other parameters as listed below: 
 











































Figure 5. Haematoxylin and eosin (H&E) staining of a formalin-
fixed paraffin-embedded stage III ovarian cancer tissue section 
with tissue-type annotations by a pathologist. The tumour region is 
coloured in red, the stroma region is coloured in blue and the 
adipose region is coloured in yellow.   
 
 
9.19. Scroll down and at the bottom of the page, click the Start 
GlycoMod button. 
 
9.20. Click on the UniCarbKB link next to the generated 





 is a database of known N-glycan structures 
reported in previous publications. There are often multiple N-
glycan isomers of the same m/z value and this makes it difficult 
to annotate the spectrum with the correct structural isomer. 
Figure 5(B) shows a few examples of different N-glycan 
isomers for the same m/z value, but confirmation by 
LC/MS/MS is required as in situ MALDI-MS/MS is not 
detailed enough. The product ion spectrum from LC/MS/MS 
can confirm if the N-glycan structure is bisecting or tri-
antennary. 
 
Our group has previously identified and confirmed 18 N-glycans 
from FFPE murine kidney
[19]
 and 20 N-glycans  
from FFPE human ovarian tumour.[27] Several N-glycan families 
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Figure 6. MALDI-MSI of a formalin-fixed paraffin-embedded stage III ovarian cancer tissue section. (A) The summed 
spectrum and the ion intensity map of m/z 2012.775 from the non-treated (control) region and (B) the summed MS spectrum 
and ion intensity map of m/z 2012.775 from the PNGase F-treated region. The m/z 2012.775 ion was observed in the stroma 
and adipose regions, based on the pathologist’s annotation of the H&E-stained section in Fig. 5. Potential N-glycan structural 
isomers that correspond to m/z 2012.775 (of monosaccharide composition HexNAc5Hex5dHex1) are shown, but LC/MS/MS 
analysis of this N-glycan mass is required as in situ MALDI-MS/MS does not provide enough detail to elucidate the correct 
























hybrid, complex, bisected, fucosylated and sialylated. Sialylated 
N-glycans have been identified as sodium adducts in positive 
mode; for example, a singly sialylated species is detected with two 
sodium ions while a doubly sialylated species is detected with 
three sodium ions. Tri-antennary and tetra-antennary N-glycans 
have rarely been observed in our MALDI-MSI datasets, but they 
are routinely identified by LC/MS from the same sample. Further 
investigation is required to elucidate why these structures are not 
observed in MALDI-MSI. 
 
 
10. LC/MS/MS DATA ACQUISITION 
 
Since in situ MALDI-MS/MS does not provide enough detail to 
elucidate the correct N-glycan isomer, LC/MS/MS is required. A 
consecutive tissue section is sectioned from the same FFPE block 
used in the MALDI-MSI experiment and  
 
PNGase F is applied in-solution to release N-glycans from  
all the glycoproteins. This part of the protocol has been adapted 
from Gustafsson et al.
[19]
 and Jensen et al.
[14]
 (see Fig. 7). 
 
10.1. Incubate the tissue section on the PEN membrane slide 
on a heating block at 60°C for 5 min. 
 
10.2. Remove paraffin from the tissue section by placing the slide 
in a glass Coplin staining jar containing 100% (v/v) xylene and 
allow the tissue to stand in solution for 90 s. 
 
10.3. Wash the tissue section by removing the slide from the 
staining jar and place it in a rectangular staining dish (EMS, USA) 
containing 100% (v/v) ethanol. Allow the tissue to stay in solution 
for 60 s. 
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Figure 7. A workflow on how to structurally characterize the N-glycome by LC/MS/MS of microdissected regions of FFPE 
clinical samples. First, the FFPE tissue is sectioned onto PEN slides, treated with citric acid antigen retrieval (CAAR) and 
digested with PNGase F in-solution to release N-glycans from glycoproteins. Secondly, the released N-glycans are dried and 
reduced using sodium borohydride (NaBH4). Thirdly, the released N-glycans are desalted using cation-exchange resin packed 
into a C18 ZipTip and then cleaned using graphitised carbon packed into a C18 ZipTip. Lastly, the released N-glycans are 
separated using a porous graphitised carbon (PGC) column and tandem mass spectrometry data is acquired using a three-




10.4. Isolate the tissue sections by manual microdissection and 
transfer the sections into separate microcentrifuge tubes. 
 
 
• The microdissection size will vary depending on the 
region of interest from the tissue section. 
 
10.5. Incubate tissue sections in 200 μL of 10 mM NH4HCO3 
buffer and incubate for 5 min at room temperature. Remove and 
discard liquid. 
 
10.6. Repeat step 10.5. once. 
 
10.7. Add 200 μL of 10 mM citric acid at pH 6 to tissue 
sections and heat at 98°C for 45 min. 
 
10.8. Wash tissue sections twice in 10 mM NH4HCO3 buffer. 
 
10.9. Add 2 μL of glycerol-free PNGase F (0.5 U/μL, Roche) and 
40 μL of 25 mM NH4HCO3 buffer to tissue sections. 
 
 
• If a different commercially available PNGase F is used, 
make sure to prepare the enzyme in a buffer that is 
compatible with mass spectrometry and pH-specific for 
the PNGase F of choice. 
 
 
10.10. Incubate for 16 h at 37°C. 
 
10.11. Centrifuge the reaction tube at 14,000 g for 10 min and 
collect supernatant in individual centrifuge tubes. 
 
10.12. Dry samples to completeness in a SpeedVac 
concentrator (Savant SVC 100) without heating. 
 
10.13. Wash the tubes twice in 20 μL of water, and pool the 
washes with the sample. 
 
10.14. Add 10 μL of 100 mM ammonium acetate (pH 5) to the 
samples and incubate at room temperature for 1 h.  
 
10.15. Dry samples to completeness in a SpeedVac 

















































































10.16. Add 20 μL of 1 M NaBH4 in 50 mM KOH to the dried N-
glycans and incubate for 3 h at 50°C.  
 
10.17. Collect the sample at the bottom of the tube by 
centrifugation at 2000 g for 30 s. 
 
10.18. Neutralise the reaction by adding 2 μL of glacial acetic acid 
and mix the samples vigorously. 
 
• Some effervescence might be seen upon the addition of 
acid. 
 
10.19. Collect the sample at the bottom of the tube by 
centrifugation at 2000 g for 30 s. 
 
10.20. Prepare a cation-exchange column (one per sample), and 
transfer a small fraction of cation-exchange resin (AG 50 W X8 
resin in methanol) onto a ZipTip C18 tip. 
 
10.21. Put the columns into microcentrifuge tubes and 
centrifuge at 2000 g for 30 s. 
 
• Add more resin to get approximately 25 μL packed 
volume. 
 
10.22. Wash the columns with 50 μL of 1 M HCl followed by 
three times with 50 μL of methanol by centrifugation at 2000 g for 
30 s. 
 
10.23. Transfer the columns into new microcentrifuge tubes and 
wash them three times with 50 μL of water. 
 
10.24. Place the columns in final sample-collection 
microcentrifuge tubes. 
 
10.25. Apply the glycan samples to the columns and centrifuge at 
2000 g for 30 s or until only ~5 μL remains on top of the column. 
 
10.26. Wash the original sample tube with 20 μL of water.  
Add this to the column and centrifuge as before. 
 
10.27. Elute glycans by adding 50 μL of water and centrifuge as 
before. Combine the eluents. 
 
10.28. Remove the columns from the tubes and dry the eluted 
glycans in the SpeedVac concentrator. 
 
10.29. Add 100 μL of methanol to the samples. Vortex to mix the 
samples and dry the samples in the SpeedVac concentrator. 
 
10.30. Repeat step 10.29. three to five times. 
 
10.31. Add 10 μL of 0.1% (v/v) TFA to tube and mix well by 
vortexing. Samples are now ready for carbon clean-up procedure.  
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10.32. Prepare the column material by transferring 50 mg of 
carbon material into a fresh microcentrifuge and then add 1 mL of 
methanol. 
 
• The slurry should have an approximate concentration of 50 
mg/mL. 
 
10.33. Load approximately 50 μL (≈2.5 mg) of the slurry onto a 
ZipTip C18 tip. 
 
10.34. Place the tips into microcentrifuge tubes, spin down to 
pack column in the tips. 
 
10.35. Wash the column with 50 μL of acetonitrile containing 
0.1% (v/v) TFA by centrifugation at 2000 g for 30 s. Repeat this 
step with three washes. 
 
10.36. Wash the tips three times with 50 μL of 0.1% (v/v) 
TFA. 
 
10.37. Load the sample dissolved in 10 μL of 0.1% (v/v) TFA 
onto the top of the column and centrifuge at 2000 g for 30 s. 
 
10.38. Wash column three times with 50 μL of 0.1% (v/v) 
TFA. 
 
10.39. Discard the wash. 
 
10.40. Transfer the columns to new microcentrifuge tube. Elute 
bound glycans twice with 10 μL of 50% (v/v) acetonitrile 
containing 0.1% (v/v) TFA. 
 
10.41. Dry the eluted sample in the SpeedVac concentrator 
without heating. 
 
10.42. The reduced N-linked glycans are dissolved in 10 μL of 10 




11. LC/MS/MS DATA ANALYSIS 
 
11.1. Open Data Analysis (Bruker Daltonics) by 
double-clicking on the desktop icon. 
 
11.2. Click on File and select Open to open the LC/MS file 
(name.D). 
 
11.3. Click on the file located under Analysis List and press 
delete on the keyboard. 
 
11.4. Create an Extracted Ion Chromatogram (EIC) by clicking 
on the Edit Chromatograms icon and selecting EIC as the type. 
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Table 3. Details of the mass spectrometric analyses 
 
Agilent 1100 Series LC system  
Column: Hypercarb KAPPA capillary 
column, (0.18 × 100) mm, 5 μm 
particle size (Thermo Scientific, 
Waltham, MA, USA) 
Mobile phase: A: 10 mM NH4HCO3 
B: 45% (v/v) acetonitrile in buffer A 
Gradient: 100% A for 8 min 
0–35% B for 45 min 
35–100% B for 20 min 
100% B for 5 min 
100–0% for 1 min 
100% A for 4 min 
Flow rate: 2 μL/min 
Column temperature: Ambient 
 
Agilent MSD three-dimensional ion trap XCT plus mass 
spectrometer 
Polarity: Negative 
MS full scan mass m/z 100–2000 
range: 
Top 2 most intense precursor ions  
 
 
11.5. In the Masses box, enter the m/z value of interest. 
 
• Make sure to convert m/z values from MALDI-MS 
values into LC/MS values. For example, m/z 
[2012.775]
1+
 from the MALDI-MSI dataset is non-
reduced and sodiated while 
 
 
the same N-glycan of m/z [994.9]
2
 from the LC/MS dataset is 
reduced and non-sodiated. Therefore, m/z 994.9 would be 
entered into the Masses box to create an EIC of that m/z value.  
 
• In Fig. 8(A), the component producing the ion at m/z [994.9]
2
 
elutes at 40.8 min as shown by the EIC. Although the 
composition of the glycan mass corresponds to 
(Gal)2GlcNAc)3(Fuc)1 + (Man)3(GlcNAc)2, several isomeric 
structures are biologically possible as shown in Fig. 6(B). 
Through detailed negative mode product ion analysis, the 
glycan structure corresponding to m/z [994.9]
2
 can be 
elucidated. 
 
11.6. Keep the Width at ±0.5 m/z units and click on the Add 
button. 
 
11.7. Then click the Ok button to close the window. 
 
11.8. Click on the Select Range/View Spectra icon and scan 
across the peaks in the chromatogram to find MS/MS spectra for 
the m/z value. 
 
• If there are multiple peaks in the chromatogram, there 
are multiple N-glycan isomers of the same m/z value. 
 
11.9. Copy the MS/MS spectra into the Compound Spectra by 
right clicking on the MS/MS and left clicking on Copy to 
































Figure 8. (A) Extracted ion chromatogram of m/z 994.9
2– corresponding to the glycan composition Gal2GlcNAc3Fuc1 + Man3GlcNAc2 
eluting at 40.8 min. (B) MS/MS product ion spectra derived from the doubly charged negative ion of m/z [994.9]
2
 . The product ions are 
labelled according to the scheme of Domon and Costello.
[35]
 Identified structures with key fragmentation are shown. Monosaccharide 
symbols are as defined by Essentials of Glycobiology. Asterisk denotes doubly charged ions.   
 
 










































11.10. Once the MS/MS spectra of interest have been copied over 
to the Compound Spectra, the product ions can be annotated 
using GlycoWorkbench 2 to identify the N-glycan isomers 
present. 
 
11.11. Download GlycoWorkbench 2
[34] 
 
11.12. Once downloaded, double-click on the 
GlycoWorkbench 2 desktop icon. 
 
11.13. Click on the Structure tab and select a paucimannose N-
glycan core structure. 
 
11.14. Create multiple isomeric structures observed in the 
UniCarbKB database
[33]
 by clicking on the monosaccharide units 
of interest. 
 
11.15. Once completed, left click and drag to select a single 
isomeric structure and right click. 
 
11.16. Select Mass Options of Selected Structures and a 
window called Mass Options will appear. 
 
11.17. Enter the information in Table 4 for LC/MS data and click 
the Ok button. 
 
11.18. Left click and drag again to select a single isomeric 
structure, and then click on the Tools tab. 
 
11.19. Move the cursor over Fragments and select Complete 
fragments for current structure. 
 
11.20. In the Fragment options window, select the product ion 
types that you expect to observe and click the Ok button. 
 
11.21. A product ion list will appear on the right with m/z values 
that correspond to the theoretical ions. Match these theoretical 
ions from the product ionlist to the ions in the compound spectra 
to characterize the glycan structure observed. 
 
For example, in Fig. 8(B), the Z1` ion at m/z 350.2 and the Y2 ion 
at m/z 571.3 from the product ion spectrum are evidence for the 
presence of the chitobiose core fucose. Another diagnostic ion 
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of significant importance is the so called D-ion.
[36]
 The D-ion 
arises from the loss of the chitobiose core (C ion cleavage between 
Manβ1–4GlcNAc), and the Z ion cleavage between Manα1–
3Man forming the 3-antennae; thus, the D-ion mass corresponds to 
the composition of the six-arm antenna plus the two remaining 
branching core mannoses. Routinely, the D and [D–18] ions have 
been used to identify the composition of the N-glycan 6-antenna. 
If the N-glycan has a bisecting GlcNAc residue, the additional loss 
of this bisecting β1–4-linked GlcNAc gives rise to the D–221 ion. 
Figure 8(B) shows the product ion spectra contain the D–221 ion 
corresponding to m/z 670.3. The ion at m/z 508.3 further validates 
the bisecting structure as it is a consequence of the loss of the 
terminal Gal residue from the D-221 ion. 
 
Our group has previously identified and confirmed 34 N-glycans 
(including structural and compositional isomers) from FFPE 
murine kidney
[19]
 and 56 N-glycans (including structural and 
compositional isomers) from FFPE human osteoarthritis 
cartilage.
[37]
 Several N-glycan families have been observed, 
including paucimannose, high mannose, hybrid, complex, 
bisected, fucosylated and sialylated. 
 
12. CONCLUDING REMARKS 
 
This protocol paper describes the capacity of MALDI-MSI to 
delineate tissue types simply by measuring the spatial distribution 
of the masses of glycans released from FFPE tissue glycoproteins. 
The approach stresses the importance of incorporating structural 
characterisation (LC/MS/MS) when spatially profiling (MALDI-
MSI) N-glycans in order to confirm their composition and 
isomeric form. Without LC/MS/MS, the N-glycan masses and 
their corresponding monosaccharide compositions, but not their 
structures, can be assigned, therefore making it difficult to 
understand the biological significance of the mass distributions. 
Consequently, this protocol provides the detailed information 
required for other groups to adopt our group’s complementary 
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Table 4. List of mass options for the select glycan structure 
such as derivatisation, reducing end, negative mode, and 
numbers of hydrogen and sodium ions  
 
 LC/MS MALDI-MS 
   
Derivatization Und Und 
Reducing end redEnd freeEnd 
Negative mode ✓ N/A 
# H ions 2 0 
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3.1 | Summary 
 
Multiple N-glycan structures have been observed in the disease progression of osteoarthritis, although 
the N-glycome of bone marrow has not yet been characterised. Bone marrow lesions (BMLs) are 
typically visualised by magnetic resonance imaging (MRI) which provides diagnostic and prognostic 
information, however, this strategy does not provide a molecular understanding. Therefore, we modified 
our combined MALDI-MSI and PGC-LC-ESI-MS/MS workflow (see the original workflow outlined in 
Chapter 2) to identify and characterise N-glycan structures of interest on FFPE tibial cartilage and 
subchondral bone from knee osteoarthritis patients of different BML stages.  
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Magnetic resonance imaging (MRI) is a non-invasive technique routinely used to investigate 
pathological changes in knee osteoarthritis (OA) patients. MRI uniquely reveals zones of the 
most severe change in the subchondral bone (SCB) in OA, called bone marrow lesions (BMLs). 
BMLs have diagnostic and prognostic significance in OA, but MRI does not provide a molecular 
understanding of BMLs. Multiple N-glycan structures have been observed to play a pivotal role 
in the OA disease process. We applied matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry imaging (MSI) of N-glycans to formalin-fixed paraffin-embedded (FFPE) SCB 
tissue sections from patients with knee OA, and liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS) was conducted on consecutive sections to 
structurally characterize and correlate with the N-glycans seen by MALDI-MSI. The application 
of this novel MALDI-MSI protocol has enabled the first steps to spatially investigate the N-
glycome in the SCB of knee OA patients. 
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Human osteoarthritis (OA) is an increasingly prevalent age-
related joint disease with a high burden of personal and eco-
nomic cost. The disease is characterized by articular cartilage 
degeneration, with the addition of both generalized and focal 
changes of the subchondral bone [1, 2]. Bone marrow lesions 
(BMLs) are features that have been identified in both early 
asymptomatic and severe late-stage OA patients and their 
presence associates with loss of overlying cartilage [3, 4]. 
Classically, BMLs are identified using magnetic resonance  
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Figure 1. Knee osteoarthritis (OA) patients (A) without bone mar-
row lesions (No BML), (B) with BML stage 1 (BML 1), and (C) with 
BML stage 2 (BML 2). Each panel includes (from top to bottom) a 
PDFS-weighted MRI of the tibial plateau (BML stage 1 and 2 are 
annotated in pink and green, respectively), a haematoxylin and 
eosin (H&E) stain, and a Safranin-O/Fast Green stain of consec-




imaging (MRI) by either fat-suppressed and/or proton dense 
T2 weighted scans. The difference between T1 and T2 
weighted scans is that BML areas appear hypointense (i.e. low 
signal) for T1 and hyperintense (i.e. high signal) for T2 [5, 6]. 
Therefore, T2 weighted scans depict BMLs to their full extent, 
while T1 weighted scans usually assess cartilage. A combina-
tion of these sequences provides diagnostic and prognostic 
information regarding OA disease progression [7, 8]. How-
ever, MRI does not provide a molecular understanding of 
BML formation and OA disease progression. 
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Adjacent to BMLs in the SCB is overlying cartilage com-
posed of extracellular matrix (ECM) glycoproteins [9, 10]. Be-
sides proteoglycans, there are glycosylated cell surface pro-
teins, such as CD44 and integrins, which play an important 
role in mediating chondrocyte and ECM interactions [11, 12]. 
Glycans attached to these cartilage ECM glycoproteins are 
classified into mainly two groups: (i) N-linked glycans that are 
attached to asparagine residues and (ii) O-linked gly-cans that 
are attached to serine/threonine residues [13]. N-glycans are 
the most common glycan, with well-established methods for 
analysis from tissue [14, 15]. Multiple N-glycan structures 
have been observed to play a pivotal role in OA disease 
progression. Recently, using HPLC-MS, it has been shown 
that high-mannose type N-glycans are significantly decreased 
on proteins from both murine and human OA car-tilage tissue 
[16]. In 2013, glycophenotyping of OA cartilage was carried 
out using several techniques, such as RT-PCR, MS and 
immunohistochemistry. Liquid chromatography-electrospray 
ionization-tandem mass spectrometry (LC-ESI-MS/MS) 
separation and structural identification of the released glycans 
confirmed 21 N-glycans on the human OA chondrocyte 
proteins isolated from femoral condyle articular cartilage [17]. 
The N-glycome of bone marrow from OA patients has not yet 
been characterized.  
MALDI mass spectrometry imaging (MALDI-MSI) has 
previously been applied to the proteomic analysis of fresh 
frozen human OA knee cartilage and synovial tissue. Deep and 
superficial knee cartilage from human healthy and OA patients 
were sectioned and analysed by MALDI-MSI of the tryptic 
peptides [18]. Fibronectin and cartilage oligomeric matrix 
protein (COMP) were 2 glycoproteins identified in the OA 
patients, but not in the healthy controls. Moreover, the glyco-
protein fibronectin was identified in the synovial membranes 
from OA patients, but not in healthy controls. In summary, 
glycoproteins have been observed to play an important role in 
OA changes of human knee cartilage and synovial tissue.  
The measurement of N-glycans by MALDI-MSI on fresh 
frozen mouse brain tissue and various formalin-fixed paraffin-
embedded (FFPE) tissues has been established previously [19, 
20], with regions of interest, such as tumour and non-tumour, 
differentiated based on the pattern of N-glycans released. The 
limitation of MALDI analysis is that N-glycan masses can 
identify the glycan compositions but cannot identify the 
sequence and branching of the glycan structures. This has 
recently been overcome with a new workflow combining N-
glycan analysis by MALDI-MSI and LC-ESI-MS/MS [21].  
Here we investigate the N-glycome of FFPE cartilage and 
bone marrow tissue. Human knee SCB, from OA patients with 
BMLs (stage 1 and 2) or without BMLs were analysed to 
investigate N-glycosylation patterns.  
Tibial plateaus were obtained from three patients (one male 
aged 52 years, two females aged 68 and 74 years) undergoing 
knee arthroplasty surgery for radiographic and severe 
symptomatic OA. Tibial plateau specimens were scanned ex 
vivo, using an MR scanner with an 8-channel wrist coil (3T 
MRI Siemens TRIO), at two specific sequences; fat 
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Figure 2. (A) LC-ESI-MS profiles of bone marrow and cartilage regions, and (B) MALDI-MS profiles of bone marrow and cartilage regions, 
annotated with confirmed N-glycan structures from LC-ESI-MS/MS. (A) N-glycans were released in-solution from formalin-fixed paraffin-
embedded (FFPE) tissue sections using PNGase F prior to LC-ESI-MS/MS. (B) N-glycans were released in situ from FFPE tissue sections using 
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Figure 3. Safranin-O stained images and ion intensity maps of complex/hybrid, sialylated and high-mannose N-glycans observed in patients 
without bone marrow lesions (No BML), with BML stage 1 (BML 1) and with BML stage 2 (BML 2). N-glycans were released in situ on FFPE 
tissue sections using PNGase F and analysed by MALDI-TOF/TOF-MS. m/z values were selected and visualized in SCiLS lab software (V2015a, 
Bruker Daltonics, Bremen, Germany). Ion intensity maps were co-registered with safranin-O stained images to identify the distribution of the 
selected N-glycans. There was no distinct pattern between the same families (i.e. complex/hybrid, sialylated and high-mannose) of N-glycans. 
Control and calibrant regions (i.e. regions not treated with PNGase F) are annotated in black. 
 
 
suppressed (FS) fast spin-echo proton density-weighted 
(PDFS) and T1 weighted spin echo in sagittal and coronal 
plane. Sagittal slice thickness was 1.6 mm with distance fac-
tor of 25%. Coronal slice thickness was 3.0 mm with 10% 
distance factor. Ex vivo MR imaging was confirmed to corre-
spond to pre-operative imaging, by comparing pre- and post-
operative MR data. BMLs were defined as changes of the MRI 
signal intensity in the bone marrow, located beneath cartilage 
and visible at least on two consecutive slices. BMLs detected 
on the PDFS sequence only (no signal on T1) are classified as 
BML stage 1 and correspond to mild-to-moderate osteo-
chondral OA pathology; BMLs detected on both PDFS and T1 
sequences are classified as BML stage 2 and represent severe 
OA osteochondral pathology [22]. Using precise mapping of 
BMLs (OsiriX software, Pixmeo-SARL, Switzerland), a 
sagittal slice of cartilage-subchondral bone (width 5 mm x 
depth 5 to 12 mm) containing the BML area (Fig. 1) was 
dissected using a low speed diamond wheel saw (Model 660, 
South Bay Technology, Inc.). Sagittal blocks of tissue were 
fixed in 4% (w/v) paraformaldehyde and slowly decalcified in 
15% (w/v) ethylenediaminetetra acetic acid (EDTA). Follow-
ing complete decalcification as determined by X-ray, samples 
were processed, embedded in paraffin and cut on a rotary 
 
 
microtome (Leica RM 2235 Nussloch, Germany) into 5mm 
thick sections.  
FFPE human OA tissue sections on indium tin oxide (ITO) 
or polyethylene naphthalate (PEN) slides were rehydrated 
using a modified procedure of citric acid antigen retrieval 
(CAAR) at 70°C for 3 h instead of 98°C for 30 min and 
printing 15 nL of PNGase F instead of 30 nL [21]. Mass 
spectra were acquired using an ultrafleXtreme MALDI-
TOF/TOF mass spectrometer or LC-iontrap ESI-MS/MS 
analysis as described previously [21, 23].  
BMLs were identified using PDFS and T1 weighted scans 
in MRI of the tibial plateaus. As depicted in Fig. 1 Panel A, 
there was no BML detected in this patient, while in Fig. 1 Pan-
els B and C, BML stage 1 and 2, respectively, were detected. 
These BMLs are annotated in pink and green, as indicated on 
the MRI. Below each MRI, staining of FFPE tissue sections 
are shown. Haematoxylin and eosin (H&E) staining provides 
histological information and Safranin-O highlights the carti-
lage in red. Following acquisition of the MRI, the image was 
overlaid with the stained FFPE tissue sections and regions of 
interest were annotated in black. Although the identification of 
these BMLs using MRI is useful, it does not provide molec-
ular information. Therefore, we performed MALDI-MSI of 
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the released N-glycans to investigate the molecular mecha-
nisms behind BMLs.  
For the CAAR [21, 24], we reduced the temperature and 
incubated longer to maintain adherence to the ITO slide. 
MALDI-MSI experiments were conducted in parallel with 
LC-ESI-MS/MS structural characterization. Consecutive tis-
sue sections were manually micro-dissected, and the N-
glycans were released and structurally characterized by LC-
ESI-MS/MS. Figure 2 represents the summed LC-ESI-MS and 
MALDI-MS profiles of both bone marrow and cartilage. In 
Fig. 2 Panel A (LC-ESI-MS profiles), 52 individual N-glycan 
structures (including structural and compositional isomers) 
were identified from bone marrow proteins compared to 56 
individual N-glycan masses (including structural and 
compositional isomers) identified from cartilage proteins, 
based on LC-ESI-MS/MS data (Supporting Information Table 
1). The detailed structures were manually assigned from the 
MS/MS fragmentation data as illustrated in Supporting 
Information Fig. 1. A comparison of the LC-ESI-MS mass 
profiles revealed differences in intensity of particular m/z 
values. For example, m/z 1111.4 was observed as a lower 
intensity peak in the cartilage relative to the bone marrow.  
Ion intensity maps were then generated by MALDI-MSI for 
N-glycan structures from the complex/hybrid, sialylated and 
high-mannose families that had been determined by LC-ESI-
MS/MS analysis (refer to Fig. 2 Panel A for the summed LC-
ESI-MS profiles). Figure 3 shows Safranin-O stained images 
and ion intensity maps for the same three patients described in 
Fig. 1. The region annotated in black represents the control 
(i.e. non-treated) and calibrant regions while the region 
annotated in white is cartilage. There were no differ-ences 
observed between the complex/hybrid N-glycan masses in 
both the cartilage and bone marrow (even between fuco-
sylated and non-fucosylated N-glycans). The log ion intensity 
map for (NeuAc)1(Hex)2(HexNAc)2 + (Man)3(GlcNAc)2 was 
observed as a doubly sodiated species only in the cartilage 
whereas the core fucosylated version of this N-glycan was 
observed in both the cartilage and bone marrow. In addition, 
(NeuAc)2(Hex)2(HexNAc)2 + (Man)3(GlcNAc)2 was observed 
as a triply sodiated species only in the bone marrow of the 
patient with BML stage 1, but not in patients with no BML or 
BML stage 2 as classified by MRI. This particular N-glycan 
was observed in LC-ESI-MS/MS profiles of both the cartilage 
and bone marrow, but exhibited decreased intensity in carti-
lage. This suggests that this N-glycan is too low in abundance 
in the cartilage for MALDI-MSI detection. High mannose N-
glycans such as (Man)3 + (Man)3(GlcNAc)2, (Man)4 + 
(Man)3(GlcNAc)2 and (Man)5 + (Man)3(GlcNAc)2 were 
compared between the three knee OA patients. The ion in-
tensity map for (Man)3 + (Man)3(GlcNAc)2 showed that this 
N-glycan was only observed in the cartilage region, whereas 
(Man)4 + (Man)3(GlcNAc)2 and (Man)5 + (Man)3(GlcNAc)2 
were highlighted in both the cartilage and bone marrow.  
Regions of interest (i.e. bone marrow and cartilage) were 
also selected based on histology and summed spectra were 
extracted from the MALDI-MSI dataset. Figure 2 panel B 
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represents summed spectra from these regions and show a 
lower sensitivity of detection compared to LC-ESI-MS/MS. A 
comparison of those structures found by MALDI-MSI and 
LC-ESI-MS/MS are shown in Supporting Information Table 1.  
The detected m/z from LC-ESI-MS corresponded to doubly 
charged [M−2H]2− masses and the m/z from MALDI– MSI 
corresponded to the sodiated mass ([M+Na+ ])+ . A to-tal of 17 
individual N-glycan masses were identified from bone marrow 
compared to 20 individual N-glycan masses from cartilage. As 
previously seen in the ion intensity maps, 
(NeuAc)1(Hex)2(HexNAc)2 + (Man)3(GlcNAc)2 was only de-
tected in the cartilage while (NeuAc)2(Hex)2(HexNAc)2 + 
(Man)3(GlcNAc)2 was only detected in the bone marrow.  
There was a major difference between the intensity of the N-
glycan m/z values observed with (Man)3 + (Man)3(GlcNAc)2 
being prominent in the cartilage relative to the bone marrow.  
In summary, we have established a MALDI-MSI and LC-
ESI-MS/MS workflow for FFPE tibial cartilage and SCB of 
knee OA patients. For the first time, the N-glycome of differ-
ent regions of the same OA sample have been investigated, 
with individual N-glycan structural and compositional iso-
mers in bone marrow and cartilage (a total of 52 and 56 
respectively) being identified by LC-ESI-MS/MS. Using tar-  
geted masses in the MALDI-MSI experiments, the disialylated 
biantennary complex glycan, (NeuAc)2(Hex)2(HexNAc)2 + 
(Man)3(GlcNAc)2 was identified to be prominent in the bone 
marrow for the BML stage 1 patient relative to all other 
patient samples. However, larger patient studies will be 
required in order to understand the biological relevance of this 
observation. Overall, further development of this novel 
MALDI-MSI protocol has enabled the first steps to investigate 
the spatial distribution of the N-glycome of knee OA patients. 
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3.3 | Supplementary Information 
 
Table 1: Proposed N-glycan structures detected and characterized by negative ion mode LC-ESI-ion trap MS/MS. Provided 
in this table are the detected m/z of the N-glycan structures found in formalin-fixed paraffin-embedded bone marrow and 
cartilage tissue sections. The detected m/z from LC-ESI-MS correspond to doubly charged [M−2H]2− masses and the m/z 
from MALDI-MSI correspond to the sodiated mass ([M+Na+])+. *denotes the presence of additional sodium adducts 
observed in sialylated structures. 
 
  
Glycan composition Glycan structure Detected m/z in LC-ESI Detected m/z MALDI 
imaging    
Bone Marrow Cartilage Bone Marrow Cartilage 
1 (Hex)2 + (Man)3(GlcNAc)2 
 
617.2 617.2 1257.4 1257.4 
2 (HexNAc)2 + (Man)3(GlcNAc)2 
 
ND 658.2 ND 1339.5 
3 (Hex)3 + (Man)3(GlcNAc)2 
 
698.3 698.3 1419.5 1419.5 
4 (HexNAc)2 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2 
 
731.3 731.3 1485.5 1485.5 
5 (Hex)1 (HexNAc)2 + (Man)3(GlcNAc)2 
 
739.3 739.3 1501.5 1501.5 
6 (Hex)4 + (Man)3(GlcNAc)2 
 
779.3 779.3 1581.5 1581.5 
7 (Hex)1 (HexNAc)2 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2 
 
812.3 812.3 1647.6 1647.6 
8 (Hex)2 (HexNAc)2 + (Man)3(GlcNAc)2 
 
820.3 820.3 1663.6 1663.6 
9 (HexNAc)3 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2 
 
832.8 832.8 1688.6 1688.6 
10 (Hex)1 (HexNAc)3 + (Man)3(GlcNAc)2 
 
840.8 840.8 ND 1704.6 
11 (Hex)5 + (Man)3(GlcNAc)2 
 
860.3 860.3 1743.6 1743.6 
12 (Hex)1 (HexNAc)2 (NeuAc)1 + 
(Man)3(GlcNAc)2 
 
884.8 884.8 ND ND 
13 (Hex)2 (HexNAc)2 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2 
 
893.4 893.4 1809.6 1809.6 
14 (Hex)1 (HexNAc)3 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2 
 
913.9 913.9 1850.7 1850.7 
15 (Hex)6 + (Man)3(GlcNAc)2 
 
941.3 941.3 1905.6 1905.6 
16 (Hex)1 (HexNAc)2 (Deoxyhexose)1 (NeuAc)1 
+ (Man)3(GlcNAc)2  
957.9 957.9 ND ND 
17 (Hex)2 (HexNAc)2 (NeuAc)1 + 
(Man)3(GlcNAc)2 
 
965.9 965.9 ND ND 
18 (Hex)1 (HexNAc)3 (Deoxyhexose)2 + 
(Man)3(GlcNAc)2 
 
986.9 986.9 ND 1997.1 
19 (Hex)2 (HexNAc)3 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2 
 
994.9 994.9 2012.7 2012.7 
20
* 
(Hex)2 (HexNAc)2 (Deoxyhexose)1 (NeuAc)1 
+ (Man)3(GlcNAc)2  
1038.9 1038.9 2123.1 2123.1 
21
* 
(Hex)1 (HexNAc)3 (Deoxyhexose)1 (NeuAc)1 
+ (Man)3(GlcNAc)2 
 
1059.3 1059.3 2163.0 2163.0 
22 (Hex)2 (HexNAc)2 (Sulphate)1 (NeuAc)1 + 
(Man)3(GlcNAc)2  




(Hex)2 (HexNAc)2 (NeuAc)2 + 
(Man)3(GlcNAc)2  
1111.9 1111.9 2290.1 ND 
24 (Hex)2 (HexNAc)2 (Deoxyhexose)1 
(Acetate)1(NeuAc)2 + (Man)3(GlcNAc)2 
 
1132.4 1132.4 ND ND 
25 (Hex)2 (HexNAc)2 (Deoxyhexose)1 (NeuAc)2 
+ (Man)3(GlcNAc)2  




































Figure S1: Tandem mass spectrometry fragmentation spectra derived from the doubly charged negative ion isomers of (A) 
m/z 698.32− and (B) m/z 1038.92−, respectively. The identified structures with their key fragments are shown. 




Chapter 4 | Investigating the Intrapatient Variation of 
Late-Stage Ovarian Cancer Tissues using  
N-Glycan MALDI Mass Spectrometry Imaging 
 
 
4.1 | Summary 
 
Matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry imaging (MSI) has been used 
for the past two decades to spatially map biomolecules, such as proteins, lipids and metabolites, on 
formalin fixed paraffin embedded (FFPE) tissue sections which can correlate molecular infromation with 
histopathological changes found in patient-derived tissues. This chapter asked the question as to 
whether N-glycans, which are known to be aberrant in ovarian cancer, can be used to differentiate 
tissue-specific regions from FFPE tissue sections of late-stage ovarian cancer patients.  
 
To summarise, this study showed that tissue regions (i.e. tumour, stroma, adipose and necrotic 
regions), isolated from FFPE tissue sections of late-stage serous ovarian cancers, can be clearly 
discriminated by the masses of the released N-glycans. Combined with liquid chromatography 
electrospray ionisation tandem mass spectrometry (LC-ESI-MS/MS), it was possible to characterise 
these masses that were visualised by high resolution MALDI-MSI, therefore providing strong evidence 
that these masses are true N-glycan structures. 
 
 
The results from this study further indicate that the location and classification of various ovarian cancers 
and their subtypes could be made possible by high resolution MALDI-MSI combined with structural 
characterisation by LC-ESI-MS/MS analysis. It is envisioned that MALDI-MS, which already has 
instruments in pathology laboratories used for bacterial biotyping, will identify tissue-specific N-glycans 
which may improve ovarian cancer diagnosis and further lead to tissue-targeted therapeutic strategies 
to improve survival rates for pateints. 
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Ovarian cancer is a fatal gynaecological malignancy in adult 
women with a five-year overall survival rate of only 30%. 
Glycomic and glycoproteomic profiling studies have 
reported extensive protein glycosylation pattern alterations 
in ovarian cancer. Therefore, spatio-temporal investigation 
of these glycosylation changes may unearth tissue-specific 
changes that occur in the development and progression of 
ovarian cancer. A novel method for investigating tissue-
specific N-linked glycans is using matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry imaging 
(MSI) on formalin-fixed paraffin-embedded (FFPE) tissue 
sections that can spatially profile N-glycan compositions 
released from proteins in tissue-specific regions. In this 
study, tissue regions of interest (e.g. tumor, stroma, adipose 
tissue and necrotic areas) were isolated from FFPE tissue 
sections of advanced serous ovarian cancers (n 3). PGC-LC-
ESI-MS/MS and MALDI-MSI were used as complementary 
techniques to firstly generate structural information on the 
tissue-specific glycans in order to then obtain high 
resolution images  
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of the glycan structure distribution in ovarian cancer tissue. 
The N-linked glycan repertoires carried by the proteins in 
these tissue regions were structurally characterized for the 
first time in FFPE ovarian cancer tissue regions, using 
enzymatic peptide-N-glycosidase F (PNGase F) release of N-
glycans. The released glycans were analyzed by porous 
graphitized carbon liquid chromatography (PGC-LC) and 
collision induced electrospray negative mode MS 
fragmentation analysis. The N-glycan profiles identified by 
this analysis were then used to determine the location and 
distribution of each N-glycan on FFPE ovarian cancer 
sections that were treated with PNGase F using high 
resolution MALDI-MSI. A tissue-specific distribution of N-
glycan structures identified particular regions of the ovarian 
cancer sections. For example, high mannose glycans were 
predominantly expressed in the tumor tissue region 
whereas complex/hybrid N-glycans were significantly 
abundant in the intervening stroma. Therefore, tumor and 
non-tumor tissue regions were clearly demarcated solely on 
their N-glycan structure distributions. Molecular & Cellular 





Ovarian cancer is the fifth most fatal malignancy in adult 
women with an estimated 21,290 new cases diagnosed and 
14,180 deaths recorded in the United States during 2015 (1). 
There are several reasons for the poor prognosis of ovarian 
cancer and its diagnosis at advanced stage—lack of diagnos-
tic markers for the early detection (2, 3), rapid metastasis of 
the disease (4), and limited or modest understanding of the 
etiology, origin and the diverse clinical and pathological be-
havior of the tumors (5). Moreover, epithelial ovarian cancer 
comprises of several distinct sub-types based on their histo-
pathological features into serous, endometrioid, clear-cell, 
mucinous, and undifferentiated subtypes (6, 7).  
Protein glycosylation is an important post-translational 
modification which has relevance in many biological 
processes such as cell signaling, immune responses, 
extracellular interaction and cell adhesion (8, 9). Aberrant 
protein glycosylation such as the expression of truncated 
glycans as well 
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as neo-expression of glycans are hallmarks of various 
cancers (10 –12). These glycomic changes facilitate the 
discrimination between healthy and cancerous cells or 
potentially reflect tumor microheterogeneity caused by the 
variation between cancer subtypes (13, 14). Increased 
branching of N-glycans is a commonly observed glycosylation 
change in cancer, which has been shown to alter the overall 
structure and function of the glycoprotein (15–17). For 
example, the synthesis of increased branching antennas on 
the glycans creates available sites for the addition of sialic 
acids (Neu5Ac) by sialyltransferases, leading to increased 
sialylation being reported in many cancers (18 –21). Similarly, 
changes in the expression of long chains of lactosamine 
(polyLacNAc) have also been reported to be associated with 
cancer (15). Likewise, terminal modifications of glycans on 
the cancer cell surface, such as fucosylation, give rise to the 
presence of Lewis and sialyl Lewis antigens that have been 
implicated in tumor progression and metastasis (22–26). 
These aberrant glycosylations play a significant role in 
malignant transformation and therefore afford a valuable 
opportunity to exploit cancer-specific protein glycosylation 
markers for prognosis and diagnosis (16).  
Mass spectrometry (MS)-based glycomic methodologies 
are now regularly used for the reliable profiling of glycans 
from clinical samples (17–22). In fact, MS identification and 
measurement of glycans are being pursued as a structurally-
informative approach as opposed to the clinically-established 
immunological assays (23–25) or arrays (26). Several quanti-
tative glycomic profiling studies have identified N-glycan 
changes that were statistically elevated in ovarian cancer 
patients’ plasma (17, 27–29). A significant increase in 
branching and sialylation patterns as well as increased 
expression of α2– 6 sialylation in ovarian cancer plasma as 
compared with healthy controls have been reported (28). 
Saladova et al., reported specific N-glycosylation changes on 
serum glycoproteins from ovarian cancer patients, including a 
decrease in galactosylation of IgG and an increase in sialyl 
Lewis X (SLe(x) on haptoglobin beta-chain, alpha1-acid 
glycoprotein and alpha1-antichymotrypsin (30). We have also 
observed membrane glycosylation changes between non-
cancerous ovarian surface epithelial (HOSE 6.3 and HOSE 
17.1) and serous ovarian cancer cell lines (SKOV 3, IGROV1, 
A2780, and OVCAR3) (31). The “bisecting N-acetyl-
glucosamine” type N-glycans, increased levels of a 2– 6 
sialylated N-glycans and “N,N-diacetyl-lactosamine” type N-
glycans were predominantly observed in serous ovarian 
cancer cell lines while absent in the noncancerous ovarian 
cells. Most of these studies yielded clinically relevant 
information on the differential expression of glycans, but the 
major focus of their analysis was on plasma-based tests to 
differentiate between healthy and diseased patients rather on 
the spatial tissue location of the expressed glycans.  
To address this challenge, we have employed glycomic 
profiling strategy to first identify the detailed N-glycan struc-  
 
 
tural changes that occur on different regions of FFPE ovarian 
tissues clinically diagnosed as serous ovarian cancer. 
Routine mass spectrometric glycoanalysis is well-established 
and reliable, but the analysis of whole tissues destroys any 
information relating to the spatial distribution of the analytes. 
Matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry imaging (MSI) is an emerging technique that 
seeks to utilize the analytical advantages of mass spectrom-
etry while preserving the spatial information of the biological 
molecule of interest inherent in the sample. The 
unambiguous correlation between histopathology and 
MALDI-MSI allows the mass measurement of sugars, 
proteins, peptides, lipids, and metabolites directly from tissue 
regions. The distribution and intensity of the detected 
biomolecules can then be visualized as an image. 
Furthermore, conventional histological staining can be 
compared on the same tissue section. Overlaying the MS 
images and optical microscope morphological images then 
can differentiate the specific molecules in each minute tissue 
section and can relate molecular distribution to the biological 
functions and morphological changes of an organ/organelle.  
MALDI-MSI can be used for both targeted and untargeted 
molecular mass analysis. A typical example of a targeted 
analysis is the measurement of a single metabolite mass 
distribution in tissue, whereas untargeted analysis could in-
clude the mass distribution of biomolecules such as protein, 
lipid or carbohydrates in a tissue. Some MALDI-MSI applica-
tions include gaining a fundamental understanding of the 
expression of biomolecules in a disease state, investigating 
and characterizing the biomolecules spatially across tissue 
sections, and developing new ways of imaging in situ There 
have been a few MALDI-MSI based analyses on the spatial 
localization of N-glycans on tissue (32–35). Recently glycan 
MALDI-MSI was used to image released glycan masses from 
Tissue MicroArrays (TMAs) of liver cancer in which many 
small tumor tissue samples from different patients were 
assembled on a single slide, and provided proof of concept 
that released glycans could be imaged on FFPE liver cancer 
tissue sections (33).  
Specifically, in this study we (1) identify the structural 
glycan features that are characteristic of serous ovarian 
cancer spec-imens by detailed PGC-LC-ESI-MS/MS, (2) use 





1 The abbreviations used are: MALDI, matrix-assisted laser 
desorption/ionization; MSI, mass spectrometry imaging; FFPE, 
formalin-fixed paraffin-embedded; CID, collision-induced dissociation; 
ESI, electrospray ionization; LC, liquid chromatography; MS/MS, 
tandem mass spectrometry; GnT-V, N-acetylglucosaminyltransferase 
V; NeuAc, N-acetylneuraminic acid; NeuGc, N-glycolylneuraminic 
acid; Man, mannose; PGC, porous graphitized carbon; PNGase F, 
peptide-N-Glycosidase F; Lea, Lewis a antigen; Gal, galactose; Fuc, 
fucose; GlcNAc, N-acetylglucosamine; ITO, Indium tin oxide; TFA, 
Trifluoroacetic acid; DHB, 2,5-Dihydroxybenzoic acid; EtOH, Ethanol; 
H&E, haematoxylin and eosin. 
 
 
3004 Molecular & Cellular Proteomics 15.9 
 
MS Imaging of N-glycans from Ovarian FFPE Tissues  
 
 
order to discriminate between tumor and nontumor tissue by 
high resolution MALDI-MSI, and (3) perform a rigorous eval-
uation of the tissue diagnostic glycan structures using inde-
pendent statistical procedures. It is envisioned that the iden-
tification of the differential localization of glycan structures 
may improve ovarian cancer diagnosis and further lead to 
novel therapeutic strategies to improve survival rates for this 
malignancy. 
 
MATERIALS AND METHODS 
 
Reagents—Glycerol free PNGase F (P0705L, 75,000 NEB units) 
was purchased from New England Biolabs (Ipswich, MA). DHB 
matrix were purchased from Sigma-Aldrich (Steinheim, Germany) 
and Bruker Daltonics (Bremen, Germany). Formalin was from Sigma-
Al-drich. Trifluoroacetic acid (TFA), ethanol and NaCl were from 
Merck (Darmstadt, Germany). Nitrocellulose membranes (0.025 µm 
VSWP) for dialysis were purchased from Millipore (Cork, Ireland). 
Xylene was purchased from Chem-Supply (Gillman, South Australia). 
Indium tin oxide (ITO) slides were purchased from Bruker Daltonics, 
whereas PEN membrane slides were from MicroDissect (Herborn, 
Germany). GLY3 standards (Man5GlcNAc2, Man3GlcNAc5, 
Man3Gal4GlcNAc6) were purchased from Prozyme (Hayward, CA). 
Unless otherwise stated, all H2O used was ultrapure (i.e. ≥18.2 Ω and 
≤5 ppb TOC). 
Tissue Sectioning—Tissue sectioning was performed as previously 
described with some minor modifications (36). Ovarian tumors tissue 
was taken from FIGO stage III ovarian cancer patients as part of 
experiments with full ethics approval and in accordance with the 
policies of the University of Adelaide Ethics Committee. Formalin was 
diluted 1:9.25 in 1 PBS and tissues were immersed in this solution 
overnight at 4°C. Tissue was then removed from the formalin, rinsed 
with de-ionized H2O and stored in 70% EtOH before processing with 
a Leica TP 1020 processor (Leica Biosystems, North Ryde, 
Australia). Protocol: 70% EtOH for 5 min, 80% EtOH for 2 h, 95% 
EtOH for 2 h, 3 x 100% EtOH for 2 h each, 2 x xylene for 2 h each 
and 2 x paraffin for 2 h each. A Leica EG 114OH embedder (Leica 
Biosystems) was used to create paraffin embedded tissue blocks. 
FFPE blocks were sectioned (6 µm thick) on a Microm HM325 
microtome (Zeiss, Go¨ ttingen, Germany) and water bath mounted 
(39°C) onto ITO slides (Bruker Daltonics) or PEN membrane slides 
(MicroDissect). Slides were left to dry at 37°C for one hour prior to 
storage at 4 °C.  
PGC-LC-ESI-Ion Trap MS and MS/MS Analysis of N-glycans Re-
leased from FFPE Tissue Sections—  
In-solution PNGase F Digestion—Tissue sections on PEN mem-
brane slides (n = 3) were used and processed as described 
previously (34), with modifications. Briefly, following a 5 min 60°C 
heating block incubation, 90 s xylene wash and 60 s EtOH wash, the 
whole FFPE tissue section was scraped off slide by a scalpel and 
deposited into micro-vials. The tissue sections were incubated (2 x 5 
min) in 10 mM NH4HCO3. Solution was removed and replaced with 
10 mM citric acid (pH 6) and heated at 98°C for 45 min. The samples 
were washed twice with 10 mM NH4HCO3. Glycerol free PNGase F 
(2 µl, non-dialyzed) was added to the FFPE tissue in a 40 µl total 
reaction volume (with 25 mM NH4HCO3). The tissue digests were left 
overnight at 37 °C.  
N-linked Glycan Release—The released N-linked glycans were re-
duced and desalted according to previously described methods (34). 
After acidification with 100 mM NH4COOH pH 5 (10 µl) for 60 min at 
room temperature, the samples were dried in a vacuum centrifuge 
and were reduced with 20 µl of 1 M NaBH4 in 50 mM KOH at 50°C for 
3 h. The reduction was quenched with 1 µl glacial acetic acid and the 
N-linked glycan alditols were desalted as described below.  
 
 
Glycan Purification—The released N-glycans were desalted using 
cation exchange columns comprising 30 µl AG50W-X8 cation-ex-
change resin (BioRad, Hercules, CA) packed on top of a C18 
StageTip Frit. Residual borate was removed by the addition of 
methanol (x3) and drying under vacuum. The glycans were further 
purified by tips using porous graphitised carbon slurry manually 
packed onto C18 StageTip Frits as previously described.  
PGC-LC-ESI-Ion Trap MS and MS/MS—The N-glycans were 
resuspended in 10 µl of milli-Q water and subjected to PGC-LC-ESI 
MS/MS separation and analysis using an Agilent 1100 capillary LC 
(Agilent Technologies, Santa Clara, CA) and analyzed using an 
Agilent MSD, three-dimensional Ion-trap XCT mass spectrometer 
coupled to the LC. Separation was performed on a Hypercarb Porous 
Graphitized Car-bon column (PGC, 3 µm particle size, 100 x 0.18 
mm, Hypercarb, Thermo Scientific). N-linked glycan alditols were 
separated across an 85 min gradient with a constant flow rate of 2 
µl/min using a linear gradient up to 45% (v/v) CH3CN in 10 mM 
NH4HCO3. ESI-MS was performed in negative ion mode with two 
scan events; MS full scan with mass range 100–2000 m/z and data 
dependent MS/MS scan after collision-induced dissociation (CID) of 
the top two most intense precursor ions. 
MALDI-MSI Analysis of N-glycans Released In Situ From FFPE 
Tissue Sections— 
Tissue Section Antigen Retrieval—Tissue sections were re-hy-
drated using a standard procedure for citric acid antigen retrieval 
(CAAR) (34). Briefly, the tissue sections were heated at 60°C for 1 h 
over a heatblock; washed in 100% xylene (2 x 5 min) and 100% 
ethanol (2 x 2 min). Sections were washed in 10 mM NH4HCO3 (2 5 
min) followed by a 10 min incubation in boiling 10 mM citric acid (pH 
6.0) and then by heating at 98°C for 30 min on a heating block. 
Finally, tissue sections were immersed twice in 10 mM NH4HCO3 (1 
min) and dried at room temperature in a humid chamber.  
In Situ PNGase F Digestion and Matrix Deposition—Neat PNGase 
F enzyme (40 ml) spotted onto a nitrocellulose membrane and drop 
dialyzed against water for 2 h at room temperature. NH4HCO3 (25 
mM, pH 8.2) was added to the dialyzed PNGase F to a total volume 
of 200 µl and the PNGase F was printed onto retrieved tissue 
sections (15 nL at 250 µm spacing) using a ChIP-1000 (Shimadzu, 
Japan). Buffer control arrays (25 mM NH4HCO3) were printed using 
the same conditions on adjacent sections. Tissue sections were 
incubated overnight at 37 °C in a humid chamber and GLY3 standard 
was manually spotted (0.5 µl) on an adjacent section. DHB (20 
mg/ml) in 0.1% (v/v) TFA and 1 mM NaCl was sprayed onto prepared 
tissues using a TM-sprayer. Instrument specific settings: 16 passes, 
0.05 ml/min flow rate, 4 psi N2 pressure, 65°C capillary temperature, 
800 mm/min.  
MALDI-TOF/TOF Mass Spectrometry and Histological Staining— 
MS data was acquired using an ultrafleXtreme MALDI-TOF/TOF 
mass spectrometer (Bruker Daltonics) controlled by flexControl (v3.4, 
Bruker Daltonics) and flexImaging (v4.0, Bruker Daltonics). Instru-
ment-specific settings were as follows: 800 – 4500 m/z range, 700 
Da matrix suppression, 2 kHz laser repetition rate and 2.5 GS/s. 
Method-specific settings were as follows: 75% laser power and 2698 
V detector gain. A total of 1000 shots were acquired at each position 
with no walk. Data was acquired by oversampling from an arbitrary 
array with center to center acquisition distance of 100 µm overlaid 
onto the 250 µm PNGase F array. The MALDI-TOF/TOF instrument 
was externally calibrated using the included GLY3 standard spots 
prior to MALDI imaging.  
Following analysis, DHB matrix was eluted using 70% EtOH and 
tissue sections were hematoxylin and eosin (H&E) stained as de-
scribed previously (34). 
Data Analysis—MALDI-MSI data was analyzed by SCiLS Lab (ver-
sion 2014a, SCiLS, Bruker Daltonics). Raw data was loaded and 
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FIG. 1. Hematoxylin and eosin (H&E) stains of tissue sections from each patient (P1, P2 and P3) that were used for MALDI mass 
spectrometry imaging (MSI) analysis. Tissue-types were annotated by a pathologist post-MALDI-MSI based on the histology with tumor 

































FIG. 2. Negative ion mode summed MS spectrum of patient P1 ovarian tissue annotated with proposed structures for N-glycans 
identified by PGC-LC-ESI MS/MS. N-glycans released in-solution from formalin-fixed paraffin-embedded ovarian cancer tissue (P1) using 
PNGaseF were reduced, de-salted and purified on a carbon column prior to porous graphitic column chromatography coupled online to an 
ESI-IT-MS system. The proposed glycan structures were deduced from their doubly charged negative ion monoisotopic masses [M-2H]2. 
 
reduced to 50,000 points per spectrum. Data was preprocessed by 
baseline subtraction and normalization to total ion current (TIC). 
Peaks were picked, aligned and the preprocessed data was used to 
generate log ion intensity maps. These log ion intensity maps were 
weakly denoised with automatic hotspot removal. Data analysis of 
the LC-ESI-MS/MS data was carried out in ESI-Compass 1.3 (Bruker 
Daltonics, Bremen, Germany).  
 
RESULTS  
In this study, we employed the N-linked glycan mass spec-
trometry imaging technique that we have previously estab-
lished (34). Briefly, the method combines released N-glycan 
MALDI-MSI of FFPE tissue with parallel detailed N-glycan 
structural characterization by negative ion PGC-LC-ESI- 
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TABLE 1  
N-glycan structures assigned by PGC-LC-ESI-ion trap MS/MS. N-glycan structures found in formalin-fixed paraffin-embedded ovarian cancer 
tissue (P1 and P2) by PGC-LC-ESI-MS/MS (singly negatively charged monoisotopic masses (M-H 1- were calculated from their observed 
doubly negatively charged monoisotopic masses (M-2H 2-), matching composition and proposed structure. Y = Yes, N = No; observed in the 









































MS/MS (36). The N-glycan analysis was applied to FFPE 
sections of the ovarian tissue from three FIGO stage III 
ovarian cancer patients labeled P1, P2 and P3. Fig. 1 shows 
hematoxylin and eosin (H&E) stains for tissue sections from 
patients P1, P2, and P3.  
We initially characterized the N-glycans of whole tissue 
sections in detail using negative ion mode PGC-LC-ESI-
MS/MS to construct a repository which could be used for 
assigning a glycan structure to the corresponding glycan 
masses from spatially localized MALDI-MSI data. N-glycan 
structures were manually assigned via the following steps: (1) 
The monosaccharide composition was deduced based on the 
mass of the released N-glycan masses (using GlycoMod 
http://web.expasy.org/glycomod/) (36) whereas structures, 
where shown, were deduced by interpretation of the MS2 









































matching of theoretical fragment mass ions produced by tan-
dem MS for each structure, (3) use of diagnostic fragment 
ions in negative ion mode that have been previously reported 
for the identification of specific glycan structural features (19, 
37, 38), and (4) known expression of glycans based on bio-
logical pathway constraints. A representative summed nega-
tive mode MS profile of patient P1 with assigned glycan 
structures is shown in Fig. 2.  
In total, 40 individual N-glycan masses (including structural 
and compositional isomers) were detected across the whole 
FFPE sections from in-solution enzyme release of the N-
glycans from a whole FFPE ovarian tissue section (see Table 
I). These N-glycan classes included high mannose, core fu-
cosylated, hybrid and complex (neutral and sialylated). Sialy-
lated N-glycans were further classified based on the number 
of sialic acid residues, in which mono-, di- and tri-sialylated 
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N-glycans were all observed to be present, Specifically the 
three most abundant glycan structures were comprised of 





























































sis, Structural isomers corresponding to differences in sialic 
acid linkages were also observed for some of the N-glycan 
masses. (1111.42 and 1184.42 ). Isomers with α 2–3 or α 
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FIG. 3. MALDI mass spectrometric imaging of N-linked glycans released from patient P1 ovarian cancer tissue sections. Formalin-
fixed paraffin-embedded ovarian cancer tissue sections were treated with antigen retrieval prior to printing of 15 nL/spot dialyzed PNGase F or 
buffer control arrays with 250 µm spacing. DHB (20 mg/ml) was sprayed onto the sections and MS spectra were acquired by oversampling at 
100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as 
(M Na) adducts. Panel A shows the log ion intensity map for the m/z 933.3 of a pauci mannose structure was observed to be localized and 
relatively highly expressed in the adipose tissue region of the FFPE tissue. The agalactosylated bisecting structure of m/z 1339.4 was 
observed only in the necrotic tissue of the sample P1. Five high mannose structures (m/z 1257.4, 1419.4, 1581.5, 1743.4, and 1905.6) were 
observed predominantly in the tumor region as shown in panel B. The hybrid/complex N-glycan structures were indicative of the stroma region 
as shown in panel C (m/z 1501.5, 1663.5, 1485.4, 1809.6, 1647.6, 1850.6, 2012.7, and 2174.7) and the sialylated structures are represented 
in panel D shows log ion intensities of the sialylated glycans of m/z 1954.6, 2245.7, 2100.7, and 2391.8.  
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FIG. 4. MALDI mass spectrometry imaging of N-linked glycans released from patient P2 ovarian cancer tissue sections. Formalin-
fixed paraffin-embedded ovarian cancer tissue sections were treated with antigen retrieval prior to printing of 15 nL/spot dialyzed PNGase F or 
buffer control arrays with 250 µm spacing. DHB (20 mg/ml) was sprayed onto the sections and MS spectra were acquired by oversampling at 
100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as 
(M Na) adducts. Panel A, shows the log ion intensity map for the m/z 933.3 of a pauci mannose structure was observed to be localized and 
relatively highly expressed in the adipose tissue region of the FFPE tissue. Five high mannose structures (m/z 1257.4, 1419.4, 1581.5, 
1743.4, and 1905.6) were observed predominantly in the tumor region as shown in panel B. The hybrid/complex N-glycan structures were 
indicative of the stroma region as shown in panel C (m/z 1501.5, 1663.5, 1485.4, 1809.6, 1647.6, 1850.6, 2012.7, and 2174.7) and the 
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FIG. 5. MALDI mass spectrometry imaging of N-linked glycans released from patient P3 ovarian cancer tissue sections. Formalin-
fixed paraffin-embedded ovarian cancer tissue sections were treated with antigen retrieval prior to printing of 15 nL/spot dialyzed PNGase F or 
buffer control arrays with 250 µm spacing. DHB (20 mg/ml) was sprayed onto the sections and MS spectra were acquired by oversampling at 
100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as 
(M Na) adducts. Panel A shows the log ion intensity map for the m/z 933.3 of a pauci mannose structure was observed to be localized and 
relatively highly expressed in the adipose tissue region of the FFPE tissue. Five high mannose structures (m/z 1257.4, 1419.4, 1581.5, 
1743.4, and 1905.6) were observed predominantly in the tumor region as shown in panel B. The hybrid/complex N-glycan structures were 
indicative of the stroma region as shown in panel C (m/z 1501.5, 1663.5, 1485.4, 1809.6, 1647.6, 1850.6, 2012.7, and 2174.7) and the 
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2– 6 sialic acids were differentiated based on the chromato-
graphic behavior and retention times of previous studies (31, 
38, 39). Detailed structural characterization of the N-glycans 
was carried out by tandem MS fragmentation analysis. Exam-
ples of the collision-induced dissociation (CID) fragmentation 
of N-glycans in negative mode analysis characterized in this 
study is described using two examples in supplemental Fig. 
S2 for glycan masses of (1) m/z 693.32 and (2) m/z 832.82. 
For MALDI imaging analysis, duplicate FFPE ovarian tumor 
sections of each patient (P1, P2 and P3) were then prepared 
for N-glycan MALDI-MSI by antigen retrieval and PNGase F 
printing onto the tissue sections followed by overnight incu-
bation at 37°C and spray deposition of DHB. 
Intensity ion maps for the three FFPE samples (P1, P2, P3) 
of the glycan masses detected (Table 1) in the LC-ESI-MS 
analysis were constructed. Representative ion intensity maps 
of the positive ion monoisotopic masses of the tissue sections 
are shown in Figs. 3, 4 and 5. The spatial distribution and 
localization of these structures were observed to be class 
dependent. For example, the adipose tissue region 
corresponded to the location of the pauci-mannose glycan 
(Man)3(GlcNAc)2 of mass m/z 933.3 in all patient samples 
(Fig. 3A, 4A, 5A). Similarly, all high mannose glycans were 
significantly abundant in the tumor region across the three 
samples (Fig. 3B, 4B, and 5B) corresponding to glycan 
masses of m/z 1257.4, 1419.4, 1581.5, 1743.4, and 1905.6. 
Although com-plex bi-antennary and tri-antennary antennary 
structures were abundantly observed in the stromal region 
(masses m/z 1501.5, 1663.5, 1485.4, 1809.6, 1647.6, 
1850.6, 2012.7, and 2174.7 (Fig. 3C, 4C, and 5C), mono and 
di-sialylated structures (m/z 1954.6, 2245.7, 2100.7, and 
2391.8) were observed as sodiated adducts as shown in Fig. 
3D, 4D, and 5D, predominantly in the stromal region, 
although traces of these species were also observed in the 
tumor regions.  
The In situ PNGase-F released N-glycans were easily able 
to discriminate these four tissue-types by single unique gly-
can masses; for example, four distinct N-glycan masses that 
are representative of different glycan classes discriminated 
the four different tissues within the FFPE section as shown in 
Fig. 6. The log ion intensity map for the m/z 1339.4 corre-
sponding to the agalactosylated bi-antennary glycan (Gl-
cNAc)2 (Man)3(GlcNAc)2 was observed to be localized and 
relatively highly abundant only in the necrotic region of the 
FFPE tissue section (Fig. 6C). On the other hand, the mass 
m/z 2175.5 corresponding to a complex fucosylated tri-an-
tennary structure ((Gal)3 (GlcNAc)3 (Fuc)1 (Man)3(GlcNAc)2) 
was observed predominantly in the stroma region. The adi-
pose tissue region was demarcated solely by the mass of the 
of the pauci-mannose glycan (Man)3(GlcNAc)2 of mass m/z 
933.3 (Fig. 6A). Importantly, the high mannose mass of m/z 
1743.5 ((Man)5 (Man)3(GlcNAc)2) was indicative of the tumor 
region (Fig. 6B).  
Statistical analysis by receiver operating curve (ROC) anal-
ysis and determination of the area under the ROC curve 
(AUC), was carried out to determine the specificity and sen-
sitivity of using these N-glycans as potential discriminators of 
different tissue types. The AUC value from the ROC test is 
indicative of the diagnostic value of a specific indicator; spe-
cifically by a plot of sensitivity (i.e. the true-positive rate) 

























FIG. 6. MALDI imaging MS of N-linked glycans released from 
ovarian cancer sections. Formalin-fixed ovarian cancer sections 
were treated with antigen retrieval prior to printing of 30 nL/spot 
dialyzed PNGase F or buffer control arrays with 250 µm spacing. 
DHB (20 mg/ml) was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/ 
TOF MS instrument. Monoisotopic glycan masses were measured in 
the positive ion reflectron mode as (M Na) adducts. Panel A shows 
the log ion intensity map for the m/z 1339.4 that corresponds to a 
(GlcNAc)2 (Man)3(GlcNAc)2 that was observed to be localized and 
relatively highly expressed in the necrotic tissue region of the FFPE 
tissue. Similarly, B m/z 2175.5 (Gal)3 (GlcNAc)3 (Fuc)1 (Man)3 
(GlcNAc)2 corresponding to a complex tri-antennary structure was 
observed predominantly in the stroma region. The high mannose 
mass of C m/z 1743.5 (Man)5 (Man)3(GlcNAc)2 was indicative of the 
tumor region. The adipose tissue region corresponded to the pauci-
mannose glycan D (Man)3(GlcNAc)2 of mass m/z 933.3.  
 
The four glycan masses used to discriminate the different 
tissue regions observed in Fig. 6 (masses m/z 1339.4, 
2175.5, 1743.5, and 933.3) showed high AUC values 
between 0.84 to 0.99 (Fig. 7), confirming their potential power 
as discriminators between tumor, stromal, adipose, and 
necrotic tissue regions.  
A data-driven approach was also implemented to discover 
whether glycan structural data alone can be used to define 
tissue morphology. To achieve this, the MALDI imaging data 
spectra were loaded into SCiLS Lab 2D software (version 
2014a, SCiLS GmbH), which provides computational meth-
ods to analyze MALDI imaging datasets. A key feature of this 
software is spatial segmentation which allows whole spectra 
with similar features (i.e. peaks) to be clustered and thereby 
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FIG. 7. Receiver operating characteristics (ROC) plots of glycan m/z from Fig. 6 used to discriminate tissue regions from sample P1.  
A, ROC plot for the glycan m/z 1743.5 B, ROC plot for the glycan m/z 1339.4 C, ROC plot for the glycan m/z 933.3 D, ROC plot for the glycan 
m/z 2175.5. 
 
The segmentation map for the entire data set of patient P1 as 
shown in Fig. 8 discriminates between tumors (dark blue), 
stromal (light blue) and adipose (orange) of the sections at 
the segmentation levels selected (see insert). The 
segmentation map illustrates the potential that glycans 
possess in distinctly segmenting a histologically complex 
tissue section, and also highlights the heterogeneity of cancer 
tissue samples.  
This striking tissue segmentation map demonstrates the 
potential to use individual N-glycan masses to identify spe-
cific tissue regions, however the summed mass spectra from 
the different tissue regions could also be used as a mass-
spectral pattern to identify and discriminate unique tissue  
 
regions as shown in supplemental Fig. S3. Using a series of 
masses with distinctive relative intensities as observed in the 
summed mass spectra in supplemental Fig. S3, could in-
crease the sensitivity and facilitate high throughput analysis 




MALDI-MSI of N-glycans is a relatively new technique that 
has immense potential in several clinical applications includ-
ing identification and validation of biomarkers in cancer tis-
sues. Glycosylation changes are a hallmark of disease states 
and identification of the aberrant glycan changes directly 
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FIG. 8. MALDI imaging MS of N-linked glycans released from 
formalin-fixed ovarian cancer sections. Formalin-fixed ovarian 
cancer sections were treated with antigen retrieval prior to printing of 
(30 nL/position) dialyzed PNGase F or buffer control arrays with 250 
µm spacing. DHB (20 mg/ml) was sprayed onto the sections and MS 
spectra were acquired by oversampling at 100 µm intervals using a 
MALDI-TOF/TOF MS instrument. Data was loaded raw into SCiLS, 
pre-processed for baseline subtraction and normalization to total ion 
current (TIC) prior to segmentation analysis (maximum processing 
mode, interval width of 0.5 Da, strong smoothing). The segmentation 
map for the entire data set of patient P1 discriminates between tumor 
(dark blue), stroma (light blue), adipose (orange) necrotic (green) and 
tissue border (brown) of the sections at the segmentation levels 
selected (see insert). The dendrogram (Fig. insert) shows the number 
of spectra clustered together for each region.  
 
relates to molecular changes in the glycosylation machinery. 
Cancer cells frequently display glycans at different levels or 
with fundamentally different structures than those observed 
from normal cells (10). There are several advantages offered 
by the analysis of these post-translationally added glycans, 
because aberrant glycosylation affects several glycoproteins 
simultaneously and is therefore an amplified effect that may 
be easily distinguished compared with other biomolecules. 
This is clearly demonstrated in this study, where the obser-
vation of significant abundances of the entire class of high-
mannose N-glycans is apparent specifically in the tumor tis-
sue of all three patients. This high abundance localization of 
the early products of the N-glycan biosynthetic pathway spe-
cifically in the tumor may reflect the incomplete time for 
processing of the structures in the rapidly dividing cancer cell 
environment.  
MALDI-MS is known to result in a loss of sialylation of 
glycan species. This limitation for the measurement of sialy-
lated N-glycans by MALDI-MSI is confirmed by this study 
where the sialylated species were observed in negative ion 
mode by ESI and CID fragmentation whereas MALDI-MSI in 
the positive ion mode had few sialylated species detected. 
The masses of the low abundance sialylated species that 
were detected in the MALDI-MSI analysis corresponded to 
multiply sodiated adducts. The prominence of sialyated gly-
cans in these samples and their isomeric differentiation ob-
served by PGC-LC-ESI-MS illustrates the need in the future 
development of this technique for the use of derivatization 
techniques for MALDI-MSI analysis of these labile glycans  
(40) or by optimization of MALDI-MSI analysis in the negative 
ion mode that protects the sialylation. Very recently Holst et 
al., have demonstrated a promising linkage-specific in situ  
 
 
sialic acid derivatization for N-Glycan mass spectrometry im-
aging of formalin-fixed paraffin-embedded tissues (41).  
Through the combination of detailed structural character-
ization by negative mode PGC-LC-ESI-MS/MS analysis and 
positive mode high resolution MALDI-MSI, we were able to 
differentiate tumor from non-tumor tissue regions in three 
ovarian cancer FFPE tissue sections by using only 4 masses 
corresponding to four specific N-glycan structures that are 
representative of different N-glycan classes. Distinct N-gly-
cans were identified that were consistently able to differenti-
ate between the tissues across biological samples. Surpris-
ingly, specific single glycan masses were able to discriminate 
between necrotic, tumor, adipose and stromal tissue regions. 
The N-glycan based tissue differentiation observed in this 
study offers a unique advantage in analysis of ovarian 
cancer. The results from this study indicate that the location, 
diversification or classification of the various ovarian cancers 
and their subtypes could be made possible by high resolution 
MALDI-MSI aided by structural characterization of the impli-
cated glycan structures by PGC-LC-ESI-MS/MS analysis.  
The increase in high mannose structures have been previ-
ously reported in breast cancer progression in mouse 
models, colorectal cancer cell lines and hepatocellular 
carcinoma, among others (42– 44). The increased expression 
of high-mannose glycans could suggest a premature 
termination of the glycosylation pathway during glycan 
synthesis. Although we observed some sialylation in the 
tumor region, it was considerably lower than that of the 
underlying stroma. It would be of interest to compare the 
sialylation of ovarian tumor region with its health counterpart.  
The need to constantly improve and advance MALDI-MSI 
is also evident from this study. The PGC-LC-ESI-MS analysis 
revealed several N-glycans, specifically the sialylated and 
highly branched structures, which were not detected using 
the MALDI-MSI technique. There is also a need to further 
optimize and improve the sensitivity of detection for N-glycan 
MALDI-MSI and extend the detection into the O-glycan 
space. Although several challenges and limitations are 
evident, the combination of structural detail from PGC-LC-
ESI-MS/MS and spatial localization from MALDI-MSI is a 
unique tool, is able to be performed with current technologies 
and offers far more information for distinguishing and 
classifying tissue compared with the more conventional 
histopathology staining methods. 
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Figure S1: Combining N-glycan MALDI imaging and PGC-LC-ESI-MS/MS in FFPE-preserved tissue type tissue with 
































Figure S2: Negative ion mode fragmentation analysis of N-glycans of m/z 693.32- (a) and m/z 832.82- (b). The fragmentation 
analysis was carried out using structural feature ions observed in negative mode analysis of oligosaccharides and N-
glycosylation biological pathway constraints. Figure S2a shows the tandem mass spectrum in negative ion mode of a high 
mannose structure ((Man)3+(Man)3(GlcNAc)2) of m/z 698.2 (M-2H)2-. Figure S2b shows the tandem mass spectra resulting 
from CID in the negative mode of a core-fucosylated bisecting biantennary agalactosylated glycan structure of m/z 832.82-

































Figure S3: Positive ion mode summed MS spectrum of various tissue regions and annotated glycans with proposed 
structures identified by PGC-LC-ESI MS/MS. Formalin-fixed ovarian cancer sections (patient P1) were treated with antigen 
retrieval prior to printing of 30 nL/spot dialyzed PNGase F or buffer control arrays with 250 µm spacing. DHB (20 mg/mL) as 
matrix was sprayed onto the sections and MS spectra were acquired by oversampling at 100 µm intervals using a MALDI-
TOF/TOF MS instrument. 
 
 
Chapter 5 | Investigating the Interpatient Variation of 
Early- and Late-Stage Ovarian Cancer Tissues using 




5.1 | Summary 
 
Studies on protein N-glycosylation have extensively reported aberrant patterns in the ovarian cancer 
tumour microenvironment. Therefore, obtaining spatial information is essential to uncover tumour-
specific N-glycan alterations in ovarian cancer development and progression. Matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry imaging (MSI) was employed to investigate the 
spatial distribution of N-glycans on formalin-fixed paraffin-embedded (FFPE) ovarian cancer tissue 
sections from both early- and late-stage patients. Tumour-specific N-glycans were identified and 
structurally characterised by PGC-LC-ESI-MS/MS. A total of 14 N-glycans were visualised as ion 
intensity maps using MALDI-MSI while 42 N-glycans (including structural and compositional isomers) 
were identified and structurally characterised by PGC-LC-ESI-MS. The spatial distribution of 
oligomannose, complex neutral, bisecting and sialylated N-glycan families were only observed to be 
localised to the tumour regions of late-stage ovarian cancer patients relative to early-stage patients.  
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Epithelial ovarian cancer is one of the most fatal gynaecological malignancies in adult women. 
Studies on protein N-glycosylation have extensively reported aberrant patterns in the ovarian cancer 
tumour microenvironment. Therefore, obtaining spatial information is essential to uncover tumour-
specific N-glycan alterations in ovarian cancer development and progression. Matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry imaging (MSI) was employed to investigate the 
spatial distribution of N-glycans on formalin-fixed paraffin-embedded (FFPE) ovarian cancer tissue 
sections from both early-stage (n = 3) and late-stage (n = 3) patients. Tumour-specific N-glycans 
were identified and structurally characterised by PGC-LC-ESI-MS/MS, and then assigned to images 
obtained from MALDI-MSI. A total of 14 N-glycans were visualised as ion intensity maps using 
MALDI-MSI while 42 N-glycans (including structural and compositional isomers) were identified and 
structurally characterised by LC-MS. The spatial distribution of oligomannose, complex neutral, 
bisecting and sialylated N-glycan families were only observed to be localised to the tumour regions of 
late-stage ovarian cancer patients relative to early-stage patients. Potential N-glycan diagnostic 
markers that emerged include the high mannose structure, (Hex)6 + (Man)3(GlcNAc)2, the bisecting 
structure, (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2, and the sialylated structure, (Hex)2 
(HexNAc)2 (NeuAc)1 + (Man)3(GlcNAc)2. These observations require validation on large patient 





Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy in adult women with an 
estimated 1,580 new cases diagnosed and 1,047 deaths estimated in Australia during 2017 
(Australian Institute of Health and Welfare, 2017). Ovarian cancer is asymptomatic, leading to late-
stage diagnosis of patients with stage III or IV cancer based on the International Federation of 
Gynaecology and Obstetrics (FIGO) staging system (see Table 1). 
 
 
Table 1: FIGO stages of epithelial ovarian cancer and the extent of tumour spread. 
FIGO stage Tumour spread 
I Confined to ovaries 
II Ovaries and pelvic extension 
III Ovaries, peritoneum outside the pelvis and/or retroperitoneal lymph nodes 
IV Distant metastasis excluding peritoneal metastasis 
 
Surgery combined with chemotherapy is the standard treatment protocol for late-stage ovarian cancer. 
The effectiveness of this treatment strategy is poor, which leads to poor prognosis and a five-year 
overall survival rate of 30% (Zhu et al., 2006). Furthermore, the ability to diagnose ovarian cancer 
patients in the early-stages of the disease is also poor. Improvements in treatment and diagnosis may 
be possible by utilising clinical information such as grade, metastatic status and/or treatment response 
in conjunction with molecular level information, such as ‘omics’ data, from these patients. 
 
It has been well documented that genomics can divide ovarian cancer into two distinct groups. Group I 
contains low-grade and ‘borderline’ serous tumours, endometrioid, mucinous and clear cell tumours, 
while group II contains high-grade serous and endometrioid tumours, and many low incidence tumours 
(Vang et al., 2009). Although there are benefits of this classification strategy, there are also 
disadvantages, such as gene transcription levels not mirroring levels of protein translation (Lu et al., 
2007). In addition, genomics can only predict sites of post-translational modifications (PTMs), which do 
not necessarily correlate with genuine PTM sites (Kim et al., 2008). A holistic molecular understanding 
of globally regulated pathways in ovarian cancer therefore require the combination of genomic 
information with protein abundance and modification state. 
 
Proteomics is well established has been widely applied to ovarian cancer tissue samples. For example, 
El Ayed, M. et al measured the spatial distribution of intact proteins and tryptic peptides across stage III 
and IV adenocarcinoma, borderline and benign tumour tissue sections (El Ayed et al., 2010). It was 
concluded that S100 proteins, cytoskeleton modifying proteins and even an oviduct-specific 
glycoprotein (OGP, Mucin-9), a marker of normal oviductal epithelium, were all observed to be spatially 
localised to tumour regions. Mucin-9 has previously been found to be a tubal differentiation marker, 
therefore indicating early events of ovarian carcinogenesis. Glycoproteomics is a rapidly emerging field 
where glycoproteins are extensively studied; however there are limitations with determining glycan 
structure. Therefore, to address this caveat, glycans are released from biological samples and analysed 
through the field of glycomics. 
 
 
Glycomics is the comprehensive study of sugars present on complex molecules, such as proteins, 
lipids and proteoglycans, in an organism. The attachment of glycans to such molecules is a widely 
studied PTM that is relevant to several biological processes such as cell signalling, immune responses, 
extracellular interaction and cell adhesion (Ohtsubo and Marth, 2006). There are two main types of 
protein linked glycosylation; N- and O-linked, which are attached to asparagine and serine/threonine 
residues respectively (North et al., 2009). In the tumour microenvironment, there have been reports of 
aberrant N-linked glycosylation patterns associated with tumour growth, cancer development and 
metastasis (Carvalho et al., 2016; Dube and Bertozzi, 2005; Hakomori, 2002). These observations of 
aberrant glycosylation provide molecular-level glycomic profiles of different disease states relative to 
healthy samples (Abbott et al., 2010). The N-glycome can be studied by enzymatic release using 
PNGase F followed by reduction and clean-up, and then run on porous graphitised carbon (PGC) liquid 
chromatography (LC) electrospray ionization (ESI) tandem mass spectrometry (MS/MS), which is one 
of the most sensitive and comprehensive mass spectrometry techniques (Jensen et al., 2012). 
 
Anugraham, M. et al used PGC-LC-ESI-MS/MS to structurally characterize N-glycans released from ovarian 
cancer (SKOV 3, IGROV1, A2780, OVCAR 3) and normal ovarian cell lines (HOSE 6.3 and HOSE 17.1) 
(Anugraham et al., 2014). It was discovered that bisecting structures were highly expressed in serous 
ovarian cancer cell lines relative to the normal ovarian cell lines. This observation was then correlated with 
gene expression profiles of the glycostransferase enzyme (MGAT3), which adds a GlcNAc residue in a β 1-
4 linkage to the N-glycan core to create bisecting structures. Additionally, this study also concluded that 
MGAT3 expression may be epigenetically regulated by DNA hypomethylation, leading to an increase of 
abundance in bisecting N-glycans. SKOV 3, and its highly metastatic derivative SKOV 3-ip, were also 
studied in 2014 (Zhang et al., 2014). A total of 17 N-glycans were identified and structurally characterised, 
with bisecting N-glycans featuring a significant decrease in the highly metastatic cell line SKOV 3-ip 
relative to SKOV 3 cell line. This observation was subsequently validated using real-time PCR, western 
blotting, transwell assay, lectin blotting and immunohistochemistry (IHC) analysis. The decrease of 
bisecting N-glycans from SKOV 3-ip cells requires investigation to further understand this observation. 
Although ovarian cancer cell lines provide a wealth of biological information, it has been documented 
that the most frequently used cell lines do not represent high-grade serous ovarian cancer, based on 
their genomes (Domcke et al., 2013). 
 
Evaluation of tissue excised from ovarian cancer patients offers the ability to directly correlate glycan 
changes with classified low- and high-grade ovarian cancer. Excised samples can be preserved in two 
 
conventional ways; as fresh frozen (FF) or formalin-fixed paraffin-embedded (FFPE). Fresh frozen 
tissue has been utilized in several studies; however, most studies have turned to formalin-fixation due 
to specific handling/storage requirements and expense associated with storage and transport of fresh 
frozen samples. There have been only a handful of publications that study the glycomes of ovarian 
cancer tissue. In 2015, Allam, H. et al isolated N-glycans from FF endometrioid, serous and healthy 
ovarian cancer tissue sections (Allam et al., 2015). It was discovered that bisecting N-glycan structures 
were elevated in the serous ovarian cancer tissue as well as the glycosyltransferase enzyme, MGAT 3. 
More recently, the glycomes from cancer tissue originating from the ovaries and peritoneum were 
compared using PGC-LC-ESI-MS/MS (Anugraham et al., 2017). This study reported high levels of α2-6 
sialylated and bisecting N-glycan structures from both cancers originating from the ovaries and 
peritoneum. However, there were several glycan structures specific to the cancer originating from the 
ovaries, such as LacdiNAc-type (GalNAcβ1-4GlNAc) motifs that were correlated with gene expression 
of B4GALNT3 and B4GALNT4. In 2017, Chen, H. et al used MALDI-MS to compare N-glycan profiles 
of different pathological grades of epithelial ovarian cancer tissue and healthy controls (Chen et al., 
2017). A total of 
 
80 N-glycan compositions were detected, with high mannose N-glycans highly expressed in cancer 
relative to healthy. Four oligomannose and three fucosylated neutral complex N-glycans were 
combined together and analysed by receiver operating characteristic (ROC) using binary logistic 
regression rule to generate good discrimination between cancer and healthy samples. 
 
Overall, these three publications concluded that there are N-glycan families specific to ovarian cancer. 
However, there is no mention confirming that tumour regions were isolated from underlying stroma or 
adipose, for instance, by laser capture microdissection (LCM) (Hinneburg et al., 2017). The caveat with 
LCM is the removal of spatial information as it is difficult to isolate tissue-specific regions. This is a key 
concept as it would be ideal to correlate changes in N-glycosylation pathways with tissue morphology, 
and in particular, surgical annotations. This has recently been overcome with a novel workflow that 
combines mass spectrometry techniques, providing both spatial and structural information (Briggs et 
al., 2017). 
 
Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is a spatial 
technique applied to tissue sections to measure the distribution of analytes, such as proteins, peptides, 
lipids, drugs, metabolites and N-glycans. The recent complementation of N-glycan MALDI-MSI and 
PGC-LC-ESI-MS/MS as a workflow for comprehensive N-glycan analysis was first employed in 2015 as 
 
a proof-of-principle (Gustafsson et al., 2015). This straightforward method utilised FFPE murine kidney, 
therefore identifying confirmed N-glycan structures that could distinguish between the cortex, medulla 
and pelvis. We have recently published a detailed protocol paper that provides readers with step-by-
step instructions on combining MALDI-MSI with PGC-LC-ESI-MS/MS in order to obtain both spatial and 
structural information on protein linked N-glycans respectively (Briggs et al., 2017). 
 
Powers, T. et al have utilised MALDI Fourier-transform ion cyclotron resonance (FTICR) for its mass 
accuracy and on-tissue collision-induced dissociation (CID) fragmentation to identify and characterise 
N-glycan structures from MALDI-MSI experiments (Powers et al., 2015; Powers et al., 2014). As an 
example, a singly core fucosylated N-glycan was analysed from FFPE hepatocellular cancer tissue 
using MALDI-FTICR and continuous accumulation of selection ions (CASI), coupled with CID, 
generated a fragmentation pattern capable of characterising its structure. In this analysis, only two 
fragment ions were generated, therefore providing incomplete structural information of the isolated N-
glycan. Additionally, this approach does not provide comprehensive structural information on the 
possible related N-glycan isomers (i.e. N-glycoforms). In 2016, Holst, S. et al developed a novel 
method to address this issue by using a derivatization approach of the differently linked sialic acids for 
subsequent MALDI-MSI to identify linkage-specific sialylated species (i.e. α2-3 and α2-6 sialic acid) 
(Holst et al., 2016). However, only sialylated N-glycoforms could be identified as potential N-glycan 
candidates, while non-sialylated N-glycoforms could not be considered due to limitations with 
methodology. 
 
We recently applied our released N-glycan MALDI-MSI and PGC-LC-ESI-MS/MS protocol to FFPE 
ovarian cancer patient tissues (Everest-Dass et al., 2016). Late-stage (or stage IIIC) patient FFPE 
sections were selected (n = 3) and analysed for the glycan distribution across the tissue sections. We 
identified 40 individual N-glycan structural and compositional isomers by PGC-LC-ESI-MS/MS and 
could discriminate between tumour, stroma, adipose and necrotic regions of the ovarian tissue sections 
based on specific N-glycan families. For example, oligomannose N-glycans were predominantly 
expressed in tumour regions while complex N-glycans were the abundant protein-linked structure in the 
adjacent stroma. 
 
This study extends this work using MALDI-MSI with PGC-LC-ESI-MS/MS to investigate whether N-
glycans released from proteins in ovarian cancer FFPE tissue sections could discriminate between 
early-stage (i.e. stage I) and late-stage (i.e. stage III) ovarian cancer. The combination of spatial and 
structural information of the N-glycans offers the potential to discover specific N-glycans that are 
 
indicative of ovarian cancer progression and could lead to the development of targeted therapeutic 
strategies for ovarian cancer patients. 
 
 




See Table 1 from our previous publication for a comprehensive list of chemicals, consumables and 
equipment used in this protocol (Briggs et al., 2017). 
 
2.2. Tissue Sectioning 
 
Tissue sectioning was performed as previously described (Briggs et al., 2017). Epithelial ovarian cancer 
tissue from FIGO stage IA/IC and IIIC were obtained from patients at surgery from 2009 to 2016 and 
staged by a pathologist according to the approved protocol from the Royal Adelaide Hospital (RAH) 
Human Ethics Committee (RAH protocol number: 140101). The tissues were fixed in 10% (w/v) 
formalin (F1635, Sigma Aldrich) for 48 hours at 4°C. Tissue was then removed from the formalin, rinsed 
with de-ionized H2O and stored in 70% (v/v) EtOH before processing with a Leica TP 1020 processor 
(Leica Biosystems, North Ryde, Australia). Protocol: 70% (v/v) EtOH for 5 min, 80% (v/v) EtOH for 2 h, 
95% (v/v) EtOH for 2 h, 3 x 100% (v/v) EtOH for 2 hours each, 2 x xylene for 2 h each and 2 x paraffin 
for 2 h each. A Leica EG 114OH embedder (Leica Biosystems) was used to create paraffin embedded 
tissue blocks. FFPE blocks were sectioned (6 µm thick) on a Microm HM325 microtome (Zeiss, 
Göttingen, Germany) and water bath mounted (39ºC) onto ITO slides (Bruker Daltonics) or PEN 
membrane slides (MicroDissect). Slides were left to dry at 37°C for one hour prior to storage at 4°C. 
 
2.3. N-glycan MALDI-MSI of FFPE Tissue Sections 
 
2.3.1. Tissue Section Antigen Retrieval 
 
Tissue sections were re-hydrated using a standard procedure for citric acid antigen retrieval (CAAR) 
(Briggs et al., 2017). Briefly, the tissue sections were heated at 60 °C for 1 h over on a heatblock; 
washed in 100% (v/v) xylene (2 x 5 min) and 100% (v/v) ethanol (2 x 2 min). Sections were washed in 
10 mM NH4HCO3 (2 x 5 min) followed by a 10 min incubation in boiling 10 mM citric acid (pH 6.0) and 
then by heating at 98 °C for 30 min on a heating block. Finally, tissue sections were immersed twice in 
10 mM NH4HCO3 (1 min) and dried at room temperature in a humid chamber. 
 
2.3.2. In Situ PNGase F Digestion and Matrix Deposition 
 
 
40 µL of glycerol-free PNGase F (75,000 units, New England Biolabs) was spotted onto a nitrocellulose 
membrane and drop dialyzed against water for 2 h at room temperature. NH4HCO3 (25 mM, pH ~8.2) 
was added to the dialyzed PNGase F to a total volume of 200 µL and the PNGase F was printed onto 
tissue sections (15 nL at 250 µm spacing) using a ChIP-1000 (Shimadzu, Japan). Buffer control arrays 
(25 mM NH4HCO3) were printed using the same conditions on adjacent sections. Tissue sections were 
incubated overnight for approximately 16 h at 37°C in a humid chamber and GLY3 standard was 
manually spotted (1 µL) on an adjacent section. ITO slides are marked at the edges with water-based 
white out and tissue sections are scanned at 2400 dpi on a CanoScan 5600 F (Canon) scanner for 
instrument teaching purposes. 2,5-DHB (20 mg/ml) in 0.1% (v/v) TFA and 1 mM NaCl was sprayed 
onto prepared tissues using a HTX TM-sprayer. Instrument specific settings: 16 passes, 0.05 ml/min 
flow rate, 4 psi N2 pressure, 65 °C capillary temperature, 800 mm/min. The addition of NaCl to the 2,5-
DHB mixture is necessary to detect sodiated N-glycan adducts in positive ion-MS. 
 
2.3.3. MALDI-TOF/TOF Mass Spectrometry 
 
MS data was acquired using an ultrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker 
Daltonics) controlled by flexControl (v3.4, Bruker Daltonics) and flexImaging (v4.0, Bruker Daltonics) 
in reflectron positive ion mode. Instrument-specific settings were as follows: 800– 4500 m/z range, 
700 Da matrix suppression, 2 kHz laser repetition rate and 2.5 GS/s. Method-specific settings were 
as follows: 75% laser power and 2698 V detector gain. A total of 1000 shots were acquired at each 
position with no walk. Data was acquired by oversampling from an arbitrary array with centre to 
centre acquisition distance of 100 µm overlaid onto the 250 µm PNGase F array at the Smartbeam 
‘4_large’ setting. N-glycan delocalisation was assessed by acquiring spectra off-tissue. The MALDI-
TOF/TOF instrument was externally calibrated using a quadratic fit prior to acquisition using the 
GLY3 standard spots prior to MALDI-MSI (see Table 2). 
 
Table 2: N-glycan standard mixture (GLY3; Prozyme, Hayward, CA, USA) used for calibration of the MALDI-
TOF/TOF MS instrument. 
 
N-glycan composition [M] [M + Na+]+ 
Man5GlcNAc2 1234.4333 1257.4225 
Man3GlcNAc5 1519.5659 1542.5551 
Man3Gal4GlcNAc6 2370.8565 2393.8457 
Concentration: 1 pmol/µL   
 
 
2.3.4. Histological Staining 
 
Following MALDI imaging, 2,5-DHB matrix was eluted using 70% EtOH and tissue sections were 
haematoxylin and eosin (H&E) stained as described previously (Briggs et al., 2017). Tumour regions 
on tissue sections were annotated by pathologist Professor Gurjeet Kaur. 
 
2.3.5. Data Analysis 
 
Raw MALDI-MSI data was analysed by SCiLS Lab (version 2016b, SCiLS, Bruker Daltonics). Raw 
data was loaded and pre-processed by baseline subtraction (TopHat at default peak width) and 
normalization to total ion current (TIC). Peaks were picked, aligned and the pre-processed data was 
used to generate log ion intensity maps. These log ion intensity maps were weakly denoised with 
automatic hotspot removal. 
 
2.4. PGC-LC-ESI-Ion Trap MS and MS/MS of N-glycans released from Laser Captured 
Microdissected FFPE Tissue Sections 
 
2.4.1. In-solution PNGase F digestion 
 
Tissue sections on PEN membrane slides (n = 6) were used and processed as described previously, 
with modifications (Briggs et al., 2017). Briefly, following a 5 min 60ºC heating block incubation, 90 sec 
xylene wash and 60 sec EtOH wash, the tissue sections were stained with haematoxylin and a 604, 
259 µm2 tumour region was selected and isolated by LCM from each section (using a Leica AS LCM 
microscope), and deposited into a micro-vial. The tissue was incubated (2 x 5 min) in 10 mM NH4HCO3. 
Solution was removed and replaced with 10 mM citric acid (pH 6) and heated at 98°C for 45 min. The 
tissue regions were washed twice with 10 mM NH4HCO3. Glycerol free PNGase F (2 µL, non-dialysed) 
was added to the FFPE tissue in a 10 µL total reaction volume (with 25 mM NH4HCO3) for the tumour 
regions. The tissue digests were left overnight for approximately 16 h at 37°C. 
 
2.4.2. N-linked glycan reduction 
 
The released N-linked glycans were reduced and desalted according to previously described methods 
(Jensen et al., 2012). After acidification with 100 mM NH4COOH pH 5 (10 µL) for 60 min at room 
temperature, the samples were dried in a vacuum centrifuge and were reduced with 20 µL of 1 M 
 
NaBH4 in 50 mM NaOH at 50oC for 3 h. The reduction was quenched with 2 µL glacial acetic acid and 
the N-linked glycan alditols were desalted as described below. 
 
2.4.3. Glycan purification 
 
The released N-glycans were desalted using cation exchange columns comprising 30 µL AG50W-X8 
cation-exchange resin (BioRad, Hercules) pipetted on top of a C18 ZipTip (0.1-10 µL, Millipore). 
Residual borate was removed by the addition of methanol (x 3) and drying under vacuum. The glycans 
were further purified by tips using porous graphitised carbon slurry (GlycoClean H Cartridges, Prozyme) 
manually pipetted onto C18 ZipTip (0.1-10 µL, Millipore) as previously described (Jensen et al., 2012). 
 
2.4.4. PGC-LC-ESI-Ion Trap MS and MS/MS 
 
The reduced N-glycans were resuspended in 10 µL of ultra-pure water and subjected to PGC-LC-ESI-
MS/MS based on previously published settings (Hinneburg et al., 2017). A 1100 capillary and nano-
pump LC system (Agilent Technologies, CA) was used and coupled to an amaZon ETD Ion Trap MS 
(Bruker Daltonics, Bremen, Germany) via a CaptiveSpray nano ionisation source with nanoBooster 
(Bruker Daltonics) under the control of HyStar software (version 3.0.394.0, Bruker Daltonics) and 
TrapControl (version 7.2, Bruker Daltonics). 1 µL of reduced glycans was loaded onto a trapping 
column (Hypercarb, 30 x 0.32 mm, 5 µm particle size, Thermo Scientific) at a flow rate of 8 µl/min in 10 
min using buffer A (ultra-pure water). Glycan separation was performed on a Hypercarb analytical 
column (100 x 0.075 mm, 3 µm particle size, Thermo Scientific) using water as buffer A and 60 % (v/v) 
ACN as buffer B, at 800 µL/min flow rate using a linear gradient of 3 to 15.8 % buffer B for 1 min, 15.8 
to 40.3 % buffer B for 49 min before washing in 60 % buffer B for 10 and a 15 min column equilibration 
in 3 % buffer B. A total of 85 min chromatographic time was performed. The amaZon ETD ion trap MS 
was operated in negative mode with CaptiveSpray capillary voltage set to 1200 V in the mass range of 
m/z 300 to 1800. Scan mode of ultrascan with ICC target of 40,000 in 200 ms maximum accumulation 
time averaging 5 spectra and rolling average of 2 were set. Top three precursors were subjected to 
data-dependent acquisition where an ion threshold of 25,000 with -2 as preferred charge stage in the 
scanning range of m/z 100 to 2500. Exclusion was activated to exclude precursor after 1 spectrum and 
release after 0.2 min for CID fragmentation using enhanced smart fragmentation of 32 ms 
fragmentation time and 27% default collision energy at an amplitude of 70%. Raw data was analysed 
using Data Analysis (version 4.0, Bruker Daltonics) and GlycoWorkbench (version 2.1). N-glycans 
identified and confirmed by PGC-LC-ESI-MS/MS were matched to the corresponding m/z values from 




In this study, we performed N-glycan MALDI mass spectrometry imaging (MSI) on FFPE serous 
ovarian cancer tissue from early-stage (n = 3) and late-stage (n = 3) patients (see Supplementary Table 
1), as previously described in our protocol paper (Briggs et al., 2017). Briefly, the FFPE tissue sections 
were prepared by citric acid antigen retrieval (CAAR) and printed with dialyzed glycerol-free PNGase F 
using a Chemical Inkjet Printer (ChIP-1000, Shimadzu, Japan), followed by an overnight incubation at 
37°C and DHB matrix deposition using a HTX TM-Sprayer (Shimadzu, Japan). The PNGase F treated 
and non-treated (i.e. control) regions were then imaged using an UltrafleXtreme MALDI-TOF/TOF mass 
spectrometer (Bruker Daltonics) and the data was analysed by SCiLS Lab. In SCiLS Lab, the spectra 
from the early-stage patients were summed and compared to the late-stage patients. To identify 
putative N-glycan structures from PNGase F treated regions, we compared the summed spectra from 
treated and non-treated regions to generate unique m/z values. We identified 14 unique m/z values 
specific to PNGase F treated regions (see Figure 1). The remaining m/z values were assigned to DHB 
matrix clusters. However, to confirm that these 14 unique m/z values were N-glycan structures, we 
required further structural information. 
 
Detailed structural information was obtained by PGC-LC-ESI-MS/MS analysis of N-glycans released 
from laser capture microdissected tumour regions, isolated from haematoxylin stained consecutive 
tissue sections of early-stage (n = 3) and late-stage (n = 3) serous ovarian cancer patients. Briefly, the 
tumour-specific regions were selected using annotated H&E stained images and images from MALDI-
MSI. N-glycans were released from tumour regions from consecutive sections of the H&E and MSI 
sections by in-solution digest using PNGase F and then reduced, desalted, purified and separated over 
a porous graphitized carbon (PGC) column coupled to electrospray ionization (ESI) tandem mass 
spectrometry (MS/MS). The raw data was analysed using Data Analysis (version 4.0, Bruker Daltonics) 
to identify and characterise all N-glycan structures and their compositions. We used the following tools 
and methods to achieve comprehensive identification and characterisation of these structures: (1) 
GlycoMod (http://web.expasy.org/glycomod/), which calculates the theoretical monosaccharide 
composition based on the parent mass obtained from LC-MS, and then links to the UniCarbKB 
database (Campbell et al., 2011), which lists known N-glycan structures from the literature (Cooper et 
al., 2001), (2) negative mode diagnostic fragmentation ions which match previously reported N-glycan 
structures (Everest-Dass et al., 2013a; Everest-Dass et al., 2013b), and (3) the knowledge of N-
glycosylation synthesis pathways. 
 
 
A total of 42 N-glycan structures (including structural and compositional isomers) were identified and 
characterised from the laser microdissected tumour-specific regions using PGC-LC-ESI-MS/MS 
analysis (see Table 2 for the full list). This approach allowed the assignment of actual glycan structures 
to the 14 unique m/z values obtained by MALDI-MSI, which categorised into oligomannose, complex 
neutral, bisecting and sialylated N-glycan families (see Table 2 for the full list). Interestingly, hybrid N-
glycan structures were only detected by PGC-LC-ESI-MS/MS analysis and were not part of the 14 
unique m/z values generated from MALDI-MSI analysis. 
 
The early- and late-stage serous ovarian cancer summed spectra (see Supplementary Figure 1) were 
annotated using the N-glycan structures identified and characterised by PGC-LC-ESI-MS/MS analysis 
(see Figure 1). Overall, oligomannose N-glycans (see Figure 2 and Supplementary Figures 2-5) were 
observed to be more abundant in the summed MALDI-MSI spectra glycans released from the ovarian 
tissues of late-stage patients relative to early-stage patients. Several complex neutral N-glycan 
structures, such as m/z 1809.639 (Hex)2(HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2, were observed 
only in the late-stage patients (see Figure 3). Specific bisecting (see Figure 4) and sialylated (see 
Supplementary Figures 11 and 12) N-glycan structures followed a similar trend with m/z 1850.665 
(Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2 and m/z 1977.666 (Hex)2 (HexNAc)2 (NeuAc)1 + 
(Man)3(GlcNAc)2 being detected at low intensity or absent from the early-stage sum spectrum. 
 
 
Table 3: N-glycan structures identified and characterised by PGC-LC-ESI-MS/MS and MALDI-MSI. N-glycans were released from early-stage (n = 3) and late-stage (n = 3) ovarian cancer 
patients. Singly negatively charged monoisotopic masses [M-H] were calculated from their observed doubly negatively charged monoisotopic masses ([M-2H]2-), matching composition and 
proposed structure. Y = Yes, N = No, states the occurrence of the glycan in the patient cohort based on the chromatography, fragmentation, and the 14 unique m/z values from MALDI-MSI. 
*Doubly and triply sodiated N-glycans. 
PGC-LC-ESI-MS/MS  Stage I Stage III MALDI-MSI  
Number RT (mins) [M-2H]2-  [M-H]1- 277 1575 1934 847 1943 1890 [M+Na]1+ Composition Structure 
1a 38.5 
698.3 1397.6 
N Y Y N N N  
1419.5 (Hex)3 + (Man)3(GlcNAc)2 
 
1b 40.1 
Y Y Y Y Y Y 
2 43.3 731.4 1463.8 
N Y N Y Y Y  
1485.5 (HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2 
 
3 40.4 739.3 1479.5 
N N N Y N N N 







































N N N Y Y Y 
5a 39.3 
783.2 1567.6 
Y Y Y Y Y Y N 
(Hex)1 (HexNAc)1 (NeuAc)1 + (Man)3(GlcNAc)2 
 
5b 46.8 N N N N Y Y 
5c 57.4 N N N N Y Y 
 
6 41.5 799.7 1600.4 
N N N Y Y Y N 




N N N Y N N  
1647.6 (Hex)1 (HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2 
 
7b 44.9 
N Y N Y N Y 
8 41.8 820.3 1641.6 
N N N Y N Y  
1663.6 (Hex)2 (HexNAc)2 + (Man)3(GlcNAc)2 
 
9 38.2 832.8 1666.6 
Y Y Y N Y Y  
1688.6 
(HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2 
 
10 63.0 856.1 1713.6 
N N N N Y Y N 
(Hex)1 (HexNAc)1 (NeuAc)1 (Deoxyhexose)1 + (Man)3(GlcNAc)2 
 
11 39.4 860.3 1721.6 
Y Y Y Y Y Y  
1743.6 (Hex)5 + (Man)3(GlcNAc)2 
 
12 46.4 893.3 1785.6 
N Y N Y Y Y  
1809.6 (Hex)2 (HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2 
 
13 38.8 913.8 1827.6 
N Y N Y Y Y  
1850.6 






















N N N N Y N N 
(Hex)3 (HexNAc)1 (NeuAc)1 + (Man)3(GlcNAc)2  
15b 60.0 N N N N Y N 
16a 51.9 
965.9 1932.8 
Y N N N N N  
1977.6* (Hex)2 (HexNAc)2 (NeuAc)1 + (Man)3(GlcNAc)2 
 
16b 56.4 N N N Y N N 
16c 59.9 N N Y N Y Y 
17 39.6 994.9 1990.8 
N Y N Y Y Y  
2012.7 (Hex)2 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2 
 
18 41.3 1022.4 2045.8 
N Y N Y Y Y N 




N N N Y N N  
 
2123.7* (Hex)2 (HexNAc)2 (Deoxyhexose)1 (NeuAc)1 + (Man)3(GlcNAc)2 
 
19b 64.1 Y N N N Y Y 
19c 68.3 N N N Y N N 
19d 68.8 N N N Y N N 
19e 73.1 N N N N Y Y 
20a 54.1 
1140.5 2282 
N N N Y N N N 
(Hex)2 (HexNAc)3 (Deoxyhexose)1 (NeuAc)1 + (Man)3(GlcNAc)2 
 
20b 57.8 
N N Y N Y Y 
 
21 40.4 1062.3 2125.6 
N Y N N N N N 




Y N N Y N Y N 
(Hex)2 (HexNAc)2 (NeuAc)2 + (Man)3(GlcNAc)2 
 
22b 45.9 N N N Y N N 
22c 57.3 N N N Y N Y 
22d 60.4 N N N N Y N 
23 48.2 1184.4 2369.8 
Y N N Y N N N 
(Hex)2 (HexNAc)2 (Deoxyhexose)1 (NeuAc)2 + (Man)3(GlcNAc)2 
 
24 59.5 1221.4 2443.8 
N N N Y N N N 
(Hex)3 (HexNAc)3 (Deoxyhexose)1 (NeuAc)1 + (Man)3(GlcNAc)2 
 
25 46.1  1235.5 
N Y Y Y Y Y  
1257.4 (Hex)2 + (Man)3(GlcNAc)2 
 
26 42.8 1285.9 2572.8 
N N N Y N N N 

















































Figure 1: Representative N-glycan MALDI mass spectrometry imaging summed spectra (zoomed in m/z range) of 
combined stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. The raw data was loaded into SCiLS Lab 
(version 2016b, SCiLS, Bruker Daltonics) and pre-processed by TopHat baseline subtraction, normalization to total ion 
current (TIC), peak picking and alignment. This figure was manually annotated based on MS/MS fragmentation from PGC-
LC-ESI-MS/MS data. The figure was formatted and created in Inkscape (version 2.0, www.inkscape.org). 
 
Ion intensity maps for early-stage (n = 3) and late-stage (n = 3) FFPE serous ovarian cancer tissue 
sections were constructed from the 14 unique m/z values acquired in MALDI-MSI (see Figures 2-5 and 
Supplementary Figures 2-12). The corresponding N-glycan masses were spatially localised by MALDI-
MSI and structurally characterised by PGC-LC-ESI-MS/MS, as already described (see Table 2). Figure 
2 and Supplementary Figures 2-5 show that all oligomannose N-glycans were predominantly observed 
in the tumour microenvironment of the late-stage patients. For example, m/z 1905.633 (Hex)6 + 
(Man)3(GlcNAc)2, was observed to be abundant in tumour regions of late-stage patients (see Figure 2 
 
Panels A-F). Figure 2 Panel G shows the N-glycan structure assigned to the ion intensity maps in 











































Figure 2: Single N-glycan mass MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous 
ovarian cancer patients. Formalin-fixed paraffin-embedded tissue sections were treated with citric acid antigen retrieval prior to 
printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were acquired 
by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the 
positive ion reflectron mode as (M + Na) ± 0.3 Da adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negative 
charged monoisotopic masses ([M-2H]2-). Panels A-F show annotated tumour regions (black – annotated by pathologist) of H&E 
stained tissue sections and ion intensity maps of m/z 1905.633 from stage I (green) and stage III (red) patients. The N-glycan, 
(Hex)6 + (Man)3(GlcNAc)2, corresponding to m/z 1905.633 in G is the confirmed structure based on the extracted ion 
chromatography of 941.3 (Panel H) and the MS/MS fragmentation (Panel I). 
 
Furthermore, complex neutral N-glycans (see Figure 3 and Supplementary Figures 6-8) were more 
intense in the tumour microenvironment of the late-stage patients compared to early stage, as well as 
 
being intense in the adjacent cancer-associated stroma regions. However, fucosylated, truncated 
biantennary neutral N-glycan, m/z 1485.533 (HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2 was not 
consistent with this observation as it was only observed in necrotic regions, which is consistent with the 
literature (see Supplementary Figure 6) (Everest-Dass et al., 2016). The larger m/z 1809.639 (Hex)2 
(HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2 was an example of a complex neutral N-glycan that is 
predominantly in the tumour microenvironment of late-stage patients (see Figure 3 Panels A-F). This N-
glycan was structurally characterised by PGC-LC-ESI-MS/MS analysis, therefore confirming its 












































Figure 3: Single N-glycan mass MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) 
serous ovarian cancer patients. Formalin-fixed paraffin-embedded tissue sections were treated with citric acid antigen 
retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS 
spectra were acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan 
masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da adducts for MALDI-MSI whereas PGC-LC-
ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show annotated tumour 
regions (black – annotated by pathologist) of H&E stained tissue sections and ion intensity maps of m/z 1809.639 from the 
stage I (green) and stage III (red) patients. The N-glycan, (Hex)2 (HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2, 
corresponding to m/z 1809.639 in G is the confirmed structure based on the extracted ion chromatography of 893.3 (Panel 
H) and fragmentation (Panel I). 
 
Another tumour-specific N-glycan predominantly observed in late-stage patients, relative to early-stage, 
were galactosylated bisecting structures (see Figure 4 and Supplementary Figures 9-10). For example, 
m/z 1850.665 (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2 was observed mostly in the tumour 
microenvironment of late-stage patients (see Figure 4 Panels A-F). As detailed in Panel H, the 
 
galactosylated bisecting structure eluted at around 40 minutes. This specific N-glycan was 
characterised by PGC-LC-ESI-MS/MS analysis (see Figure 4 Panel I) with the m/z 350 fragment ion 







































Figure 4: Single N-glycan mass MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) 
serous ovarian cancer patients. Formalin-fixed paraffin-embedded tissue sections were treated with citric acid antigen 
retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS 
spectra were acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan 
masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da adducts for MALDI-MSI whereas PGC-LC-
ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show annotated tumour 
regions (black – annotated by pathologist) of H&E stained tissue sections and ion intensity maps of m/z 1850.665 from the 
stage I (green) and stage III (red) patients. The N-glycan, (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2, 
corresponding to m/z 1850.665 in G is the confirmed structure based on the extracted ion chromatography of 913.8 (Panel 
H) and fragmentation (Panel I). 
 
 
In summary, several N-glycan structures were identified as potential markers for early-stage diagnosis 
of serous ovarian cancer, including the high mannose structure, (Hex)6 + (Man)3(GlcNAc)2 (see Figure 
2), the galactosylated bisecting structure, (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2 (see 




We applied our established N-glycan MALDI-MSI and PGC-LC-ESI-MSMS workflow to FFPE serous 
ovarian cancer tissue sections and confirmed that there are notable aberrant N-glycans in the ovarian 
cancer tumour microenvironment between early- and late-stage patients. Sample numbers were low in 
this study due to difficultly with early-stage patient sample accessibility. These alterations have 
previously been observed as a result of changes to the N-glycosylation pathway in cancer as reflected 
by expression of different glycosyltransferase genes and glycan structures (Allam et al., 2015; 
Anugraham et al., 2014; Everest-Dass et al., 2016). Oligomannose N-glycans have consistently been 
found to be highly abundant on membrane glycoproteins from ovarian cancer cell lines (Anugraham et 
al., 2014) and from stage IIIC serous ovarian cancer (Everest-Dass et al., 2016). This was the first time 
that the spatial protein glycosylation of late-stage ovarian cancer patients has been compared to early-
stage patients using this approach. This study has confirmed that oligomannose N-glycan structures 
are predominantly in the late-stage tumour microenvironment, based on combined MALDI-MSI and 
PGC-LC-ESI-MS/MS analysis (see Figure 2 and Supplementary Figures 2-5). In the literature, murine 
and human pluripotent stem cells have presented increased oligomannose N-glycans, therefore 
indicating cancer stem cell populations could present a similar glycosylation pattern (An et al., 2012; 
Nairn et al., 2008). Additionally, Man9 structures have been found in mouse breast tumour models and 
human sera of patients with breast cancer (de Leoz et al., 2011). 
 
Furthermore, complex neutral and fucosylated N-glycan structures were also observed to be localized 
to the late-stage tumour microenvironment; however they were more intense in the cancer-associated 
stroma regions than in the tumour, as previously detailed in the literature (Everest-Dass et al., 2016). 
Through MALDI-MSI analysis, (HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2 was determined to be 
spatially distributed across a mixture of early- and late-stage patients, which is not consistent with the 
other complex neutral and fucosylated N-glycan structures that are only seen in the late-stage patients 
(see Supplementary Figure 6). Upon further investigation, the pathologist noticed that this early-stage 
patient, shown in Panel C of All Figures, contains necrotic and tumour regions. Therefore, the 
observation of (HexNAc)2 (Deoxyhexose)1 + (Man)3(GlcNAc)2 in this patient is consistent with previous 
data that concludes this specific N-glycan structure is localised to necrotic regions (Everest-Dass et al., 
2016). Other complex neutral N-glycan structures, (Hex)2 (HexNAc)2 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2 and (Hex)2 (HexNAc)2 + (Man)3(GlcNAc)2, were observed to be highly intense in both 
tumour and stroma regions of late stage tissues (see Figure 3 and Supplementary Figure 8 
respectively). These structures were confirmed by PGC-LC-ESI-MS/MS fragmentation analysis, but, to 
 
the contrary these complex neutral and fucosylated N-glycans were found in cell lines to be more 
intense in healthy cells compared to tumour cells (Anugraham et al., 2014). This may suggest that 
ovarian cancer cell lines do not present identical N-glycomes to ovarian cancer tissue. In serous and 
endometrioid ovarian cancer tissues, it has been discovered that core fucosylation is elevated (Abbott 
et al., 2008; Nairn et al., 2008; Takahashi et al., 2000). This observation is consistent with the results 
presented herein. 
 
Bisecting N-glycan structures have been extensively observed in the tumour microenvironment of 
serous ovarian cancer from cell lines and tissue (Allam et al., 2015; Anugraham et al., 2014). This 
observation is consistent with the MALDI-MSI analysis reported here, where two galactosylated 
bisecting structures were detected predominantly in the tumour region of late-stage patients relative to 
early-stage patients (see Figure 4 and Supplementary Figures 10). The galactosylated bisecting N-
glycan structure, (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2, was observed to be the most 
intense based on both MALDI-MSI analysis, and PGC-LC-ESI-MS/MS analysis (see Figure 4). 
However, the agalactosylated bisecting N-glycan strcutre, (HexNAc)3 (Deoxyhexose)1 + 
(Man)3(GlcNAc)2, was not consistent with the galactosylated structures (see Supplementary Figure 9). 
This observation is novel and requires further investigation into specific glycosyltransferase activities 
surrounding early- and late-stage patients. Recently, bisecting N-glycan structures have been found to 
be associated with ovarian cancer cell survival by correlation with MGAT 3 expression (N-
acetylglucosaminyltransferase III, GnT-III), which synthesises bisecting GlcNAc by addding GlcNAc in a 
β1-4 linkage to the core N-glycan (Kohler et al., 2016). However, in breast cancer tissue, the levels of 
the GnT-III enzyme are low compared to the ovarian cancer studies. For example, breast cancer 
tissues have lower levels of GnT-III relative to normal breast tissue (Potapenko et al., 2010) while 
ovarian cancer tissues have higher levels of GnT-III relative to normal ovarian and fallopian tube tissues 
(Abbott et al., 2008; Nairn et al., 2008). The expression of GnT-III in ovarian cancer cell lines is believed 
to be regulated by epigenetic hypomethylation (Anugraham et al., 2014). Additionally, GnT-III mRNA 
levels and enzymatic activity were seen to be increased in ovarian tumour tissues derived from mouse 
models and human samples of endometrioid ovarian carcinoma (Abbott et al., 2010). 
 
Sialylated N-glycan structures have previously been found to be glyco-markers of tumorigenesis 
(Anugraham et al., 2017; Anugraham et al., 2014). (Hex)2 (HexNAc)2 (NeuAc)1 + (Man)3(GlcNAc)2 was 
discovered in our study to be predominantly in late-stage ovarian cancer patients relative to the early-
stage patients based on MALDI-MSI and PGC-LC-ESI-MS/MS analysis (see Supplementary Figure 12). 
However, PGC-LC-ESI-MS/MS chromatography and fragmentation was unable to elucidate different 
 
isomeric sialylated structures, such as α-2,3 and α-2,6 sialic acid linkage, due to poor chromatographic 
resolution and poor fragmentation pattern. In the literature, it has been shown that the α-2,6 linkage of 
sialic acid is increased in ovarian cancer cell lines relative to normal cell lines while α-2,3 linkage is 
increased in normal cell lines relative to ovarian cancer cell lines (Anugraham et al., 2014). Therefore, 
further investigation into sialic acid linkage differences between stages is required with a larger patient 
cohort through the construction of a tissue micro-array (TMA). MALDI-MSI analysis of a TMA would 
also reduce experimental variability as multiple patients can be analysed in a single experiment as 
opposed to single sections that are often analysed across multiple experiments. Additionally, we did not 
expect to see many sialylated species since we heated the sample in the citric acid antigen retrieval 
(CAAR) and utilised reflectron mode in MALDI-MSI analysis that is known to desialylate glycan 
structures. To address this caveat in future, we can either optimize our method for linear and/or 
negative mode or use chemical modifications to dervatize the sialylated species such that they are not 
cleaved in the MALDI-MSI analysis. For example, Holst et al., developed a novel derivatization method 
where in situ di-methylamidation is performed to identify linkage-specific sialylated N-glycans using 
MALDI-MSI (Holst et al., 2016). In that study of FFPE colon carcinoma tissue, sialylated N-glycans were 
discovered to be α2-3 linkage in stroma, tumor, and necrotic regions, while sialylated N-glycans with 
α2-6 linkage were observed in necrotic, collagen-rich, and red blood cell regions. However, the 
limitation with this novel derivatization method is that other N-glycan isomeric structures were not 




In summary, this is the first study where late-stage and early-stage serous ovarian cancer patient 
tissues have been compared by MALDI-MSI to spatially map protein N-glycans using PGC-LC-ESI-
MS/MS to structurally characterise the N-glycan masses. A total of 14 N-glycans were confirmed from 
MALDI-MSI across tumour and non-tumour regions, while 42 N-glycan structures (including structural 
and compositional isomers) were identified and characterised using PGC-LC-ESI-MS/MS. The spatial 
distribution and localisation of specific N-glycans were visualised in the tumour regions of late-stage 
serous ovarian cancer tissue sections relative to early-stage. N-glycans of interest that classified these 
late-stage patients by their abundance included the oligomannose structure, (Hex)6 + (Man)3(GlcNAc)2, 
the bisecting structure (Hex)1 (HexNAc)3 (Deoxyhexose)1 + (Man)3(GlcNAc)2, and the sialylated 
structure, (Hex)2 (HexNAc)2 (NeuAc)1 + (Man)3(GlcNAc)2. However, further investigation is required to 
validate these observations in a larger patient cohort as well as to determine the function and 
significance of the changes in N-glycans attached to specific glycoproteins to understand ovarian 
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5.3 | Supplementary Information  
 
Supplementary Table 1: FIGO stage I and stage III serous ovarian cancer patient information, including patient 















          
 Number   Collected           
 277   15/12/2009   58  IC  3  Serous Ovarian Cancer  
 1575  05/09/2014  46  IC 3  Serous Papillary Carcinoma 
 1934   11/04/2016   59  IA  3  High Grade Serous Carcinoma  
 847  18/05/2012  66  IIIC 3  Serous Papillary Carcinoma 
 1943   26/04/2016   47  IIIC  3  High Grade Serous Carcinoma  








































Supplementary Figure 1: Representative N-glycan MALDI mass spectrometry imaging sum spectra (800-4500 m/z 
range) of combined stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. The raw data was loaded into 
SCiLS Lab (version 2016b, SCiLS, Bruker Daltonics) and pre-processed by TopHat baseline subtraction, normalization to 

































Supplementary Figure 2: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 1257.422 from the stage 






























Supplementary Figure 3: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 1419.475 from the stage 































Supplementary Figure 4: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 1581.528 from the stage 






























Supplementary Figure 5: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 1743.581 from the stage 






























Supplementary Figure 6: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 1485.533 from the stage 






























Supplementary Figure 7: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 1647.586 from the stage 































Supplementary Figure 8: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 16663.581 from the 






























Supplementary Figure 9: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 1688.613 from the stage 






























Supplementary Figure 10: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 2012.718 from the stage 































Supplementary Figure 11: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show ion intensity maps of m/z 2123.724 from the stage 






























Supplementary Figure 12: N-glycan MALDI mass spectrometry imaging (MSI) of stage I (n = 3) and stage III (n = 3) serous ovarian cancer patients. Formalin-fixed paraffin-embedded 
tissue sections were treated with citric acid antigen retrieval prior to printing of dialyzed PNGase F with 250 µm spacing. 2,5-DHB matrix was sprayed onto the sections and MS spectra were 
acquired by oversampling at 100 µm intervals using a MALDI-TOF/TOF MS instrument. Monoisotopic glycan masses were measured in the positive ion reflectron mode as (M + Na) ± 0.3 Da 
adducts for MALDI-MSI whereas PGC-LC-ESI-MS/MS revealed doubly negatively charged monoisotopic masses ([M-2H]2-). Panels A-F show annotated tumour regions (black) of H&E stained 
tissue sections and ion intensity maps of m/z 1977.666 from the stage I (green) and stage III (red) patients. The N-glycan, (Hex)2 (HexNAc)2 (NeuAc)1 + (Man)3(GlcNAc)2, in G is the confirmed 
structure based on the chromatography (Panel H) and fragmentation (Panel I). 
 
Chapter 6 | Discussion 
This dissucssion will touch on the topics of glycosyltransferases and their biological significance in 
epithelial ovarian cancer (EOC), avenues for further workflow development through the stabilisation of 
sialylated N-glycans or through combining N-glycan MALDI-MSI with tryptic peptide MALDI-MSI, or 
using complimentary techniques, such as lectin or antibody histochemistry applications, to then 
eventaully translate analytical applications into clinical strategies for screening or monitoring EOC.      
 
Glycosyltransferases in Epithelial Ovarian Cancer 
 
EOC is the most fatal gynaecological malignancy in adult women [1]. Over 30 years ago, the first glycan 
changes were observed in tissue sections using periodic acid Schiff staining of mucin polysaccharides 
[2]. With advancements in mass spectrometry, there have been multiple cases of glycan changes 
documented across several types of samples, including the identification of specific glycoproteins and 
glycopeptides. Some of most recent unpublished data (see Chapter 5) has demonstrated that complex 
neutral and fucosylated N-glycans are highly intense in tissue from late-stage patients (n=3) relative to 
early-stage patients (n=3). These complex N-glycans are derived from the core N-glycan structure, 
utilising glycosyltransferases to add monosaccharide subunits such as N-acetylglucosamine, galactose, 
fucose, and sialic acid [3]. Additionally, these complex N-glycans have been observed in non-tumour 
(i.e. cancer-associated stroma) regions as well [4]. Bisecting structures have been shown to be 
primarily expressed in the tumour regions of tissue derived from late-stage patients (see Chapter 4) and 
various ovarian cancer cell lines [5]. This observation is consistent with genomic and transcriptomic 
studies on GnT-III activity, which is the glycosyltransferase responsible for attaching a GlcNAc 
monosaccharide in the β1,4 formation at the β-mannose of the mannosyl core [6]. Bisecting structures 
have been found to suppress the further processing of N-glycans catalysed by GnT-V, which is the 
glycosyltransferase responsible for β1,6 branching [7]. Ovarian cancer tissues have been found to have 
much higher levels of GnT-III compared to normal ovarian and fallopian tube tissues while other 
cancers have been found to have lower levels of GnT-III than their respective normal tissues [8]. 
 
There are six N-acetylglucosaminyltransferases (GnTs) responsible for N-glycan biosynthesis that are 
localised to the medial Golgi. GnT-V and GnT-III, as already mentioned, are two of the most extensively 
studied enzymes [9, 10]. GnT-V is involved in forming β1,6 GlcNAc branches at the α1,6 Man in the 
trimannosyl core [11]. In cancer, branching is often extended with N-acetyllactosamine (poly-LacNAc) or 
sialic acid monosaccharides. The expression of GnT-V in many cancers is regulated by oncogenic 
 
pathways that include src, ras, raf, and HER-2/neu, therefore impacting tumourgenesis and 
invasiveness [12]. Although, it appears that GnT-V has minimal activity in ovarian cancer [13]. However, 
GnT-V activity is highly expressed at the mRNA level in mouse and human endometrioid ovarian cancer 
tissues [14]. Mass spectrometry analysis of N-glycans isolated from membrane glycoproteins of ovarian 
cancer cell lines demonstrated that there was an absence of β1,6 GlcNAc branched structures [5]. This 
observation could indicate that GnT-V activity may be inhibited by high GnT-III expression levels in 
ovarian cancer. 
 
Another glycosyltransferase family, GnT-IV, exists as two isoenzymes termed GnT-IVa and GnT-IVb 
that are responsible for the formation of the β1,4 branch of the Manα1,3 arm of the N-glycan core [15]. 
These two isoenzymes have different expression profiles in normal tissues. For example, GnT-IVa is 
more abundant in pancreatic and gastrointestinal tissues while GnT-IVb is generally expressed more in 
most tissues [16]. In ovarian cancer tissue derived from human endometrioid ovarian carcinoma, it was 
determined there was a 2.5-fold and 1.5-fold increase of mRNA levels for both GnT-IVa and GnT-IVb 
respectively, relative to non-malignant ovarian tissues [17]. Additionally, a DSL lectin, specific to GnT-IV 
branching, was discovered to show increased binding to glyocoproteins in ovarian cancer tissues [17]. 
CA125, the most common clinical biomarker used for ovarian cancer monitoring, has also been shown 
to possess mono-, bi-, and tri-antennary N-glycan structures that are synthesised by GnT-IV [18]. 
However, the functional significance of these GnT-IV structures and their relation to specific 
glycoproteins have not yet been investigated in ovarian cancer. 
 
These glycosyltransferases mentioned are responsible for determining specific N-glycan composition 
and structure. This was best demonstrated in a study of glyco-gene transcripts from murine organs 
which were compared to the most abundant N-glycans from each tissue [19]. It was concluded that 
most transcripts correlated with specific N-glycan structure abundance. Recently, the transcriptome 
profiles of glycosyltransferases have been utilised to predict the N-glycan compositions and structures 
present in particular samples, and N-glycosylation reaction network analysis strategies have been 
developed [20]. The Cancer Genome Atlas (TCGA) can provide a wealth of information regarding 
multiple types of cancer and N-glycan gene expression data [21]. Utilising this platform with 
transcriptomic data and N-glycan MALDI-MSI data will provide further insight into how N-glycans are 
regulated and function in different cancer types and potentially even in cancer progression. 
 
N-glycan MALDI-MSI – The Past, Present and Future 
 
N-glycan MALDI-MSI combined with LC-ESI-MS/MS is a relatively new platform to spatially identify and 
characterise tissue-specific N-glycans that can be matched with histological and clinical information [4, 
22]. One of the first N-glycan MALDI-MSI methods to emerge was on FF murine brain tissue where 
Powers, T. et al spatially mapped the N-glycome [23]. The N-glycans were also extracted off-tissue, 
modified and processed for structural characterisation by HPLC-ESI-MS/MS. It was concluded that this 
novel approach could lead to disease-related targets for biomarkers and therapeutic applications. 
Subsequent N-glycan MALDI-MSI workflows were applied to FFPE tissue, such as glioblastoma tumor 
xenografts and normal brain sections [24]. A total of 42 N-glycans were found to be spatially distributed 
across the mouse brain coronal tissue sections. Oligomannose and non-fucosylated complex N-glycans 
were observed to be localized to the brainstem while fucosylated N-glycans were more abundant in the 
cortex. Our group was the first to combine MALDI-MSI with PGC-LC-ESI-MS/MS to both spatially map 
and comprehensively characterise the N-glycome [22]. Using this approach, we assigned N-glycan 
structures, confirmed by MS/MS, to tissue-specific regions of FFPE murine kidney. For example, the 
high mannose N-glycan (Hex)6 + (Man)3(GlcNAc)2 was observed in the medulla region while the 
fucosylated complex N-glycan (Hex)2(HexNAc)3(Deoxyhexose)3 + (Man)3(GlcNAc)2 was observed in the 
cortex region. Our group also modified our existing N-glycan MALDI-MSI workflow to spatially identify 
and characterise N-glycans from FFPE osteoarthritis tissue (See Chapter 3). We could successfully 
differentiate between cartilage and bone marrow based on the N-glycosylation patterns observed [25]. 
 
 
Throughout this thesis, it has been discussed already that these methods need to be further optimised. 
There have been suggestions for improvement in the areas of derivatization, optimisation of the citric 
acid antigen retrieval step and using negative ion mode in order to stabilise sialylated N-glycans during 
MALDI-MSI. Additionally, it has been mentioned that it would be beneficial to detect N-glycan isomers 
spatially using MALDI-MSI. In ovarian cancer, there have been several reports of level alterations in α 
2,3 and α 2,6 sialic acid linkage of sialylayed N-glycans [5, 17]. Other future prospects include the 
analysis of larger patient cohorts using tissue microarrays (TMAs), and ultimately, glycoproteomics 
analysis which would provide site-specific information on protein glycosylation. 
 
Stabilising Sialylated N-glycans and Identifying Isomeric N-glycans 
 
The detection of sialylated N-glycans by MALDI in reflectron mode is difficult due to their labile nature 
during the ionisation process. However, the Solarix series MALDI-FT-ICR instruments (Bruker 
Daltoncis) use an alternative source configuration and cooling gas, which provides softer ionisation, 
therefore limiting sialic acid cleavage [26]. Using a standard MALDI instrument results in the increased 
abundance of non-sialylated complex N-glycans due to the destabilisation of sialic acids, which 
therefore does not reflect the abundance of sialylated N-glycans present biologically. Additionally, 
standard and non-standard MALDI instruments cannot distinguish between sialylated N-glycan 
linkages. Powers, T. et al was the first to develop an approach to investigate the spatial localisation of 
isomeric sialylated N-glycan structures from FFPE human hepatocellular carcinoma (HCC) tissue by 
applying their existing N-glycan MALDI-MSI method to single sections and a TMA [27]. A total of 30 N-
glycans were detected and a novel off-tissue ethyl esterification method was developed to stabilise 
sialylated N-glycans for region-specific α 2,3 and α 2,6 linkage identification. This approach showed 
that α 2,6 sialylated N-glycans were higher in abundance of the HCC regions compared to α 2,3 
sialylated N-glycans. Additionally, N-glycan MALDI-MSI and lectin histochemistry revealed that core 
fucosylated complex N-glycans are highly expressed in HCC regions relative to normal tissue. In 2016, 
another novel derivatization method was developed by the same group, where in situ di-
methylamidation is performed to identify linkage-specific sialylated N-glycans using the existing MALDI-
MSI workflow [28]. From FFPE colon carcinoma tissue, sialylated N-glycans were discovered to be α 
2,3 linkage in stroma, tumor, and necrotic regions, while sialylated N-glycans with α 2,6 linkage were 
observed in necrotic, collagen-rich, and red blood cell regions. However, the limitation of these novel 
derivatization methods is that other N-glycan isomeric structures from different N-glycan families are not 
considered (i.e. high mannose, complex/hybrid). A recent advancement in mass spectrometry-based 
technology has emerged term Ion Mobility (IM)-MS [29]. This platform (coupled by LC) has been utilised 
most recently to characterise N-glycan isomers using post-source gas-phase separation to separate the 
isomers based on a collision cross-section [30]. There have been a few studies published recently 
where IM-MS has been applied to FF tissue sections for imaging other analytes [31]. According to 
Drake et al., there have been preliminary applications of IM-MS imaging to PNGase F digested FFPE 
tissue sections (data not shown). 
 
Combined N-glycan and Tryptic Peptide MALDI-MSI 
 
N-glycan MALDI-MSI allows the visualisation of tissue-specific N-glycan structures which can potentially 
lead to identifying corresponding glycoproteins and glycopeptides in subsequent experiments. The most 
conventional way to approach this would be by targeting tissue-specific regions with trypsin, followed by 
enrichment of glycopeptides. Although this is a direct way to study both the glycan and peptide 
sequences through high-resolution LC-ESI-MS/MS, large quantities of sample are required which is 
difficult to achieve if the regions of interest are small. A novel approach was recently developed to 
image N-glycans and tryptic peptides in the same experiment while sequencing the peptides for protein 
identification and correlating the N-glycans with regions that overlap. Heijs, B. et al established this 
alternative workflow in 2016 [32]. The N-glycans and tryptic peptides were both measured by MALDI-
FTICR-MS, and then these analytes were extracted from consecutive tissue sections for structural 
characterisation by MALDI-TOF/TOF-MS/MS and Q-Exactive MS/MS respectively. A total of 509 unique 
proteins were identified from PNGase F and trypsin treated FFPE colorectal cancer, which 
corresponded to 1334 unique peptides. There were considerably more protein and peptide 
identifications relative to consecutive sections that were treated with trypsin alone, totalling 236 unique 
proteins and 948 unique peptides. Therefore, the evidence suggests that the sequential digestion 
workflow improved protein identification with the most likely explanation belonging to N-glycans 
preventing tryptic digestion at specific sites. The cleavage of N-glycans from asparagine residues 
results in deamidation, thereby converting these residues to aspartic acid which is easily detectable and 
identifiable during LC-ESI-MS/MS analysis [33]. However, this modification can also form without the 
proper sample preparation processes in place. It was determined that there were 20 deamidated 
peptides from the FFPE colorectal cancer tissue after combined glycan and peptide digestion, relative 
to the trypsin digestion sample alone which had no deamidated peptides detected. In 2017, this novel 
workflow was published as a protocol paper so other groups can adapt it [34]. It is hoped that the 
glycoproteins indentified spatially can then be validated using standard techniques, such as 
immunohistochemistry, which involves the application of the relevant antibody regents [35]. Fortunately, 
most of these glycoproteins are highly abundant which provides further opportunities to develop clinical 
biomarker assays. 
 
Lectin and Anti-Carbohydrate Antibody Applications 
 
Specific lectins and anti-carbohydrate antibodies are routinely used to evaluate the spatial localisation 
of N-glycans and other carbohydrates in situ. For example, the carbohydrate antigen CA19-9 is 
measured in the clinic to determine the prognosis of pancreatic and other gastrointestinal cancers [36, 
37]. The CA19-9 antibody used recognises a distinct carbohydrate motif (GlcNAc-Gal, α 1,4 fucose, 
and α 2,3 sialic acid. Another antigen, F77 for prostate cancer, has also been previously described in 
the literature [38]. The corresponding antibody for F77 recognises the blood group H antigen-related 
Lewis Y glycan structures with α 1,2 fucose. It is established that most antibodies for carbohydrate 
detection are required to recognise between 1-4 structural epitopes [35]. Using such antibodies are 
quite useful for tissue immunohistochemistry-based staining methods, however, these methods cannot 
distinguish between the types of glycan classes (i.e. glycolipids, O-glycans, N-glycans). Alternatively, 
lectins or carbohydrate-binding proteins (CBPs) for many decades have evaluated glycoproteins and 
their structural features [39]. In a similar way to antibodies for carbohydrate antigens, lectins recognise 
between 2-4 structural epitopes. However, lectins possess poor affinity-binding constants in the low 
micromolar range, which limits the tissue histochemistry applications mentioned previously. Although, 
lectin histochemistry applications have been successfully established to analyse FFPE tissue [40]. 
Again, it has been described as difficult to distinguish between glycan classes since the recognisable 
glycan motif is often the same between N- and O-glycans. Hence, MALDI-MSI is an important tool that 
provides not only spatial information, but also specific N-glycan structural features. However, there is 
potential for the development of MALDI-MSI workflows to incorporate these antibody or lectin 




Other future prospects following the conclusion of this project would include large patient studies using 
tissue microarrays (TMAs) of patients at different stages (i.e. early-stage vs. late-stage ovarian cancer). 
Powers, T. et al was the first to apply their N-glycan MALDI-MSI workflow to FFPE tissue sections of 
murine kidney, pancreatic and prostate cancers, and human hepatocellular carcinoma (HCC) in the 
form of a TMA [41]. A total of 21 known or previously identified N-glycans were observed to be 
distributed across the TMA, with the majority of N-glycans being highly abundant in HCC regions 
relative to non-tumour regions. The authors’ concluded that this was the first study that applied N-
glycan MALDI-MSI to a TMA, therefore developing a method for high-throughput analysis of clinical 
samples. However, the N-glycans were identified based on known N-glycosylation pathway constraints 
and on-tissue collision-induced fragmentation, which does not elucidate isomeric information. 
 
There are also areas where the existing workflow can be modified or optimised to improve sensitivity 
and obtain more structural information in situ. For example, other glycosidic enzymes could be applied 
to tissue sections in combination with PNGase F to provide more comprehensive structural information. 
Glycosidic enzymes include galactosidase for the cleavage of galactose, fucosidase for the cleavage of 
fucose, and sialidase or neuraminidase for the cleavage of sialic acid [42]. The advantage with many of 
these glycosidic enzymes is the linkage specific information obtained, which provides structural, 
compositional and isomeric information not typically obtained by PNGase F digestion. For example, 
there is a glycosidic enzyme that only cleaves core fucosylated N-glycans which could be optimised for 
an existing N-glycan MALDI-MSI workflow. 
 
Clinical Applications of N-glycan MALDI-MSI 
 
A new MALDI-MSI platform with potential clinical applications has emerged called the rapifleX MALDI 
Tissuetyper TOF instrument (Bruker Daltonics). This advancement in instrumentation and technology 
has significantly decreased the acquisition and processing time by fivefold or even more, increased the 
resolution to 10-20 µm, and refined the laser spot sizes. With improved acquisition times, it may be 
feasible to analyse multiple patient biopsy samples and other pathological samples (e.g. serum) in a 
matter of minutes. 
 
 
Identifying the location of N-glycan structures in tissue-specific regions, in particular within the tumour 
microenvironment, provides a potentially better understanding of biological mechanisms behind cancer 
progression. Additionally, this may also lead to the development of specific lectin-based assays that can 
be used to detect specific N-glycans directly (i.e. a lectin histochemistry tissue assay), as already 
discussed. Another possible approach not yet discussed could include the use of anti-carbohydrate 
epitope antibodies in fluorescent or light microscopy experiments to visualise tissue-specific 
biomarkers. Although these lectins and antibodies recognise N-glycan structural motifs, they also 
recognise similar features on glycosphingolipids or O-glycosylated proteins.  
 
In summary, N-glycan MALDI-MSI has been developed immensely in recent times, with improvements 
in sensitivity and mass accuracy, structural and compositional analysis by complementary techniques 
(i.e. PGC-LC-ESI-MS/MS and lectin histochemistry staining), and identification of linkage-specific 
sialylated N-glycans by in situ derivatization methods. However, further work in the field is required to 
comprehensively answer clinical questions and discover disease-specific biomarkers or develop new 
diagnostic methods based on N-glycans. 
 
 
Chapter 7 | Conclusion:  





N-glycan MALDI-MSI is a relatively new platform that has shown much promise in the area of cancer 
research; however, there are still strides to make in order for MALDI-MSI to be able to (1) screen and 
detect ovarian cancer in the early-stages, (2) monitor treatment effectiveness, (3) detect ovarian cancer 
recurrence and (4) stratify ovarian cancer patients. As detailed in the discussion, such improvements can 
be made through multiple strategies including the stabilisation of sialylated N-glycans while also spatially 
mapping α 2,3 and α 2,6 sialic acid linkages, combining N-glycan MALDI-MSI with tryptic peptide MALDI-
MSI to obtain comprehensive biological information, and investigating larger patient cohorts through the 
means of tissue microarrays (TMAs). With these improvements implemented, it may be possible to work 
towards creating a library of biomolecules that can be rountienly measured by clinicians to diagnoise 
ovarian cancer in its early-stages or monitor regimens for patients.    
  
The evidence obtained throughout this PhD project suggests that the N-glycome is aberrantly expressed 
in the tumour microenviroment of early- and late-stage ovarian cancer tissues. For example, mass 
spectrometry and molecular biology techniques have been revealed that there are increased levels of 
bisecting structures in late-stage ovarian cancer tissues relative to early-stage. This observation requires 
further investigation once the workflow has been further developed to be more sensitive and specific as 
outlined above.   
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Ovarian Cancer 
Ovarian cancer is the most lethal gynaecological 
malignancy with an estimated 1,470 new cases diagnosed 
in 2014 and 1,640 expected by 2020 in Australia (1, 2). Due 
to the asymptomatic nature of the disease, most patients 
are diagnosed at late-stage (International Federation of 
Gynaecology and Obstetrics (FIGO) stages III and IV) (3). 
The standard treatment regimen for patients is surgery 
followed by chemotherapy. Since treatment for many 
patients is not effective, prognosis is poor, with a five-year 
overall survival rate of only 44% (4). 
 
Genomics of Ovarian Cancer 
The genomic status of the patients allows us to divide the 
disease into two distinct groups. Group I contains low-
grade and ‘borderline’ serous tumours, endometrioid, 
mucinous and clear cell tumours. These tumours generally 
contain mutations in PTEN, PI3K catalytic subunit-a 
(PI3KCA), KRAS, BRAF and β-catenin (CTNNB1). Group  
II contains high-grade serous and endometrioid 
tumours, and many low incidence tumours. This group 
typically presents with mutations in TP53 in 60–80% of 
cases. Genetic instability is observed more frequently 
with BRCA1/BRCA2 mutations, suggesting a role for 
TP53 in hereditary ovarian disease (5).  
Although there are benefits in the use of this classification 
strategy (6), there are also disadvantages such as gene 
transcript levels not always mirroring levels of protein 
translation (7). In addition, genomics can only predict sites 
of post-translational modifications (PTMs), which do not 
necessarily correlate with genuine PTM sites (8). In 2015, a 
Nature paper was published on whole-genome sequencing 
of 92 chemo-resistant ovarian cancer patients (9). The 
results revealed the most common genetic mutations and 
highlighted the heterogeneity of the disease. A holistic 
molecular understanding of globally regulated pathways 
in ovarian cancer therefore requires the combination of 
genomic information with protein abundance and 
modification state. With these details elucidated it may be 
possible to identify tissue or tumour subtype-specific 




Proteomics of Ovarian Cancer 
Proteomics, a term coined by Marc Wilkins in 1994, 
describes the quantitative analysis of proteomes through 
high sensitivity measurement of hundreds to thousands of 
proteins in a complex mixture (10). Proteomics has been 
successfully implemented in ovarian cancer. However, 
there are limitations that have significantly hampered 
proteomic analysis. For example, proteomics does not 
directly address the position and nature of PTMs, which 
has led to the growth of niche-fields such as 
phosphoproteomics and glycoproteomics (11). These fields 
use modification-specific methods (e.g. enrichment and 
improvements to ionisation efficiency in the mass 
spectrometer) to facilitate the determination of PTM 
location and, in the case of glycoproteomics, composition. 
 
Glycoproteomics of Ovarian Cancer  
Glycoproteomics is the branch of proteomics where 
glycosylated proteins (glycoproteins) are identified and 
characterised from cells, tissue, or bodily fluid (12). 
Glycosylation is the enzymatic process where sugars (glycans) 
are attached to proteins, lipids or other organic molecules. In 
the human body it is estimated that 50–60% of proteins are 
glycosylated (13). N-linked glycans (sugars attached to 
asparagine residues in proteins) are of particular interest in 
ovarian cancer because structural alterations have been 
observed in the tumour microenvironment that promote 
tumour invasion and metastasis.  
A structural alteration of interest is formation of bisecting N-
acetylglucosamine (GlcNAc) on several N-glycan complexes. 
Previous studies have found that the glycoprotein CA125, an 
ovarian tumour marker, contains monofucosylated, bisecting 
GlcNAc N-glycans (14). The most recent work confirmed the 
expression of bisecting GlcNAc, but also correlated this 
observation with the gene expression of a glycosyltransferase 
enzyme (MGAT3), which complexes the core of N-glycans in a 
β1-4 linkage (15). Bisecting GlcNAc was not detected in the 
control tissue, while in ovarian cancer cells 13% of N-glycans 
contained this modification. MGAT3 is believed to be 
involved in N-glycosylation patterns on E-cadherin, which is 
involved in the regulation of epithelial-mesenchymal 
transitions (16). 
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Compositional analysis allows us to identify and quantify 
these N-glycans while correlating them with clinical 
outcomes. The most common technique used to structurally 
characterise N-glycans from biological samples is by means 
of peptide-N-glycosidase (PNGase F) release, followed by 
liquid chromatography (LC) coupled to electrospray 





key concept here as it would be ideal to correlate changes in 
protein glycosylation with tissue morphology, and in 
particular, surgical pathology annotations. To address this 
analytical shortfall, our group at the Adelaide Proteomics 
Centre have developed a novel approach to retain spatial 
information of N-glycans using a technique known as matrix-
assisted laser desorption/ionisation (MALDI) imaging mass 
spectrometry (IMS) (18 and article by Boughton and 
Roessner in this issue). 
LC-MS/MS  
A recent study from our collaborators structurally 
characterised N-glycans from non-cancerous ovarian surface 
epithelium and serous ovarian cancer cell lines (15). 
Characteristic features identified that were unique to 
ovarian cancer membrane proteins include bisecting GlcNAc, 
α 2-6 sialylated and LacdiNAc type N-glycans. The N-
glycans identified from the LC-MS/MS data were 
further verified using qRT-PCR of their corresponding 
genes (MGAT3, ST6GAL1 and B4GALNT3).  
At Macquarie University, Professor Nicolle Packer and Dr 
Arun Dass already have an established LC-MS/ MS method 
to structurally characterise N-glycans. The caveat is that LC-
MS/MS sample preparation removes spatial information 
through tissue disruption. This is a  
 
MALDI-IMS 
In the past decade, the gold standard of MALDI-IMS has 
been to spatially analyse the proteome of native or formalin-
fixed paraffin-embedded (FFPE) tissue samples. 
Preparation of these tissue sections for MALDI-IMS consists 
of chemical treatments tailored to suit detection of specific 
molecule classes. For example, FFPE tissue requires 
antigen retrieval and proteolytic digestion to access the 
proteome. After proteolytic digestion, a matrix is 
homogenously deposited across the tissue sections to co-
crystallise with the analyte. Following sample preparation, 
MALDI-TOF/TOF (time of flight) MS acquisitions are 
performed across the entire tissue section in a two-

































Fig. 1. N-linked glycan MALDI-IMS and LC-MS/MS workflow on FFPE tissues. FFPE tissue is sectioned and 
mounted onto indium tin oxide (ITO) or polyethylene naphthalate (PEN) membrane slides. Paraffin is removed and the 
tissue is treated with an antigen retrieval protocol. In MALDI-IMS, a chemical inkjet printer (ChIP-1000) prints an 
enzyme (e.g. PNGase F) in an array across the tissue section followed by matrix (e.g. DHB). Following sample 
preparation, the mass spectra are acquired in a two-dimensional grid across the tissue section. Lastly, the data are 
analysed using MALDI-IMS software (e.g. SCiLS) and overlaid with a histological stain of the section. In LC-MS/MS, 
N-glycans released in-solution are separated on a porous graphitized carbon column coupled to an ion trap. The structural 
data are analysed in DataAnalysis (Bruker Daltonics). 
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Fig. 2. MALDI imaging mass 
spectrometry of N-linked glycans 
released from murine kidney 
sections. Ion intensity maps for 
(Hex)2(HexNAc)3(Deoxyhexose)3 
+(Man)3(GlcNAc)2 (m/z 2304.932, 
red), (Hex)6+(Man)3(GlcNAc)2 
(m/z 1905.742, green) and 
(Hex)2(HexNAc)2+(Man)3(GlcNAc)2 






spectra (19). There are several advantages of MALDI-IMS 
such as: (i) multiple samples can be analysed in a single 
experiment, (ii) hundreds of molecules and multiple 
molecule classes can be measured in a single experiment, 
and (iii) prior knowledge of tissue composition is not 
essential and antibodies are not required (20).  
However, there are also disadvantages in relation to 
tissue archives. Most MALDI-IMS laboratories use native 
tissue archives, which are small in sample size and difficult 
to maintain for long periods of time. To address low 
sample numbers, multiple groups are turning to archival 
stored FFPE tissue samples. Hundreds to thousands of 
FFPE tissue samples, from healthy and diseased 
individuals, are stored in large pathology repositories 
worldwide (21). These FFPE tissue samples are 
pathologically annotated and can be linked to clinical 
information such as patient diagnosis, treatment and 
outcome. The advantage is that the formalin-fixation 
process conserves tissue samples by cross-linking of 
proteins and even N-glycans (11). As a result, FFPE tissues 
can be stored under ambient conditions for long periods of 
time without degradation of the proteins and N-glycans.  
Methods for MALDI-IMS have already been established 
for analysis of tryptic peptides on FFPE ovarian tumours in 
our laboratory (20). Our group developed a novel MALDI-
IMS method to spatially analyse N-glycans on FFPE 
murine kidney (see Fig. 1 for the workflow) (22). In 2014, 
other N-glycan MALDI-IMS methods were developed 
concurrently, such as in the Drake group at the Medical 
University of South Carolina in the USA (23,24). Our 
group, in collaboration with Professor Nicolle Packer from 
Macquarie University in Sydney, has developed a more 
comprehensive approach that extends the application to 
extract structural information from consecutive sections 
using LC-MS/MS to confirm the identification of the 
masses from the MALDI-IMS dataset.  
The strength of our novel MALDI-IMS method is 
exhibited in our proof-of-principle manuscript (also see 
Fig. 2) (22). In the top panel, consecutive FFPE murine 
kidney sections have been hematoxylin and eosin (H&E) 
stained. In the bottom panel, there are ion intensity maps 
of N-glycans identified to be confined to the cortex (red), 






this nature allows us to differentiate between different 
tissue-types based on the N-glycan patterns.  
Since publishing our proof-of-principle manuscript, we 
have investigated the N-glycan profile of FFPE ovarian 
tumours. These are advanced stage (stage III) tumour 
implants from patients (n=3) that were provided by 
Professor Martin Oehler from the Department of 
Gynaecological Oncology at the Royal Adelaide Hospital. 
Following PNGase F treatment and 2,5-DHB deposition, 
the FFPE tissue sections were analyzed by MALDI-TOF/ 
TOF MS (Bruker Daltonics) and SCiLS 2D software. In 
parallel, consecutive sections were analyzed by LC-MS/ 
MS to determine structural information for complementary 
masses. The extracted spectra from different tissue-types 
(see Fig. 3) exhibit different N-glycosylation patterns, 
therefore allowing tissue-types to be differentiated.  
In summary, our group at the Adelaide Proteomics 
Centre and collaborators from Macquarie University have 



















Fig. 3. Spatial profiling of four different tissue-
types from an advanced stage ovarian cancer implant 
(tumour, stroma, necrotic and adipose). Regions of 
interest were selected in MALDI-IMS software 
(SCiLS) and sum spectra from these regions were 
extracted. N-linked glycans were structurally 
identified from complementary LC-MS/MS data. 
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method to identify N-glycans across FFPE tissue sections. Winderbaum, L.J., Pelzing, M., McColl, S.R., Everest- 
However, further work is required to verify whether this Dass, A.A., Packer, N.H., and Hoffmann, P. (2015) Anal. 
technique can be used to discover potential biomarkers in Bioanal. Chem. 407, 2127-2139 
ovarian cancer. For example, tissue-microarrays (TMAs) 23. Toghi Eshghi, S., Yang, S., Wang, X., Shah, P., Li, X., and 
could be used allowing larger patient cohorts to be studied Zhang, H. (2014) ACS Chem. Biol. 9, 2149-2156 
in a single experiment. 24. Powers, T.W., Neeley, B.A., Shao, Y., Tang, H., Troyer, 
Overall, this novel N-glycan MALDI-IMS protocol has D.A., Mehta, A.S., Haab, B.B., and Drake, R.R. (2014) 
enabled the first steps in the Glycomic Quest for the Holy PLoS One 9, e106255  
Grail: An early stage biomarker for ovarian cancer. 
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Pathologists play an essential role in the diagnosis and prognosis of benign and can-
cerous tumors. Clinicians provide tissue samples, for example, from a biopsy, which 
are then processed and thin sections are placed onto glass slides, followed by staining 
of the tissue with visible dyes. Upon processing and microscopic examination, a 
pathology report is provided, which relies on the pathologist’s interpretation of the 
phenotypical presentation of the tissue. Targeted analysis of single proteins provide 
further insight and together with clinical data these results influence clinical decision 
making. Recent developments in mass spectrometry facilitate the collection of 
molecular information about such tissue specimens. These relatively new techniques 
generate label-free mass spectra across tissue sections providing nonbiased, 
nontargeted molecular information. At each pixel with spatial coordinates (x/y) a mass 
spectrum is acquired. The acquired mass spectrums can be visualized as intensity 
maps displaying the distribution of single m/z values of interest. Based on the sample 
preparation, proteins, peptides, lipids, small molecules, or glycans can be analyzed. 
The generated intensity maps/images allow new insights into tumor tissues. The 
technique has the ability to detect and characterize tumor cells and their environment 
in a spatial context and combined with histological staining, can be used to aid 
pathologists and clinicians in the diagnosis and management of cancer. Moreover, 
such data may help classify patients to aid therapy decisions and predict outcomes. 
The novel complementary mass spectrometry-based methods described in this 




CHCA α-cycano-4-hydroxycinnamic acid  
DESI desorption electrospray ionization  
DHB 2,5-dihydroxybenzoic acid  
FFPE formalin-fixed paraffin embedded  
FT-ICR Fourier transformed ion cyclotron resonance  
IHC immunohistochemistry  
LNM lymph node metastasis  
MALDI matrix-assisted laser desorption/ionization  
MSI mass spectrometry imaging  
PCA principle component analysis  
SIMS secondary ion mass spectrometry  





In order to optimize the treatment outcomes for cancer patients and 
even provide a cure, several issues regarding the clinical management of 
disease need to be addressed. Based on pathological and clinical parameters 
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patients are classified to receive the best possible therapy. The accuracy 
of this process would be better if a more complete understanding of the 
molecular events involved in the development and progression of cancer 
was available. Currently, mass spectrometry imaging (MSI) is being 
extensively applied to the in situ molecular analysis of cancerous cells 
and tissues with the aim of identifying tumor margins, classifying 
primary tumor tissues with regards to chemoresponse and metastatic 
status, identifying diagnostic and prognostic markers, and the analysis of 
drug response rates and resistance. Elucidation of the spatial location and 
abundance of peptides, proteins, lipids, glycans, and drug metabolites in 
relation to cancerous tissues and cells has the potential to significantly 
improve the diagnosis, staging, and treatment of disease. 
 
 
1.1 The Advantages of MSI 
 
Interpatient heterogeneity significantly impacts the success of diagnostic 
and prognostic tests, because it influences the way patients respond to 
the same treatment. Moreover, proteomic analysis is impacted by 
intratumor heterogeneity, as tumors are complex structures comprised of 
a number of different cell types, such as epithelial or endothelial, stro-
mal, vascular, and inflammatory cells. This is particularly important 
when considering concepts such as innate chemoresistance, metastasis, 
and stem-cell-like cancer cells, which are believed to consist of a small 
subset of cells within the bulk of the tumor tissue. Analysis methods that 
require homogenisation of a sample lose important information about the 
spatial location of the molecules being studied. Moreover, the 
information of a potential difference in protein abundance of a small 
number of cells might not be reflected in the average abundance of the 
tissue. Certain analysis methods, such as immunohistochemistry (IHC) 
or fluorescence microscopy, allow for the quantification of compounds 
within a spatial context. However, these methods are targeted, requiring 
prior knowledge about the target and the sample in question, and only a 
small number of molecules can be analyzed simultaneously. 
 
The rapidly evolving technique of MSI allows for the in situ analysis of 
biological samples, combining classical mass spectrometry (MS) with histo-
logical tissue analysis. MSI has the capacity to determine the relative inten-
sity and spatial distribution of several hundreds of compounds from cells 
and tissue while retaining important spatial information (Schwamborn & 
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Caprioli, 2010). In the context of cancer research this affords the tech-nique 
the ability to characterize the molecular features of a sample while 
maintaining morphology and requiring no prior knowledge of the molec-ular 
expression profile. The type of molecules detected, or ions in the con-text of 
MS, is dependent on the sample preparation, instrumentation, and 
acquisition protocols used. 
 
 
1.2 The Basic Principles of MSI 
 
MS analysis includes the processes of analyte ionization, mass analysis, and 
detection (de Hoffmann & Stroobant, 2007). During ionization analyte 
molecules become electrically charged and liberated into the gas phase. 
Once ionized the mass of the charged molecules is determined by analysis in 
the mass spectrometer; the analyte ions are separated based on their mass-to-
charge ratio (m/z) and detected, commonly by a microchannel plate 
detector. In terms of MSI, there are two basic forms: microprobe mode 
imaging and microscope mode imaging (Bodzon-Kulakowska & Suder, 
2016; Klerk, Maarten Altelaar, Froesch, McDonnell, & Heeren, 2009; 
Luxembourg, Mize, McDonnell, & Heeren, 2004). In microprobe mode 
MSI, where information is collected sequentially from each pixel (pixel 
sizes typically 5–100 μm), each mass spectrum contains information about 
the m/z and relative intensity of the detected ions at each location. 
Following data acquisition, the collected information is reconstructed into a 
molecular image. In microscope mode MSI, spectral information is col-
lected over a relatively large sample area (100–300 μm) simultaneously; in 
this form of MSI, the ions produced over the analyzed area are measured 
using a position-sensitive two-dimensional detection system. The 
information collected by both microprobe and microscope mode can be 
displayed as ion maps which show the distribution of the detected m/z 
values and their intensities, thereby characterizing cancer cells or tissues 
within their environment in a spatial context. 
 
Following MSI the sample morphology is frequently retained and can be 
histochemically analyzed postdata acquisition (Crecelius et al., 2005; 
Schwamborn et al., 2007), making it feasible to directly compare MSI 
results with histological staining. These methods are complementary and 
have a high potential for aiding pathologists and clinicians in their diagnosis 
and management of disease (Rodrigo et al., 2014). As indi-cated earlier, 
MSI usually requires very little material and, for example, 
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a single tissue section from an endoscopic biopsy is enough to perform a 
successful MSI experiment. 
 
For MSI, the ionization methods matrix-assisted laser desorption/ 
ionization (MALDI), secondary ion mass spectrometry (SIMS), and 
desorption electrospray ionization (DESI) are popular, and are frequently 
coupled to time-of-flight (TOF) or Fourier transform type mass 
analyzers. A very brief description of the commonly applied techniques 





MALDI-TOF is commonly used for the analysis of proteins, peptides, lipids, 
metabolites, and glycans (Cho et al., 2015; Signor & Boeri Erba, 2013). The 
application of MALDI-TOF to imaging MS was first introduced in 1997 
(Caprioli, Farmer, & Gile, 1997) and the technique has gained significant 
popularity over the last two decades. For analysis by MALDI-TOF-MSI, a 
sample is placed on a conductive surface such as a stainless steel plate or an 
indium tin oxide-coated glass slide. Commonly fresh frozen or formalin-
fixed paraffin-embedded (FFPE) tissue sections 4–10 μm thick are analyzed 
by MALDI-TOF-MSI, with FFPE tissues requiring additional preparation 
steps of deparaffinization and antigen retrieval (Ronci et al., 2008). Once the 
tissue is placed on the slide, depending on the type of analysis being 
performed, a digestion step may be carried out. For proteolytic peptide 
analysis, the most common enzyme utilized is trypsin, for glycan analysis a 
peptide-N-glycosidase F (PNGase F) digestion may be employed to release 
N-linked glycan structures from proteins (Gustafsson et al., 2015). The 
analysis of lipids, metabolites, endogenous peptides, and intact proteins 
directly from tissue does not require enzyme treatment. Prior to analysis a 
small organic acid, referred to as the matrix, is suspended in an acidified sol-
vent buffer and deposited over the sample (Goodwin, 2012; Kaletas et al., 
2009). During this process the matrix incorporates the analyte molecules, 
forming crystals. A focussed laser beam can then be applied to the surface in 
order to induce analyte ionization. The small organic molecules of the 
matrix mixture are designed to absorb the energy of the focussed laser beam 
resulting in an explosive desorption of the matrix and analyte crystals. The 
protons present in the acidified matrix solution also facilitate the analyte 
ion-ization. MALDI is a “soft” ionization technique, meaning many analytes 
may be analyzed without significant fragmentation. 
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Following ionization the ions are rapidly accelerated though a strong 
electric field in the ion source, the ions then enter the TOF tube or “drift” 
region, allowing separation based on velocity and thus m/z. The charged 
analyte molecules strike the detector and the number of events within a 
time period are recorded, providing intensity information. By comparing 
the measured information to calibration standards, the mass of the 
detected analyte ion can be calculated. The spatial resolution of MALDI-
TOF imaging sits at around 20 μm and can accommodate a molecular 




MALDI-FT-ICR is routinely applied to the imaging analysis of lipids, 
drugs, and metabolites. MALDI is carried out as described earlier with 
the Fourier transform ion cyclotron resonance (FT-ICR) acting as the 
mass analyser, where the m/z of analyte ions is determined by the 
cyclotron frequency of the ions within the fixed magnetic field of the 
instrument (Scigelova, Hornshaw, Giannakopulos, & Makarov, 2011). 
 
Following ionization the charged molecules are trapped in a Penning 
trap, which consists of a series of electrodes that use a homogeneous axial 
magnetic field to capture the molecules radially, and an inhomogeneous 
quadrupole electric field to confine the molecules axially. Within the Pen-
ning trap, a RF electric field is applied in the plane of ion cyclotron motion 
which excites the ions to move in a larger, synchronous, cyclotron radius. 
Once the excitation field is removed, the ions are left rotating at their cyclo-
tron frequencies in phase. The ions induce a charge which is detected as an 
image current by electrode detectors in close proximity. The recorded signal 
consists of a superposition of sine waves; this information can be used to 
calculate the masses of the detected ions using a Fourier transform equation. 
In FT-ICR a superconducting magnet is used to generate a highly stable 




SIMS utilizes beams of primary monoatomic (e.g., Bi +, Au +) or poly-
atomic (C +60, Bi +3, Cs +n) ions in a vacuum for ionization (Fletcher, 
Vickerman, & Winograd, 2011). During SIMS the sample surface is 
bombarded with a beam of primary ions, causing molecules on the surface 
of the sample to be released, a process referred to as sputtering. During 
sputtering energy from the primary ions is transferred to the analyte mole-
cules. Around 1% of the sputtered analyte molecules possess an electric 
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charge; these ions can be detected by a mass analyzer, such as a TOF (as 
described earlier). The energy of the primary ion beam is typically high 
compared to the covalent bond energies of the analyte molecules, 
resulting in their fragmentation. This makes SIMS a “hard” ionization 
technique, although polyatomic ion beams offer softer ionization than 
monoatomic ion beams (Bodzon-Kulakowska & Suder, 2016). SIMS 
requires no matrix and offers higher depth and spatial resolution (<10 
μm) as compared to MALDI. However, MALDI is more sensitive as it 
has access to higher yields of analyte and is able to detect larger 
molecules (Fletcher, Lockyer, & Vickerman, 2011), with the highest 




DESI uses an electrospray source of highly charged aqueous spray droplets 
under ambient conditions to gently desorb and ionize analyte molecules 
from the sample surface (Taka´ts, Wiseman, Gologan, & Cooks, 2004). An 
advantage of DESI is that it allows for the analysis of a sample in its native 
state. In the ion source an electrospray emitter is used to generate charged 
microdroplets from a solvent, which create a thin film on the sample surface 
that dissolves the analyte molecules. Secondary microdroplets are formed 
from the kinetic impact of the primary droplets, which contain the highly 
charged solvent and dissolved analyte. These secondary microdroplets are 
ionized from the sample surface to the mass spectrometer inlet. A DESI 
source can be coupled to most standard electrospray mass spectrometers 
(Hsu & Dorrestein, 2015) where following ionization, the analytes are sent 
via an ion transfer tube to the mass analyser for detection. During ionization 
little analyte fragmentation occurs, hence DESI is considered a “soft” ion-
ization technique with a spatial resolution of around 50–100 μm and an 
upper mass range detection limit of around 2 kDa.  
 
2. PROTEIN MSI IN CANCER RESEARCH 
 
Changes in protein function play a crucial role in the development of 
cancer. Such alterations can be caused by number of events including 
altered localization, posttranslational modifications (PTMs), and/or 
abundance levels. Furthermore, the biology of a tumor depends not only on 
the cancerous cells but also on their interaction with surrounding stroma, 
blood vessels, and the immune system (Kriegsmann, Kriegsmann, & 
Casadonte, 2015). The ability to spatially resolve different proteins while 
simultaneously 
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acquiring information concerning their relative abundance is particularly 
important in heterogeneous diseases such as cancer. Therefore, an approach 
combining high-resolution MS with in situ spatial analysis of the diseased 
area has the potential to directly identify and quantify proteins and peptides. 
 
When MSI first entered the field of tissue-based research, it was used to 
analyze the spatial distribution of proteins (Stoeckli, Chaurand, Hallahan, & 
Caprioli, 2001). Following this ground-breaking research, different imaging 
methods have been established and applied to a wide range of biological 
problems. Among the several MSI techniques, MALDI-MSI is one of the 
most commonly used. MALDI-MSI has the capability of detecting a broad 
range of compounds present in a tissue section, provided the compound can 
be ionized and desorbed into gaseous phase during the MALDI process. 
High-resolution MS, such as MALDI-FT-ICR, has greater strength in the 
field of low-molecular weight compounds, while MALDI-TOF is used for 
the analysis of peptides and small proteins up to 25 kDa (Aichler & Walch, 
2015). MALDI-MSI of thin tissue sections can result in the detection of over 
500 individual protein signals within the mass range of 2–70 kDa that can 
be directly correlated with specific morphological regions of the tissue 
(Chaurand, Schwartz, & Caprioli, 2004). 
 
Protocols have been developed for the preparation of tissue sections and 
matrix application that provide a high level of reproducibility (Gustafsson et 
al., 2013). The methodology behind protein MSI, via the analysis of their 
proteolytic peptides, is straightforward; a digestion enzyme is uniformly 
applied over the entire tissue surface either by a spotting or spray deposition 
method. Thereafter, using the same application method, internal calibrants 
and matrix are applied. Data acquisition is then carried out by a MS 
(Gustafsson et al., 2013), where analyte ionization, mass analysis, and detec-
tion occur. This results in the subsequent generation of mass spectrums at 
regular series of points across the tissue section. The mass spectra produced 
are then visualized as ion intensity maps; generating two-dimensional distri-
bution maps of the detected mass spectra containing information about the 
location and the relative intensity of the detected peptides. This visualization 
is similar in nature to images generated by histological or IHC analysis, but 
with the advantage that multiple molecules can be examined within a single 
measurement (Aichler & Walch, 2015) (Fig. 1). 
 
Three-dimensional MALDI-MS images can also be generated by 
analyzing a number of consecutively cut tissue sections, and following data 
acquisition, combining the results to generate three-dimensional maps 
(Andersson, Groseclose, Deutch, & Caprioli, 2008; Sinha et al., 2008). 
 





















Fig. 1 Workflow of MALDI mass spectrometry imaging. 
 
Recently, methods were developed for the integration of three-dimensional 
volume reconstructions of spatially resolved MALDI-MSI ion intensity 
images taken of whole mouse heads with corresponding in vivo data pro-
vided by magnetic resonance imaging (MRI) (Sinha et al., 2008). The added 
spatial dimension provides contextual information to the MALDI-MSI data 
that allow the interrogation of proteomic relationships within a tissue vol-
ume. The work displayed a correlation between the in vivo MRI and pro-
teomic profiles obtained by MALDI-MSI, with both techniques able to 
distinguish tumor from healthy tissues (Sinha et al., 2008). 
 
Until recently, MALDI-MSI had been carried out almost exclusively on 
fresh frozen samples as it was believed proteins were inaccessible from 
FFPE tissue due to the cross-linking caused by the formalin fixation. 
However, this limitation has been overcome and equal number of proteins 
can be identified from both fresh frozen and FFPE tissues (Diehl et al., 
2015). The use of FFPE tissues in cancer research is a huge advantage, 
given that the samples are well preserved by the formalin fixation process 
and can be stored for long periods of time at room temperature. Another 
attractive feature is that the samples are often well documented as they have 
been processed by clinical pathology departments, meaning information on 
patient treatment response, disease progression, and other relevant clinical 
data have been cataloged (Gorzolka & Walch, 2014). Additionally, FFPE 
tissues are well suited for the construction of tissue microarrays (TMAs), 
where needle core biopsies from multiple tissue samples are assembled into 
a paraffin block. However, 
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fresh frozen TMAs have also been studied in a limited context (Fejzo & 
Slamon, 2010). 
 
One of the main advantages of MALDI-MSI is the technique’s ability to 
detect changes in disease-associated protein expression prior to histological 
transformation, making it a useful tool in the identification of early stage 
disease biomarkers (McDonnell et al., 2010). There have been number of 
cancer studies that have successfully applied peptide imaging to the 
discovery of potential biomarkers with the capacity to differentiate tumors 
of various subtypes, stages, and/or degree of metastasis. 
 
 
2.1 Distinguishing Tissue Types by Peptide MSI 
 
The ability of peptide MSI to distinguish specific types of tissue, such as 
regions of healthy, cancer, stroma, and vasculature, has been shown multiple 
times (Mittal, Klingler-Hoffmann, Arentz, Zhang, et al., 2016). 
Schwamborn et al. performed MSI on prostate cancer specimens and was 
able to classify the cancerous tissue from normal tissue with 85% sensitivity 
and 90% specificity, with an overall cross validation accuracy of 88% 
(Schwamborn et al., 2007). Moreover, MSI of prostate cancer TMAs on a 
large scale allowed for the immediate prioritization of MSI signals based on 
associations with clinic-pathological and molecular data (Steurer et al., 
2013). A comparison of these signals with clinic-pathological features 
revealed statistical association with a favorable phenotype such as grade, 
stage, and relationship with prolonged time to prostate-specific antigen 
recurrence (Steurer et al., 2013). Peptide MSI experiments have been able to 
discriminate normal, preinvasive, and invasive lung tumor tissues with an 
accuracy of 90% (Rahman et al., 2011), to differentiate normal tissue from 
oral squamous cell carcinoma (Patel et al., 2009), to discriminate normal tis-
sue from gastric cancer tissues (Kim et al., 2010), and have identified 
mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 
2 (MEKK2) as a marker with the capacity to accurately discern can-cerous 
prostate from normal tissue (Cazares et al., 2009). 
 
One of the most challenging aspects of neurochemistry is the detection 
of endogenous neuropeptides due to their low in vivo concentrations ranging 
from pico- to femto-molar levels, which makes it difficult to obtain enough 
material for quantitative analysis (Andersson, Andren, & Caprioli, 2010; 
Strand, 2003). MALDI-MSI helps overcome this issue as it allows the direct 
detection of neuropeptides in discrete regions of a brain sections, enabling 
the study of the physiological and disease-related 
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metabolic processing of neuropeptides (Andersson et al., 2010). Recently, 
Andersson et al. has been able to sequence and identify neuropeptides by in 
situ tandem mass spectrometry (MS/MS) directly off rat brain sections using 
a MALDI-QTOF mass spectrometer (Andersson et al., 2008). 
 
Furthermore, peptide MALDI-MSI has been employed to differentiate 
benign regions from malignant in ovarian cancer (Lemaire, Ait Menguellet, 
et al., 2007) and in thyroid cancer (Pagni et al., 2015). Likewise, biomarkers 
have been identified that could distinguish Hodgkin’s lymphoma from 
lymphadenitis (Schwamborn et al., 2010). 
 
 
2.2 Determining Tumor Margins by Peptide MSI 
 
One of the major aims of clinical oncology is to ensure a tumor has been 
completely removed during surgery to minimize the possibility of disease 
recurrence (Han et al., 2011). Defining tumor margins also plays a pivotal 
role in cancer staging, which subsequently influences the administration of 
treatment. Moreover, the molecular characterization of tumor margins will 
assist in understanding the process of invasion into surrounding tissues and 
may help in the clinical management of disease (Agar et al., 2010). MALDI-
MSI has been proposed as a valuable tool for gaining information with 
regards to tumor margins and heterogeneity (Chaurand, Sanders, Jensen, & 
Caprioli, 2004). Peptide MSI has interestingly revealed histologically 
normal tissue adjacent to renal cell carcinoma regions, share many 
molecular characteristics with that of the tumor tissue, providing unprece-
dented insight into cancer development (Oppenheimer, Mi, Sanders, & 
Caprioli, 2010). The technique has also been used to identify protein bio-
markers for the differentiation of delineated hepatocellular carcinoma from 
adjacent cirrhotic tissue (Le Faouder et al., 2011). Analysis of ovarian 
cancer interface zones, the regions between tumor and normal tissues, by 
MSI revealed a unique peptide profile from both the tumor and normal 
tissue, and detected plastin 2 and peroxiredoxin 1 as interface markers 
specific to ovarian cancer (Kang et al., 2010). 
 
 
2.3 Prediction of Metastasis by Peptide MSI 
 
Metastatic status is often the defining feature in determining if a patient will 
receive chemotherapy and is currently resolved by the removal and analysis 
of local lymph nodes, which frequently results in noncancer-related health 
complications. Identification of primary tumor markers of metastasis 
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would prevent the unnecessary removal of lymph nodes, thereby reducing 
patient suffering and associated treatment costs, and allow the introduction 
of more personalized cancer therapies (Casadonte et al., 2014). However, 
identification of metastasis based on analysis of the primary tumor tissues is 
challenging, especially when the primary carcinoma site is unknown 
(Pavlidis & Pentheroudakis, 2016). A statistical classification model based 
on peptide MSI data has been developed for determining the metastatic 
status of primary cancers of pancreatic origin and their metastasis to sec-
ondary breast cancer with an overall accuracy of 83% (Casadonte et al., 
2014). In another study the HER2 status of gastric cancers could be 
predicted with 90% accuracy using peptide expression patterns originating 
from breast cancers (Balluff et al., 2010). These studies display the potential 
of peptide MSI in the profiling of cancers, independent of their site of 
origin. 
 
The likelihood of lymph node metastasis (LNM) is one of the most 
important factors to consider while determining the appropriate treatment 
for a cancer patient. Several studies have applied MALDI-MSI to the pre-
diction of LNM status. Yanagisawa et al. was able to classify primary lung 
tumors with and without LNM with an accuracy of 85% (Yanagisawa et al., 
2003). Different peptide signatures have been identified with the ability to 
distinguish melanoma (LNM) from control lymph nodes (Hardesty, Kelley, 
Mi, Low, & Caprioli, 2011). Similarly, the overexpression of S100A10, 
thioredoxin, and S100A6, have been shown to be highly associated with 
LNM in papillary thyroid carcinoma (PTC) (Nipp et al., 2011), and it was 
suggested the three proteins may be used for risk stratification regarding 
metastatic potential in PTC. Other protein biomarkers have been suggested 
for the prediction of LNM in several cancers from peptide MSI experiments, 
such as S100A8 and S100A9 for gastric adenocarcinoma (Choi et al., 2012), 
COX7A2, TAGLN2, and S100-A10 for monitoring the Barrett’s 
adenocarcinoma development as well as for predicting regional (LNM) and 
disease outcome (Elsner et al., 2012). 
 
Recently, it has been shown that the LNM status of primary endometrial 
tumors could be predicted with an accuracy of 88% using a classification 
system based on tissue peptide markers detected by MALDI-MSI (Mittal, 
Klingler-Hoffmann, Arentz, Winderbaum, et al., 2016; Winderbaum, Koch, 
Mittal, & Hoffmann, 2016). In the study FFPE-TMAs comprised of 
duplicate tumor tissue cores from endometrial cancer patients diagnosed 
with and without LNM were analyzed by MALDI-TOF-MSI. An overview 
of the sample preparation and approach used for the proteomic marker 
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identification by MALDI-MSI-(top panel) and LC-MS/MS (bottom panel) is 
outlined in Fig. 2. 
 
2.4 Analysing Chemoresponse by Peptide MSI 
 
Innate and acquired chemoresistance significantly impact the survival rates 
of late stage cancer patients. Administration of chemotherapy to patients 
with specific cancer types has traditionally been standardized, despite the 
knowledge that response can differ significantly among a cohort of patients 
due to genetic diversity and tumor heterogeneity. Identification of markers 
or tests that predict resistance to standard chemotherapy regimens would 
help save patients from damaging, ineffective treatments, and may help 
determine if an alternative treatment course may be more beneficial. 
 
IHC is one of the most widely applied proteomic techniques in clinical 
practice. However, IHC is often unable to distinguish the different isoforms 
of the same protein that may play different role in the disease development. 
Recent studies using MSI have been able to distinguish two isoforms of the 
protein defensin. This is of particular interest given the 2 defensin protein 
isoforms respond differently in breast cancer tumors when exposed to che-
motherapy (Bauer et al., 2010). The finding was discovered during the anal-
ysis of a breast cancer patient receiving neoadjuvant paclitaxel and radiation 
therapy, and was one of the first biomarker discovery studies to utilize 
MALDI-MSI (Bauer et al., 2010). Mitochondrial defects have also been 
found and linked to chemotherapy response in oesophageal adenocarcinoma 
patients using peptide MSI (Aichler et al., 2013), displaying the techniques 
potential to change classifications of tumors and chemoresponse. 
 
2.5 Identification of Diagnostic and Prognostic 
Markers by Peptide MSI 
 
A high proportion of cancer patients are diagnosed in the later stages of dis-
ease, when the cancer has already metastasized to distant lymph nodes or 
organs. Detecting cancer in the earlier stages of disease, prior to metastasis, 
would help increase survival rates and reduce the treatment burden for 
patients. In a genetically engineered mouse model, peptide MSI was used to 
detected several discriminative peptide masses that could distinguish 
between intraepithelial neoplasia, intraductal papillary mucinous neoplasm, 
and normal pancreatic tissue (Gruner€ et al., 2012). Using MALDI-MSI to 
analyze TMAs, significant differences between papillary and clear cell renal 





























Fig. 2 Workflow for proteomic marker identification by peptide MALDI-MSI and label-free quantification. 
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cancer TMAs by MSI lead to the identification of multiple signals in the 
mass spectra associated with unfavorable tumor phenotype and clinical 
characteristics, such as tumor recurrence, progression, and patient 
survival time (Steurer, Singer, et al., 2014). 
 
MALDI-MSI has also been used to identify a protein signature that can 
accurately determine the HER2 status in breast cancer with sensitivity of 
83%, for specificity of 92%, and overall accuracy of 89% (Rauser et al., 
2010). A seven-protein signature of novel tissue markers was identified as 
an independent indicator of unfavorable overall survival in intestinal type 
gastric cancer (Balluff, Rauser, et al., 2011). Other investigators identified 
histone 4 expression as specific to poorly differentiated gastric cancer 
tissues by peptide MSI (Morita et al., 2010). A comparison of genomically 
stable (diploid) and unstable (aneuploid) colon cancer tissues against normal 
mucosa by MSI identified thymosin beta 4 as an independent prognostic 
marker for colorectal cancer (Gemoll, Strohkamp, Schillo, Thorns, & 
Habermann, 2015). Analysis of lung cancer TMAs containing 112 needle 
core biopsies were used to generate a support vector machine model utiliz-
ing MSI information on 73 peptides that could classify adenocarcinomas 
with an accuracy of 97% and squamous cell carcinomas with an accuracy of 
98% (Groseclose, Massion, Chaurand, & Caprioli, 2008). 
 
 
2.6 Characterisation of Intra- and Intertumor Variability 
by Peptide MSI 
 
Understanding the spatiotemporal patterns and dynamics of intratumor 
heterogeneity is crucial for clinical management and designing personalized 
targeted regimens for cancer patients (Renovanz & Kim, 2014). Balluff et 
al. showed for the first time that MALDI-MSI of tumor tissues can reveal 
microscopically indistinct tumor populations that might have adverse 
impacts in clinical outcome (Balluff et al., 2015). In the proof-of-principal 
study tumor-specific mass spectra were grouped using an advanced statis-
tically clustering algorithm in order to obtain segmentation maps of molec-
ularly distinct regions. The distinct regions were then statistically compared 
with patient clinical data to identify phenotypic tumor subpopulations 
(Balluff et al., 2015). This approach revealed that several of the detected 
tumor subpopulations are associated with different overall survival char-
acteristics of gastric cancer patients (p = 0.025) and the presence of region-
al metastasis in patients with breast cancer (p = 0.036). This approach 
enables researchers to gain deeper insights into the underlying biological 
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process and changes of tumor subpopulations on a genetic, metabolic, and 
proteomic level, which may result in novel targeted therapies (Balluff et al., 
2015). 
 
The ability of MALDI-MSI to reveal inter- and intratumoral biomolec-
ular heterogeneity of histologically contiguous tumors has been shown, spe-
cifically in the capacity to distinguish different types and grades of myxoid 
sarcomas (Willems et al., 2010). By applying hierarchical clustering to a 
gastric cancer MALDI-MSI dataset, it has been demonstrated the different 
histological regions could be distinguished solely on the basis of their 
protein and peptide expression profiles (Deininger, Ebert, Futterer,€ 
Gerhard, & Rocken,€ 2008). Ion mobility separation combined with 
MALDI-MSI has been used to classify prostate cancer TMAs and has 
identified a number of proteins, including type I collagen and tumor necrosis 
factor receptor, directly from the tissue that could discriminate different 
tumor classes (Djidja et al., 2010). Low grade urothelial neoplasia could be 
separated from high grade urothelial neoplasia with an overall cross 
validation rate of 97.18% upon analysis of peptide MSI data (Oezdemir et 
al., 2012). Likewise, based on protein profiling, a grading system for 
meningioma was developed (Agar et al., 2010). Proteomic signatures 
associated with breast cancer-activated stromal tissues have been identified 
by MSI, and hierarchical clustering of the proteomic signals could be used 
to distinguish the activated intratumoral stroma from the quiescent 
extratumoral stroma (Dekker et al., 2014). High grade and low grade glioma 
can also be distinguished by MALDI-MSI (Chaurand et al., 2004). 
 
2.7 Practical Considerations for Proteolytic Peptide MSI: 
Sample Preparation 
 
MSI of proteolytic peptides in cancer is frequently performed on fresh 
frozen or FFPE tissues; each sample type has unique advantages and 
limitations with regards to MSI. The protein component of fresh tissues is 
easily accessible, especially when compared to FFPE tissues, due to a lack 
of chemical fixation. Hence, no retrieval steps are required prior to the 
proteolyic digestion of fresh frozen samples. A disadvantage of fresh frozen 
tissues, however, is that they require rapid freezing upon collection and 
storage at extremely low temperatures to inhibit endogenous enzymatic 
degradation (Fentz, Zornig, Juhl, & David, 2004). Fresh tissues also require 
solvent washing to remove lipids and other biomolecules that may compete 
for ionization and interrupt the detection of peptides. Washing steps must be 
performed carefully, as extensive washing may cause the loss of soluble 
proteins 
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(McDonnell et al., 2010; Seeley, Oppenheimer, Mi, Chaurand, & Caprioli, 
2008). Two significant advantages of FFPE samples are that they are widely 
used in modern clinical practice, meaning very large sample banks have 
often been developed, and that the fixation process allows for storage of the 
samples at room temperature for indefinite periods of time without loss of 
morphological information (Wisztorski et al., 2007). The downfall is that 
formalin fixation results in the formation of methylene bridges between 
amino residues that causes protein cross-linking (Metz et al., 2004). This 
cross-linking makes the proteins inaccessible to proteolysis and must be 
reversed prior to any further preparation steps. Heat-induced antigen 
retrieval prior to in situ proteolytic digestion is a widely used method for 
reversing protein cross-links, which allows for the peptide profiling of FFPE 




2.8 Practical Considerations for Peptide MSI: Spatial Resolution 
 
Currently, MALDI is the most popular ionization method applied in the 
field of MSI. The success of analyte ionization in a MALDI experiment 
relies significantly on the matrix used; the type of matrix applied will impact 
on the mass range of the detectable ions, the intensity of detection, and the 
minimum spatial resolution achievable (Lemaire et al., 2006). For peptide 
MALDI-MSI commonly used matrices include α-cycano-4-
hydroxycinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB) (van 
Hove, Erika, Smith, & Heeren, 2010). The homogeneity of matrix 
crystallization is a major limiting factor with regard to the spatial resolution 
that can be achieved by MALDI-MSI, as larger and nonuniform matrix crys-
tals result in lower resolutions. DHB matrix is prone to producing large, 
needle-like crystals, making CHCA a more suitable matrix as it commonly 
forms small, homogeneous crystals resulting in higher image resolution 
(Schwartz, Reyzer, & Caprioli, 2003). The way in which the matrix is 
applied also has a significant impact on the spatial resolution, with the appli-
cation of larger size droplets increasing the likely hood of analyte displace-
ment. Instrumentation has been developed that allows matrix solutions to be 
sprayed or spotted onto the sample surface in a more homogeneous manner 
compared to manual application (Aerni, Cornett, & Caprioli, 2006). For 
example, using a matrix spray device CHCA can be applied to form uniform 
crystals that allow for spatial resolution peptide imaging of <25 μm 
(McDonnell et al., 2010; Schuerenberg & Deininger, 2010). 
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Laser specifications also have a significant impact on the spatial 
resolution achievable. As opposed to the limitations of matrix 
crystallization, laser beam resolutions can easily reach less than 10 μm, 
theoretically allowing for pep-tide imaging at the single cell level (Balluff, 
Schone,€ Hofler,€ & Walch, 2011). However, reducing the size of the laser 
beam concurrently reduces the yield of ionized analytes. Higher frequency 
lasers and overlapping laser shots can counteract the issue of lower ion 
yields during detection (Jurchen, Rubakhin, & Sweedler, 2005). Thus, 
currently matrix is the limiting factor for the spatial resolution achievable in 
MALDI-MSI. 
 
2.9 Practical Considerations for Peptide MSI: Mass Analysers 
 
The type of mass analyser used for MSI will largely determine the mass res-
olution and mass range of the detectable ions. TOF mass analysers are com-
monly coupled to MALDI sources and have high acquisition speeds but 
typically lower mass resolution (Caprioli et al., 1997). Higher mass accuracy 
can be achieved through the use of internal or external calibrants. Other 
commonly used mass analysers include FT-ICR and Orbitraps; these instru-
ments have significantly higher mass accuracy and resolution (Taban et al., 
2007). 
 
Internal or external calibrants can be used to improve the mass accuracy 
of acquired spectra during or after data acquisition (Gobom et al., 2002). 
Calibrants are often comprised of a small number of specific analytes with 
known masses that span a specific mass range. Within this mass range, the 
use of calibrants can significantly increase the mass accuracy of the detected 
analytes. However, the mass error of any analyte molecules that fall outside 
the mass range of the calibrants cannot be corrected (Coombes, Koomen, 
Baggerly, Morris, & Kobayashi, 2005). 
 
2.10 Practical Considerations for Peptide MSI: Identification 
 
Currently, MALDI-MSI enables the discrimination of heterogeneous tis-sue 
types, but does not allow for the direct identification of the peptide 
sequences. During data acquisition the intact mass, or the m/z, of the 
detected peptides is recorded. This allows peptide mass fingerprinting 
(PMF) to be performed, a process where the intact peptide masses are mat-
ched back to a database containing the in silico digested proteome or 
proteomes of specific species (Pappin, Hojrup, & Bleasby, 1993). Due to a 
lack of peptide sequence information, often PMF can provide a list of 
potential peptide identifications but is not able to provide definitive 
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identifications for those peptides with similar masses. However, the higher 
the mass accuracy of the instrument used the more likely it is a definitive 
identification will be gained (Horn, Peters, Klock, Meyers, & Brock, 2004). 
The use of complementary MS techniques, such as matching data to 
peptides sequenced by traditional liquid chromatography electrospray 
ionization tandem mass spectrometry (LC-ESI-MS/MS) or by in situ tandem 
mass spectrometry (MALDI-MS/MS), can help clarify peptide sequence 
identifications (Lemaire, Desmons, et al., 2007). However, there can be 
significant difficulties associated with these options also. Multiple sequence 
matches are often encountered when matching MSI m/z values back to LC-
ESI-MS/MS data obtained from the same sample. Generating high quality in 
situ MS/MS spectrums is often challenging due to the issue that acquisition 
of very complex peptide mass spectra directly off tissue results in poor 
fragmentation and high MS/MS complexity, both of which limit direct 




3. LIPID MSI IN CANCER RESEARCH 
 
3.1 Profiling Lipids in Cancer by DESI-MSI 
 
The soft ionization technique of DESI has been developed for the MSI of 
small molecules and lipids. DESI uses highly charged solvent droplets trav-
eling at high velocities for analyte ionization in an ambient atmosphere. An 
advantage of DESI for the analysis of lipids and small molecules is that no 
sample preparation steps are required, unlike MALDI where matrix depo-
sition is a necessity. A further advantage is that a DESI source can be 
coupled to most standard mass analysers, such as a FT-ICR, Orbitrap, Ion 
Trap, or a TOF. 
 
In practice, DESI-MSI has been applied to the study of human cancers 
for the discrimination of tumor subtypes and grades, as well as for the iden-
tification of tumor margins (Calligaris et al., 2014; Eberlin et al., 2014). One 
particular application used DESI-MSI to generate lipid profiles for the clas-
sification of human brain tumors (Eberlin et al., 2012). This study was able 
to classify the subtype, grade, and tumor concentration of 36 human glioma 
samples via lipidomics imaging in agreement with the histopathology diag-
noses (Eberlin et al., 2012). Lipidomic analysis by DESI-MSI has identified 
the phospholipids phosphatidylserine (PS), phosphatidylinositol (PI), and 
phosphatidylethanolamine as biomarkers for distinguishing healthy tissue 
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from benign and malignant tumor tissues (Abbassi-Ghadi et al., 2014; Dill et 
al., 2011, 2009; Eberlin et al., 2012). 
 
Discriminatory lipid signatures between cancerous and normal breast 
tissue have been detected by DESI-MSI (Calligaris et al., 2014), with the 
delineation of tumor margins possible through the analysis of PI (18:0/20:4). 
PI (18:0/20:4) has been shown to be abundant at the tumor center and tumor 
edge, whereas it was absent or weak in normal tissues. This lipid sharply 
stratifies the tumor margin in agreement the histopathological staining. 
Using DESI-MSI, another study found PS (20:4/18:0) and PI (18:0/20:4) are 
significantly lower in concentration in primary tumor tissues and LNMs 
when compared to normal lymph node tissues (Abbassi-Ghadi et al., 2014). 
The same lipid, PI (18:0/20:4), was found to be a biomarker for 
distinguishing benign and malignant breast tumors (Yang et al., 2015). 
Collectively, the discussed research shows MSI lipid profiling of cancer 
tissues can be used for classifying tumor types, with high specificity in 
differentiating histopathologic grade, and in the mapping of tumor margins. 
 
 
3.2 Profiling Lipids in Cancer by SIMS-MSI 
 
A less popular ionization method for MSI in the lipidomics field is static 
SIMS. Generally, a static SIMS source is coupled to a TOF (or QTOF) 
instrument, and is particularly suitable for the analysis of intact molecules 
such as lipids and metabolites. It uses a beam of energetic primary ions with 
either monatomic source, such as Cs+ and Ga+ for limited mass range of low 
hundreds Daltons, or cluster ions such as SF+5, Bi+3, and Au+3 that have 
extended the mass range to a couple of thousands Daltons (Lanni, Rubakhin, 
& Sweedler, 2012). The potential of SIMS-TOF imaging for lipidomics has 
been shown in rat brain sections, a well-established model system for MSI 
(Benabdellah et al., 2010; Passarelli & Winograd, 2011; Sjovall, Lausmaa, 
& Johansson, 2004; Sjovall, Lausmaa, Nygren, Carlsson, & Malmberg, 
2003). In the field of cancer lipidomics, it is frequently used in cellular 
imaging, where single cells or a population of cells are isolated after drug 
treatment for the characterisation of molecules on the cell surface. For 
example, lipid composition analysis of individual human breast cancer stem 
cells (CSCs) reported significantly lower expression levels of palmitoleic 
acids FA (16:1) as compared to nonstem cancer cells (NSCCs), and is 
thought to have been successfully characterized from complex clinical 
specimens using TOF-SIMS (Waki et al., 2014). 
 




4. GLYCAN MSI IN CANCER RESEARCH 
 
Glycosylation is the enzymatic process where oligosaccharides, poly-
saccharides, and carbohydrates (i.e., glycans) are attached to proteins, lipids, 
or other organic molecules (Ohtsubo & Marth, 2006). In recent years, the 
word “glycomics” has emerged to describe the study of glycan structures 
from an organism’s “glycome.” The mammalian glycome repertoire is com-
prised of 10 known monosaccharides. These monosaccharides include 
xylose (Xyl), glucose (Glc), galactose (Gal), mannose (Man), N-
acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), fucose 
(Fuc), glucuronic acid (GlcA), iduronic acid (IdoA), and N-acetylneuraminic 
acid (NeuAc or Neu5Ac), a sialic acid (Wuhrer, Deelder, & van der Burgt, 
2011). Glycan complexity arises from variation in expression of specific 
glycosyltransferases, resulting in a diversity of monosaccharide 
arrangements. Furthermore, modifications such as sulfation, acetylation, or 
phosphorylation increase the complexity of glycosylation. 
The major type of glycosylation is protein glycosylation, where glycans 
are attached to asparagine residues by their amine group (N-linked) or at 
serine/threonine residues by their hydroxyl group (O-linked) (North, 
Hitchen, Haslam, & Dell, 2009). Protein glycosylation is an important PTM 
which has relevance in many biological processes such as cell signaling, 
immune responses, extracellular interaction, and cell adhesion (Varki, 
1993). In the tumor microenvironment, aberrant protein glycosylation such 
as the expression of truncated glycans have been well described in various 
cancers (Dube & Bertozzi, 2005). These structures may resemble glycomic 
“fingerprints” which discriminate between healthy and cancerous tissues or 
potentially discriminate between various cancer subtypes (Abbott et al., 
2010).  
One of the most common glycosylation changes in various cancers is an 
increase in branching of N-glycans, where large tetra-antennary structures 
are formed by the expression of N-acetylglucosaminyltransferase V (GnT-
V) (Lau & Dennis, 2008). The presence of increased branching antennas 
creates additional sites for the addition of NeuAc by sialyltransferases in 
various cancers (Bull et al., 2013). Likewise, terminal modifications on 
glycan structures such as fucosylation on the cancer cell surface can also 
give rise to the presence of Lewis and sialyl Lewis antigens (sialyl Lea; 
[Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ] and sialyl Lex; [Neu5Acα2-
3Galβ1-4(Fucα1-3) 
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GlcNAcβ]) which have been shown to correlate with tumor progression and 
metastasis (Nakagoe et al., 2000). It is evident that aberrant glycosylation is 
indeed a key event in metastasis and therefore the discovery of cancer-
specific protein glycosylation markers would be beneficial in the staging 
and treatment of patients (Drake et al., 2010). 
 
As glycomics gains recognition in this postgenomics era, MS-based 
methodologies are becoming indispensable and routinely used for the reli-
able profiling of glycans from clinical samples. Glycan MSI is a recent MS-
based development which allows the visualization of the tissue-specific 
spatial distribution of glycans. N-glycans have been the most comprehen-
sively studied type of protein glycosylation, as they can be easily released 
from proteins by enzymatic cleavage using PNGase F (Jensen, Karlsson, 
Kolarich, & Packer, 2012). The majority of these studies have applied opti-
mized N-glycan MALDI-MSI methods to FFPE tissues, with the most recent 
focus on various cancer tissues. 
 
One of the first N-glycan MALDI-MSI methods to emerge was 
published in 2013 (Powers et al., 2013). This proof-of-principle paper 
described the measurement of N-glycans by MALDI-MSI across fresh fro-
zen mouse brain tissue. The m/z values from the sum spectrum were 
assigned to N-glycans based on further MS structural analysis, for example, 
high-performance liquid chromatography (HPLC)-MS. The authors 
concluded that this new approach could lead to novel disease-related targets 
for biomarker and therapeutic applications. Subsequently, N-glycan 
MALDI-MSI has been successfully applied to the analysis of glioblastoma 
tumor xenografts compared to normal brain tissues (Toghi Eshghi et al., 
2014), where it was found specific N-glycans associated with distinct tissue 
regions. N-glycan imaging of FFPE pancreatic and prostate cancers, and a 
human hepatocellular carcinomas in TMAs found tumor and nontumor 
regions could be distinguished in the TMA format, enabling high-
throughput analysis (Powers et al., 2014). 
 
The use of complimentary MS methods, such as liquid chromatography 
tandem MS (LC-MS/MS) with MALDI-TOF-MSI, have been developed to 
enable the mapping of tissue-specific N-glycans at high resolution 
(Gustafsson et al., 2015). The application of these techniques has resulted in 
several interesting findings. A panel of over 30 N-glycans has been detected 
from FFPE human hepatocellular carcinoma tissues (Powers, Holst, Wuhrer, 
Mehta, & Drake, 2015), from which the N-glycans were extracted and the 
sialylated species were stabilized by an off-tissue ethylation reaction. N-
glycan sialyation linkage-specificity was further found to 
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correlate with the different tissue types analyzed. A novel method for the 
analysis of N-glycan sialylated species (i.e., α 2–3 and α 2–6) by MALDI-
MSI in colon carcinoma found sialylated N-glycans with α 2–3 linkage were 
observed in stroma, tumor, and necrotic regions, while sialylated N-glycans 
with α 2–6 linkage were observed in necrotic, collagen-rich, and red blood 
cell regions (Holst et al., 2016). 
 
The analysis of FFPE stage III ovarian cancer tissues found high 
mannose structure (Man5 + Man3GlcNAc2) in the tumor regions, while 
triantennary complex structures (Hex3HexNAc3Deoxyhexose1 + 
Man3GlcNAc2) were observed in the stromal regions (Fig. 3). This 
observation was consistent between not only the patients investigated, but 
also between each N-glycan family. The tissue analyzed in the study had 
been annotated by a pathologist, and it was found specific glycan structures 
were differentially detected in specific tissue regions, such as tumor, stroma, 
and adipose tissue. 
 
In summary, N-glycan MALDI-MSI has developed immensely in recent 



















Fig. 3 Glycan analysis of ovarian cancer. The formalin-fixed paraffin-embedded stage III 
ovarian cancer section was treated with antigen retrieval prior to printing of 15 nL/spot 
dialyzed PNGase F with 250 μm spacing. 2,5-DHB (20 mg/mL) was sprayed onto the sec-
tions and MS spectra were acquired by oversampling at 100 μm intervals using a MALDI-
TOF/TOF MS instrument. (A) Haematoxylin and eosin stain of the ovarian cancer section 
with tumor (red), stroma (green), and adipose (blue) regions annotated by a pathologist. 
(B) An ion intensity map of m/z 1743.7 (red), m/z 2174.9 (green), and m/z 933.3 (blue) on 
the ovarian cancer section. Yellow circle, galactose (Gal); green circle, mannose (Man); 
blue square, N-acetylglucosamine (GlcNAc); red triangle, fucose (Fuc). 
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compositional analysis by complementary techniques (i.e., LC-MS/MS and 
lectin histochemistry staining), and identification of linkage-specific 
sialylated species by in situ derivatization methods. However, further work 
in the field is required to properly answer clinical questions and discover 
cancer-specific markers. TMAs have not yet been fully utilized in N-glycan 
MSI experiments, but offer promise in providing researchers and clinicians 




5. DRUG IMAGING IN CANCER RESEARCH 
 
Quantification of drugs and their metabolites is crucial in oncology 
where drug distribution within the tumor tissue is thought to play a pivotal 
role in response to therapy and could partly explain the variable response 
rates observed among patients with similar tumor types (Minchinton & 
Tannock, 2006). Traditionally, autoradiography has been used to visualize 
the localization of a drug. However, this technique suffers from some sig-
nificant limitations. One of them is that the synthesis of the radiolabeled 
drug is an expensive and time-consuming process. Second, the technique 
does not provide information on the molecular structure. Hence, metabolites 
either cannot be distinguished from the parent drug or are not detected if the 
radiolabel is lost in a metabolic process (Kertesz et al., 2008). The other 
clinically used noninvasive drug imaging techniques are positron emission 
tomography and MRI. These techniques can provide information on the 
drug distribution but suffers from the limitation of low spatial resolution. 
Due to the relatively simple sample preparation steps required for MSI the 
technique has rapidly emerged as an alternative to the conventional methods 
of analysis. MSI allows detailed distribution analysis of the parent drug and 
its metabolites in a single experiment and without any labeling of the 
targeted compound in contrast to conventional immunohistochemical 
methods. Such drug characterization in situ, by both spatial and temporal 
behaviors within tissue compartments, provides a new understanding of the 
dynamic processes impacting drug uptake and metabolism at the local sites 
targeted by a drug therapy (Kwon et al., 2015). Multiple MSI techniques 
including MALDI-MSI, SIMS, and nanostructure initiator mass 
spectrometry (NIMS) have been used to analyze the distribution of the drug 
and metabolites. However, MALDI-MSI is the most frequently used method 
for looking at anticancer drug distribution in tumor samples. 
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5.1 MALDI-MSI on Tissue Sections 
 
MALDI-MSI was used for the first time in 2003 to directly analyze and 
image pharmaceutical compounds in intact tissues (Reyzer, Hsieh, Ng, 
Korfmacher, & Caprioli, 2003). From then, the technique has been applied 
to the imaging of a number of drugs. Prideaux et al. applied MALDI-MRM-
MSI to visualize the distribution of the second line tuberculosis drug 
moxifloxacin at a range of time points after dosing in tuberculosis-infected 
rabbits, which was further validated by quantitative LC-MS/MS of lung and 
granuloma extracts from adjacent biopsies taken from the same animals 
(Prideaux et al., 2011). Drug distribution within the granulomas was 
observed to be inhomogeneous, and very low levels were observed in the 
caseum in comparison to the cellular granuloma regions (Prideaux et al., 
2011). Fehniger et al. measured the occurrence of inhaled bronchodilator, 
ipratropium, within human bronchial biopsies obtained by fiber optic 
bronchoscopy shortly after dosing exposure and showed the drug is rapidly 
absorbed into the airway wall (Fehniger et al., 2011). Nilson et al. provided 
the first evidence that compounds administrated by inhaled delivery at 
standard pharmacological dosage can be quantitatively detected by MALDI-
MSI with accuracy and precision (Nilsson et al., 2010). The distribution of 
the inhaled drug tiotropium was tracked and quantified in the lungs of dosed 
rats and a concentration gradient (80 fmol–5 pmol) away from the central 
airways into the lung parenchyma and pleura was observed (Nilsson et al., 
2010). Hsieh et al. visualized the spatial distribution of astemizole 
(withdrawn in most countries due to its side effects) and its primary 
metabolite in rat brain tissues and showed that the drug alone is likely to be 
responsible for the associated central nervous system side effects upon 
elevated exposure (Hsieh, Li, & Korfmacher, 2010). Using MALDI-MSI the 
specific distribution of unlabeled chloroquine was examined in the retinas of 
rats and was found to be similar to auto-radiograms results reported 
previously (Yamada, Hidefumi, Shion, Oshikata, & Haramaki, 2011). 
 
Atkinson et al. showed the distribution of the bioreductive anticancer 
drug AQ4N (banoxatrone), its active metabolite AQ4, and ATP in treated 
human tumor xenografts (Atkinson, Loadman, Sutton, Patterson, & Clench, 
2007). The distribution of ATP was found similar to that of AQ4N, i.e., in 
regions of abundant ATP there was no evidence of conversion of AQ4N into 
AQ4, indicating that the cytotoxic metabolite AQ4 is confined to hypoxic 
regions of the tumor as intended (Atkinson et al., 2007). Using 
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MALDI-FT-ICR, Cornett et al. imaged the antitumor drug imatinib and two 
of its metabolites from a mouse brain glioma and showed the metabolites to 
be more abundant in tumor region compared to normal, which is consistent 
with other imaging studies of the drug (Cornett, Frappier, & Caprioli, 2008). 
In order to better understand the penetration of the anti-cancer drug 
oxaliplatin, MALDI-MSI of tissue sections from treated rat kidneys was 
performed and it was observed that the drug and its metabolites were 
localized exclusively in the kidney cortex, suggesting the drug did not 
penetrate deeply into the organ (Bouslimani, Bec, Glueckmann, Hirtz, & 
Larroque, 2010). Sugihara et al. demonstrated the first data on the 
localization of personalized medicine (vemurafenib) within tumor com-
partments of malignant melanoma (MM). In a proof-of-concept in vitro 
study the overexpression and localization of the drug in the MM was shown 
using MS fragment ion signatures (Sugihara et al., 2014). Using MALDI-
MSI, it has been shown the drug irinotecan reaches tumors mainly through 
microvessels whereas the conversion of the drug into its active form SN-38 
in tumors of colorectal cancer was poor compared to normal tissue (Buck et 
al., 2015). The distribution of tamoxifen in both ER-positive and ER-
negative breast cancer tumor tissues as analyzed by MALDI-MSI detected 
the drug at significantly lower intensities in tumor cells compared with 
stroma in ER-negative samples (Vegva´ri et al., 2016). Aikawa et al. 
employed a quantitative MSI method (a combination of MALDI-MSI and 
LC-MS/MS) in a preclinical mouse model to evaluate the intrabrain 
distribution of an anticancer drug (Aikawa et al., 2016). While no differ-
ences were observed between the mice for the drug concentration, diffuse 
drug distribution was found in the brain of the knockout mice vs wild mice 
(Aikawa et al., 2016). 
 
To remove the background signals from matrix degradation observed 
in MALDI-MSI, the method nanoparticle-assisted laser desorption 
ionization (n-PALDI) was developed which utilises nanoparticles as 
matrixes. It was found the protocol could be used to investigate the 
distribution of anticancer agents in primary tumors and in metastasis, to 
ascertain whether resistance is related to inadequate drug penetration in 
poorly vascularized parts of the tumor (Morosi et al., 2013). Using the n-
PALDI protocol, the different distribution of paclitaxel in tumor and 
normal tissues was visualized and related to the dosage-schedules and 
pathological features of the tumors (Morosi et al., 2013). 
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5.2 MALDI-MSI on Whole Body Sections 
 
Rohner et al. first demonstrated the MALDI-MSI of drugs in whole body 
animal sections in 2005 (Rohner, Staab, & Stoeckli, 2005). Since then, a 
wide range of drugs have been imaged in whole body animal sections, all-
owing the label-free tracking of both endogenous and exogenous com-
pounds with spatial resolution and molecular specificity (Khatib-Shahidi, 
Andersson, Herman, Gillespie, & Caprioli, 2006). MALDI-MSI has been 
used to simultaneously detect drugs and their individual metabolite dis-
tributions at various time points across whold body tissue sections (Khatib-
Shahidi et al., 2006). Stoeckli et al. measured the distribution of a 14C 
labeled compound (dosed intratracheally) in whole rat tissue sections using 
MALDI-MSI and whole body autoradiography (WBA) which dis-played 
good quantitative agreement between both techniques (Stoeckli, Staab, & 
Schweitzer, 2007). Trim et al. compared the distribution of vinblas-tine 
within whole body sections using MALDI-MSI and WBA which displayed 
MALDI-MSI to be advantageous by separating the drug from an 
endogenous isobaric lipid (Trim et al., 2008). 
 
5.3 MALDI-MSI on 3D Tissue Cultures 
 
Liu et al. applied MALDI-MSI to the analysis of 3D spheroids in order 
to assess the distribution of pharmaceuticals and their metabolites. As a 
proof-of-concept study, MALDI-MSI was applied to in HCT 116 colon 
carcinoma multicellular spheroids to analyze the distribution of 
irinotecan, showing the time-dependent penetration of the drug and three 
metabolites (Liu, Weaver, & Hummon, 2013).  
 
 
6. DATA ANALYSIS 
 
6.1 Spatial Information 
 
The main advantage of MSI over other methods is the access it provides to 
spatial information. Possibly the most common approach to leveraging the 
spatial information in MSI data is simply in displaying results as spatial 
plots. Fig. 4 shows the results of several analyses of such data. These 
analyses are blind to the spatial information in the data but their results have 
spatial patterns that can be easily seen when plotted. Plotting such results 
next to a stained image of the tissue allows for the molecular information in 
























Fig. 4 Results of various analyses of tryptic peptide MALDI-MSI data collected from the same section of tissue. (A) H&E stained 
section of several primary serous ovarian tumors embedded in surrounding stromal tissue. (B) Intensity of a single peptide peak at 
m/z = 1628.8 confirmed as belong to heterogeneous nuclear ribonucleoprotein A1 which has been shown to be of interest in the 
past (Chen, Zhang, & Manley, 2010; Lee et al., 2010). (C) Results of 4-means clustering on the log-intensities including all 
measured m/z values. (D) Results of the first principle component including all measured m/z values on the log-intensities. 
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to be correlated to the histology of the tissue, thereby allowing 
biologically relevant use of the spatial information. Such results can even 
be overlayed directly with stained images (Walch, Rauser, Deininger, & 
Hofler,€ 2008), and used to partially automate and aid in histological 
annotations in an unbiased manner (Cornett et al., 2006). A popular 
alternative to the k-means clustering shown in Fig. 4 is the so-called 
semisupervised hierarchical clustering approach applied by Deininger et 
al. (2008). These semisupervised methods allow the user to manipulate 
the clustering results until they agree with the observed histology. Jones 
et al. (2011) demonstrated how multiple approaches to multivariate 
analysis, such as k-means and principle component analysis (PCA) (Fig. 
4), could be combined in an automated manner to produce more reliable 
partitioning of spatial regions based on the multivariate MSI data. 
 
Spatial information can also be applied to the partitioning of data in a 
histology driven fashion. To use Fig. 4 as an example, one could use the his-
tology shown in the H&E stain to distinguish different tissue types such as 
tumor and surrounding stroma, and then by matching the image to the 
acquired region, partition the spectra into groups representing specific 
tissue. These groups of spectra could then be compared in an attempt to 
detect molecular differences between tissue types—this is also a very 
common approach used in the analysis of MSI data. Using this technique 
Oppenheimer et al. (2010) demonstrated that histologically healthy tissues 
within a margin of tumor tissues share molecular characteristics, and 
hypothesized that this phenomena could be involved in tumor recurrence 
postresection. Such information could be used by surgeons to identify an 
appropriate margin to excise the tissue surrounding a tumor. 
 
 
6.2 Preprocessing: Peak Detection 
 
MSI data have a uniquely complicated structure due to the spatial informa-
tion it contains, and additionally can be computationally challenging due to 
the shear amount of information recorded during acquisition. The data 
therefore require novel approaches to analysis when compared to other, 
more traditional forms of mass spectrometry (Jones, Deininger, 
Hogendoorn, Deelder, & McDonnell, 2012). Furthermore, the appropriate 
approach will vary depending on the application. One approach to 
addressing the quantity of data is to perform some, preferably computation-
ally fast, data reduction early in the data analysis workflow and then work 
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with the reduced data. This allows for analyses to be performed quickly, but 
also means that all further analyses will be affected by the choices made in 
the data reduction step. The most simplistic approach to data reduction is 
centroiding—essentially reducing spectra to their local maxima. Centroiding 
is perhaps the most simplistic approach to peak detection. Essentially 
centroiding involves reducing the acquired spectra to their local maxima, 
allowing peaks in the spectra to be identified, information relevant to these 
peaks to be stored and the remainder of the “noise” to be removed. Yang, 
He, and Yu (2009) provide a good overview of peak detection in the context 
of MALDI-MS. Wavelet approaches to peak detection, such as those 
suggested by Du, Kibbe, and Lin (2006), Lange, Gropl, Reinert, 
Kohlbacher, and Hildebrandt (2006), show some promise but have not yet 
made it into mainstream software packages, and so do not currently see 
much use. Regardless, peak detection prior to further analysis is a useful 
tool as it can reduce the volume of data by as much as three orders of mag-
nitude. However, care must be taken when interpreting final results; it is 
important to be aware that all analyses will be affected by any peak 
detection steps and that a quality control analysis of the data following peak 
detection should be implemented to ensure its performance. 
 
6.3 Classification of FFPE-TMAs and the Importance 
of Dimension Reduction 
 
The application of MSI to FFPE-TMAs for classification of various 
diagnostic and prognostic clinical factors is a particularly promising field of 
research. The ability to use FFPE tissue allows access to large archives 
including tissue samples and associated patient meta data (Hood et al., 
2005). The use of TMAs with MSI facilitates the collection of label-free and 
untargeted mass data from large numbers of patients (Groseclose et al., 
2008), which in turn allows for classification problems to be considered. 
One of the key obstacles to the classification of such data is that, due to the 
untargeted nature of MSI, the resulting data are of high-dimensionality. The 
natural approach to address the dimensionality of such data is to perform 
some dimension reduction prior to classification. Mascini et al. (2015) 
proposed the use PCA for dimension reduction prior to classification. PCA 
is a classical multivariate approach that preserves the maximum amount of 
variability in the dimension-reduced data. Winderbaum et al. (2016) 
proposed using a cross correlation analysis (CCA) to rank MSI variables 
based on their contribution to the highest multivariate correlation to the 
clinical variable and to reduce the dimension of the data by restricting to 
only the most highly ranked MSI 
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variables. Either way, dimension reduction prior to classification is crucial. 
In order to apply these ideas in clinical practice, large cohort studies and/or 
clinical trials would need to be carried out to validate the performance of 
these MS-based classifiers. To date most studies have been exploratory, 
using small samples of patients as a proof of principle, with a study by 
Steurer et al. (2013) being a notable exception. Dependent on large scale 
validation studies, classification of MSI data could potentially be used in the 
individualisation of treatments, predicting factors such as LNM or poten-
tially even chemotherapy response.  
 
 
7. CONCLUDING REMARKS 
 
7.1 The Future of MSI: Molecular Pathology 
 
For over 100 years clinical pathology has relied upon a description of mor-
phology by trained specialists for tumor classification and grading. The 
information that can be gained from such an analyses is limited, however, 
and is often purely descriptive. During the last decade mass spectrometers 
have found their way from physics and biochemistry research laboratories 
into clinical pathology laboratories, bringing together researchers from a 
wide spectrum of disciplines, such as physics, biochemistry, medicine, 
pathology, and mathematics. A key feature of MSI is the ability to discern 
molecular signatures of disease with the additional bonus that the features 
can be directly related back to the tissue morphology. In the context of 
clinical oncology, the application of MSI has the potential to shift traditional 
pathology from descriptive morphological analyses to detailed molecular 
analyses. As such, the introduction of MSI equipment into pathology 
laboratories will extend their capabilities and revolutionize management and 
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